<html><body><head><link href="edgaug_10k.css" rel="stylesheet"/></head>
<text>
<title></title>
<p style="margin: 0"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b> </b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Washington, D.C. 20549</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b> </b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM 10-K</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(Mark One)</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Wingdings">x</font><font style="font-family: Times New Roman, Times, Serif"> ANNUAL
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the fiscal year ended <b><u>September
30, 2019</u></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Wingdings">¨</font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the transition period from ______________
to________________</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission file number<b>: <u>001-37606</u></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><u>ANAVEX LIFE SCIENCES CORP.</u></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal">
<tr style="vertical-align: top">
<td style="width: 47%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nevada</font></td>
<td style="width: 6%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"> </td>
<td style="width: 47%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">98-0608404</font></td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction of incorporation or organization)</font></td>
<td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"> </td>
<td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S. Employer Identification No.)</font></td></tr>
<tr style="vertical-align: top">
<td style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"> </td>
<td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"> </td>
<td style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"> </td></tr>
<tr style="vertical-align: top">
<td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51 W 52<sup>nd</sup> Street, 7<sup>th</sup> Floor, New York, NY USA</font></td>
<td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"> </td>
<td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10019</font></td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of principal executive offices)</font></td>
<td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"> </td>
<td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip Code)</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant’s telephone number, including
area code <u>1-844-689-3939</u></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Securities registered under Section 12(b)
of the Act:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="width: 37%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Stock, $0.001 par value</font></td>
<td style="width: 2%; text-align: center"> </td>
<td style="width: 22%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AVXL</font></td>
<td style="width: 2%; text-align: center"> </td>
<td style="width: 37%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NASDAQ Stock Market LLC</font></td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title of each class</font></td>
<td style="text-align: center"> </td>
<td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading Symbol</font></td>
<td style="text-align: center"> </td>
<td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of each exchange on which registered</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Securities registered pursuant to Section
12(g) of the Act:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><u>Common Stock, $0.001 par value</u></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Title of class)</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td colspan="2"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate by checkmark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.</font></td></tr>
<tr style="vertical-align: top">
<td style="width: 75%"> </td>
<td style="width: 25%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes </font><font style="font-family: Wingdings">¨</font> <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No </font><font style="font-family: Wingdings; font-size: 10pt">x</font></td></tr>
<tr style="vertical-align: top">
<td> </td>
<td> </td></tr>
<tr style="vertical-align: top">
<td colspan="2"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate by checkmark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.</font></td></tr>
<tr style="vertical-align: top">
<td> </td>
<td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes </font><font style="font-family: Wingdings">¨</font> <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No</font> <font style="font-family: Wingdings; font-size: 10pt">x</font></td></tr>
<tr style="vertical-align: top">
<td> </td>
<td> </td></tr>
<tr style="vertical-align: top">
<td colspan="2"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate by checkmark whether the registrant has (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.</font></td></tr>
<tr style="vertical-align: top">
<td> </td>
<td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes </font><font style="font-family: Wingdings; font-size: 10pt">x</font> <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No </font><font style="font-family: Wingdings">¨</font></td></tr>
<tr style="vertical-align: top">
<td style="text-align: center"> </td>
<td style="text-align: center"> </td></tr>
<tr style="vertical-align: top">
<td colspan="2"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).</font></td></tr>
<tr style="vertical-align: top">
<td> </td>
<td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes </font><font style="font-family: Wingdings; font-size: 10pt">x</font> <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No </font><font style="font-family: Wingdings">¨</font></td></tr>
<tr style="vertical-align: top">
<td> </td>
<td> </td></tr>
<tr style="vertical-align: top">
<td colspan="2"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate by checkmark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
<td style="width: 29%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer   </font><font style="font-family: Wingdings">¨</font></td>
<td style="vertical-align: top; width: 39%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"> </td>
<td style="vertical-align: top; width: 32%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer   </font><font style="font-family: Wingdings; font-size: 10pt">x</font></td></tr>
<tr>
<td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated filer     </font><font style="font-family: Wingdings">¨</font></td>
<td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"> </td>
<td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company   </font><font style="font-family: Wingdings; font-size: 10pt">x</font></td></tr>
<tr>
<td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"> </td>
<td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"> </td>
<td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company </font><font style="font-family: Wingdings">¨</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td colspan="2" style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act </font></td></tr>
<tr style="vertical-align: top">
<td style="text-align: right"> </td>
<td style="text-align: right"><font style="font-family: Wingdings; font-size: 10pt">¨</font></td></tr>
<tr style="vertical-align: top">
<td colspan="2"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).</font></td></tr>
<tr style="vertical-align: top">
<td style="width: 75%; text-align: center"> </td>
<td style="width: 25%; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes </font><font style="font-family: Wingdings">¨</font> <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No </font><font style="font-family: Wingdings; font-size: 10pt">x</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">State the aggregate market value of the
voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last
sold, or the average bid and asked price of such common equity, as of the last business day of the registrant’s most recently
completed second fiscal quarter: $139,768,112 based on a price of $3.05 per share, being the closing price of the registrant’s
common stock on March 31, 2019.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>
<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
the number of shares outstanding of each of the registrant’s classes of common stock, as of the latest practicable date
56,123,076 issued and outstanding as of December 12, 2019.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">DOCUMENTS INCORPORATED BY REFERENCE</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">None.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
<!-- Field: Page; Sequence: 1; Options: NewSection -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="margin: 0pt"> </p></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><u>TABLE OF CONTENTS</u></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
<td style="vertical-align: top; width: 94%; padding-bottom: 5pt"><a href="#main_001"><font style="font-family: Times New Roman, Times, Serif">PART I</font></a></td>
<td style="vertical-align: bottom; width: 6%; text-align: right; padding-bottom: 5pt"><a href="#main_001">1</a></td></tr>
<tr>
<td style="vertical-align: top; padding-left: 9pt; padding-bottom: 5pt"><a href="#main_002"><font style="font-family: Times New Roman, Times, Serif">ITEM 1. BUSINESS</font></a></td>
<td style="vertical-align: bottom; text-align: right; padding-bottom: 5pt"><a href="#main_002">1</a></td></tr>
<tr>
<td style="vertical-align: top; padding-left: 9pt; padding-bottom: 5pt"><a href="#main_003"><font style="font-family: Times New Roman, Times, Serif">ITEM 1A. RISK FACTORS</font></a></td>
<td style="vertical-align: bottom; text-align: right; padding-bottom: 5pt"><a href="#main_003">14</a></td></tr>
<tr>
<td style="vertical-align: top; padding-left: 9pt; padding-bottom: 5pt"><a href="#main_004"><font style="font-family: Times New Roman, Times, Serif">ITEM 1B. UNRESOLVED STAFF COMMENTS</font></a></td>
<td style="vertical-align: bottom; text-align: right; padding-bottom: 5pt"><a href="#main_004">27</a></td></tr>
<tr>
<td style="vertical-align: top; padding-left: 9pt; padding-bottom: 5pt"><a href="#main_005"><font style="font-family: Times New Roman, Times, Serif">ITEM 2. PROPERTIES</font></a></td>
<td style="vertical-align: bottom; text-align: right; padding-bottom: 5pt"><a href="#main_005">27</a></td></tr>
<tr>
<td style="vertical-align: top; padding-left: 9pt; padding-bottom: 5pt"><a href="#main_006"><font style="font-family: Times New Roman, Times, Serif">ITEM 3. LEGAL PROCEEDINGS</font></a></td>
<td style="vertical-align: bottom; text-align: right; padding-bottom: 5pt"><a href="#main_006">27</a></td></tr>
<tr>
<td style="vertical-align: top; padding-left: 9pt; padding-bottom: 5pt"><a href="#main_007"><font style="font-family: Times New Roman, Times, Serif">ITEM 4. MINE SAFETY DISCLOSURES</font></a></td>
<td style="vertical-align: bottom; text-align: right; padding-bottom: 5pt"><a href="#main_007">27</a></td></tr>
<tr>
<td style="vertical-align: top; padding-bottom: 5pt"><a href="#main_008"><font style="font-family: Times New Roman, Times, Serif">PART II</font></a></td>
<td style="vertical-align: bottom; text-align: right; padding-bottom: 5pt"><a href="#main_008">27</a></td></tr>
<tr>
<td style="vertical-align: top; padding-left: 9pt; padding-bottom: 5pt"><a href="#main_009"><font style="font-family: Times New Roman, Times, Serif">ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</font></a></td>
<td style="vertical-align: bottom; text-align: right; padding-bottom: 5pt"><a href="#main_009">27</a></td></tr>
<tr>
<td style="vertical-align: top; padding-left: 9pt; padding-bottom: 5pt"><a href="#main_010"><font style="font-family: Times New Roman, Times, Serif">ITEM 6 SELECTED FINANCIAL DATA</font></a></td>
<td style="vertical-align: bottom; text-align: right; padding-bottom: 5pt"><a href="#main_010">29</a></td></tr>
<tr>
<td style="vertical-align: top; padding-left: 9pt; padding-bottom: 5pt"><a href="#main_011"><font style="font-family: Times New Roman, Times, Serif">ITEM 7 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION</font></a></td>
<td style="vertical-align: bottom; text-align: right; padding-bottom: 5pt"><a href="#main_011">29</a></td></tr>
<tr>
<td style="vertical-align: top; padding-left: 9pt; padding-bottom: 5pt"><a href="#main_012"><font style="font-family: Times New Roman, Times, Serif">ITEM 7A QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</font></a></td>
<td style="vertical-align: bottom; text-align: right; padding-bottom: 5pt"><a href="#main_012">34</a></td></tr>
<tr>
<td style="vertical-align: top; padding-left: 9pt; padding-bottom: 5pt"><a href="#main_013"><font style="font-family: Times New Roman, Times, Serif">ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</font></a></td>
<td style="vertical-align: bottom; text-align: right; padding-bottom: 5pt"><a href="#main_013">34</a></td></tr>
<tr>
<td style="vertical-align: top; padding-left: 9pt; padding-bottom: 5pt"><a href="#main_014"><font style="font-family: Times New Roman, Times, Serif">ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL MATTERS</font></a></td>
<td style="vertical-align: bottom; text-align: right; padding-bottom: 5pt"><a href="#main_014">35</a></td></tr>
<tr>
<td style="vertical-align: top; padding-left: 9pt; padding-bottom: 5pt"><a href="#main_015"><font style="font-family: Times New Roman, Times, Serif">ITEM 9A. CONTROLS AND PROCEDURES</font></a></td>
<td style="vertical-align: bottom; text-align: right; padding-bottom: 5pt"><a href="#main_015">35</a></td></tr>
<tr>
<td style="vertical-align: top; padding-left: 9pt; padding-bottom: 5pt"><a href="#main_016"><font style="font-family: Times New Roman, Times, Serif">ITEM 9B OTHER INFORMATION</font></a></td>
<td style="vertical-align: bottom; text-align: right; padding-bottom: 5pt"><a href="#main_016">35</a></td></tr>
<tr>
<td style="vertical-align: top; padding-bottom: 5pt"><a href="#main_017"><font style="font-family: Times New Roman, Times, Serif">PART III</font></a></td>
<td style="vertical-align: bottom; text-align: right; padding-bottom: 5pt"><a href="#main_017">36</a></td></tr>
<tr>
<td style="vertical-align: top; padding-left: 9pt; padding-bottom: 5pt"><a href="#main_018"><font style="font-family: Times New Roman, Times, Serif">ITEM 10 DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</font></a></td>
<td style="vertical-align: bottom; text-align: right; padding-bottom: 5pt"><a href="#main_018">36</a></td></tr>
<tr>
<td style="vertical-align: top; padding-left: 9pt; padding-bottom: 5pt"><a href="#main_019"><font style="font-family: Times New Roman, Times, Serif">ITEM 11. EXECUTIVE COMPENSATION</font></a></td>
<td style="vertical-align: bottom; text-align: right; padding-bottom: 5pt"><a href="#main_019">39</a></td></tr>
<tr>
<td style="vertical-align: top; padding-left: 9pt; padding-bottom: 5pt"><a href="#main_020"><font style="font-family: Times New Roman, Times, Serif">ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND <font style="text-transform: uppercase">RELATED STOCKHOLDER MATTERS.</font></font></a></td>
<td style="vertical-align: bottom; text-align: right; padding-bottom: 5pt"><a href="#main_020">43</a></td></tr>
<tr>
<td style="vertical-align: top; padding-left: 9pt; padding-bottom: 5pt"><a href="#main_021"><font style="font-family: Times New Roman, Times, Serif">ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</font></a></td>
<td style="vertical-align: bottom; text-align: right; padding-bottom: 5pt"><a href="#main_021">44</a></td></tr>
<tr>
<td style="vertical-align: top; padding-left: 9pt; padding-bottom: 5pt"><a href="#main_022"><font style="font-family: Times New Roman, Times, Serif">ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES</font></a></td>
<td style="vertical-align: bottom; text-align: right; padding-bottom: 5pt"><a href="#main_022">45</a></td></tr>
<tr>
<td style="vertical-align: top; padding-bottom: 5pt"><a href="#main_023"><font style="font-family: Times New Roman, Times, Serif">PART IV</font></a></td>
<td style="vertical-align: bottom; text-align: right; padding-bottom: 5pt"><a href="#main_023">46</a></td></tr>
<tr>
<td style="vertical-align: top; padding-left: 9pt; padding-bottom: 5pt"><a href="#main_024"><font style="font-family: Times New Roman, Times, Serif">ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES</font></a></td>
<td style="vertical-align: bottom; text-align: right; padding-bottom: 5pt"><a href="#main_024">46</a></td></tr>
<tr>
<td style="vertical-align: top; padding-left: 9pt; padding-bottom: 5pt"><a href="#main_025"><font style="font-family: Times New Roman, Times, Serif">ITEM 16. FORM 10-K SUMMARY</font></a></td>
<td style="vertical-align: bottom; text-align: right; padding-bottom: 5pt"><a href="#main_025">47</a></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></p></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Forward Looking Statements.</i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Annual Report on Form 10-K includes
forward-looking statements. All statements other than statements of historical facts contained in this Annual Report on Form 10-K,
including statements regarding our anticipated future clinical and regulatory milestone events, future financial position, business
strategy and plans and objectives of management for future operations, are forward-looking statements. The words “believe,”
“may,” “estimate,” “continue,” “anticipate,” “intend,” “expect”
“should,” “forecast,” “could,” “suggest,” “plan” and similar expressions,
as they relate to us, are intended to identify forward-looking statements. Such forward-looking statements include, without limitation,
statements regarding:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.65pt; text-align: justify; text-indent: -0.25in"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">our ability to generate any revenue or
to continue as a going concern;</font></td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">our ability to successfully conduct clinical
and preclinical trials for our product candidates;</font></td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">our ability to raise additional capital
on favorable terms and the impact of such activities on our stockholders and stock price;</font></td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">our ability to execute our research and
development plan on time and on budget;</font></td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">our products ability to demonstrate efficacy
or an acceptable safety profile of our product candidates;</font></td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">our ability to obtain the support of qualified
scientific collaborators;</font></td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">our ability, whether alone or with commercial
partners, to successfully commercialize any of our product candidates that may be approved for sale;</font></td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">our ability to identify and obtain additional
product candidates;</font></td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">our reliance on third parties in non-clinical
and clinical studies;</font></td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">our ability to defend against product
liability claims;</font></td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">our ability to safeguard against security
breaches;</font></td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">our ability to obtain and maintain sufficient
intellectual property protection for our product candidates;</font></td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">our ability to comply with our intellectual
property licensing agreements;</font></td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">our ability to defend against claims of
intellectual property infringement;</font></td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">our ability to comply with the maintenance
requirements of the government patent agencies;</font></td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">our ability to protect our intellectual
property rights throughout the world;</font></td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">competition;</font></td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">the anticipated start dates, durations
and completion dates of our ongoing and future clinical studies;</font></td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">the anticipated designs of our future
clinical studies;</font></td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">our anticipated future regulatory submissions
and our ability to receive regulatory approvals to develop and market our product candidates; and </font></td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">our anticipated future cash position.
</font></td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have based these forward-looking statements
largely on our current expectations and projections about future events, including the responses we expect from the U.S. Food and
Drug Administration, (“FDA”), and other regulatory authorities and financial trends that we believe may affect our
financial condition, results of operations, business strategy, preclinical and clinical trials, and financial needs. These forward-looking
statements are subject to a number of risks, uncertainties and assumptions including without limitation the risks described in
“Risk Factors” in Part I, Item 1A of this Annual Report on Form 10-K. These risks are not exhaustive. Other sections
of this Annual Report on Form 10-K include additional factors which could adversely impact our business and financial performance.
Moreover, we operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time and it is
not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the
extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any
forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. We cannot assure
you that the events and circumstances reflected in the forward-looking statements will be achieved or occur and actual results
could differ materially from those projected in the forward-looking statements. Except as required by applicable laws including
the securities laws of the United States, we assume no obligation to update or supplement forward-looking statements.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As used in this Annual Report on Form 10-K,
the terms “we,” “us,” “our,”, “Company” and “Anavex” mean Anavex Life
Sciences Corp., unless the context clearly requires otherwise.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p>
<!-- Field: Page; Sequence: 3; Value: 2 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></p></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><a name="main_001"></a>PART I</p>
<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-style: normal"> </font></p>
<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-style: normal"><a name="main_002"></a><section class="edgaug_item1" id="edgaug_item1_id">ITEM 1. BUSINESS</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Overview and Strategy</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Anavex Life Sciences Corp. is a clinical
stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central
nervous system (“CNS”) diseases with high unmet need. We analyze genomic data from clinical studies to identify biomarkers,
which we use to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental
diseases.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our lead compound, ANAVEX<sup>®</sup>2-73,
is being developed to treat Alzheimer’s disease, Parkinson’s disease and potentially other central nervous system diseases,
including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked
gene, methyl-CpG-binding protein 2 (“MECP2”).</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our total portfolio currently consists
of five programs. To prioritize the allocation of our resources, we designate certain programs as core programs and others as seed
programs. We currently have two core programs and three seed programs. Our core programs are at various stages of clinical and
preclinical development, in neurodegenerative and neurodevelopmental diseases.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table summarizes key information about our programs:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><img alt="" src="https://www.sec.gov/Archives/edgar/data/1314052/000173112219000784/e1624_img01.jpg"/> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Anavex has a portfolio of compounds varying
in sigma-1 receptor (S1R) binding activities. The SIGMAR1 gene encodes the S1R protein, which is an intracellular chaperone protein
with important roles in cellular communication. S1R is also involved in transcriptional regulation at the nuclear envelope and
restores homeostasis and stimulates recovery of cell function when activated. In order to validate the ability of our compounds
to activate quantitatively the S1R, we performed, in collaboration with Stanford University, a quantitative Positron Emission Tomography
(PET) imaging scan in mice, which demonstrated a dose-dependent ANAVEX<sup>®</sup>2-73 target engagement or receptor occupancy
(RO) with S1R in the brain.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="https://www.sec.gov/Archives/edgar/data/1314052/000173112219000784/e1624_img02.jpg"/> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Cellular Homeostasis</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Many diseases are possibly directly caused
by chronic homeostatic imbalances or cellular stress of brain cells. In pediatric diseases like Rett syndrome or infantile spasms,
the chronic cellular stress is possibly caused by the presence of a constant genetic mutation. In neurodegenerative diseases, such
as Alzheimer’s and Parkinson’s diseases, chronic cellular stress is possibly caused by age-correlated buildup of cellular
insult and hence chronic cellular stress. Specifically, defects in homeostasis of protein or ribonucleic acid (“RNA”)
lead to the death of neurons and dysfunction of the nervous system. The spreading of protein aggregates resulting in a proteinopathy,
a characteristic finding in Alzheimer’s and Parkinson’s diseases that results from disorders of protein synthesis,
trafficking, folding, processing or degradation in cells. The clearance of macromolecules in the brain is particularly susceptible
to imbalances that result in aggregation and degeneration in nerve cells. For example, Alzheimer’s disease pathology is characterized
by the presence of amyloid plaques, neurofibrillary tangles, which are aggregates of hyperphosphorylated Tau protein that are a
marker of other diseases known as tauopathies as well as inflammation of microglia. With the SIGMAR1 activation through SIGMAR1
agonists like ANAVEX<sup>®</sup>2-73, our approach is to restore cellular balance, i.e. homeostasis. Therapies that correct
defects in cellular homeostasis might have the potential to halt or delay neurodevelopmental and neurodegenerative disease progression.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<!-- Field: Page; Sequence: 5; Value: 1 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>ANAVEX</i></b><sup>®</sup><b><i>2-73-specific Biomarkers</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A full genomic analysis of Alzheimer’s
disease (AD) patients treated with ANAVEX<sup>®</sup>2-73 resulted in the identification of actionable genetic variants. A
significant impact of the genomic biomarkers SIGMAR1, the direct target of ANAVEX<sup>®</sup>2-73 and COMT, a gene involved
in memory function, on the drug response level was identified, leading to an early ANAVEX<sup>®</sup>2-73-specific biomarker
hypothesis. It is expected that <i>excluding</i> patients with these two identified biomarker variants (approximately 10%-20% of
the population) in prospective studies would identify approximately 80%-90% patients that would display clinically significant
improved functional and cognitive scores. The consistency between the identified DNA and RNA data related to ANAVEX<sup>®</sup>2-73,
which are considered independent of AD pathology, as well as multiple endpoints and time-points, provides support for precision
medicine clinical development of ANAVEX<sup>®</sup>2-73 by using genetic biomarkers identified within the study population
itself to target patients who are most likely to respond to ANAVEX<sup>®</sup>2-73 treatment in AD as well as indications like
Parkinson’s disease dementia (PDD) or Rett syndrome (RTT) in which ANAVEX<sup>®</sup>2-73 is currently studied.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i> </i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Clinical Studies Overview</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Alzheimer’s Disease</i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In November 2016, we completed a Phase
2a clinical trial, consisting of PART A and PART B, which lasted a total of 57 weeks, for ANAVEX<sup>®</sup>2-73 in mild-to-moderate
Alzheimer’s patients. This open-label randomized trial met both primary and secondary endpoints and was designed to assess
the safety and exploratory efficacy of ANAVEX<sup>®</sup>2-73 in 32 patients. ANAVEX<sup>®</sup>2-73 targets sigma-1 and
muscarinic receptors, which have been shown in preclinical studies to reduce stress levels in the brain believed to restore cellular
homeostasis and to reverse the pathological hallmarks observed in Alzheimer’s disease. In October 2017, we presented positive
pharmacokinetic (PK) and pharmacodynamic (PD) data from the Phase 2a study, which established a concentration-effect relationship
between ANAVEX<sup>®</sup>2-73 and study measurements. These measures obtained from all patients who participated in the entire
57 weeks include exploratory cognitive and functional scores as well as biomarker signals of brain activity. Additionally, the
study appears to show that ANAVEX<sup>®</sup>2-73 activity is enhanced by its active metabolite (ANAVEX19-144), which also
targets the sigma-1 receptor and has a half-life approximately twice as long as the parent molecule.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In March 2016, we received approval from
the Ethics Committee in Australia to extend the Phase 2a clinical trial by an additional 108 weeks, which had been requested by
patients and their caregivers. Subsequently, in May 2018, we received approval from the Ethics Committee in Australia to further
extend the Phase 2a extension trial for an additional two years. The two consecutive trial extensions have allowed participants
who completed the 52-week PART B of the study to continue taking ANAVEX<sup>®</sup>2-73, providing an opportunity to gather
extended safety data for a cumulative time period of five years.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In October 2018, we presented new long-term
clinical data for ANAVEX<sup>®</sup>2-73 in a presentation at the 2018 Clinical Trials on Alzheimer’s Disease (CTAD)
Meeting. At 148 weeks into the five-year extended Phase 2a clinical study, data confirmed a significant association between ANAVEX<sup>®</sup>2-73
concentration and both exploratory functional and cognitive endpoints as measured by the Alzheimer’s Disease Cooperative
Study-Activities of Daily Living (ADCS-ADL) evaluation and the Mini Mental State Examination (MMSE), respectively. The
cohort of patients treated with higher ANAVEX<sup>®</sup>2-73 concentration maintained ADCS-ADL performance compared to the
lower concentration cohort (p&lt;0.0001). As well, the patient cohort with the higher ANAVEX<sup>®</sup>2-73 concentration
performed better at MMSE compared to the lower concentration cohort (p&lt;0.0008). A significant impact on the drug response levels
of both the SIGMAR1 (p&lt;0.0080) and COMT (p&lt;0.0014) genomic biomarkers, identified and specified at week 57, was also confirmed
over the 148-week period. Further, ANAVEX<sup>®</sup>2-73 demonstrated continued favorable safety and tolerability through
148 weeks.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<!-- Field: Page; Sequence: 6; Value: 1 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A larger Phase 2b/3 double-blind, placebo-controlled
study of ANAVEX<sup>®</sup>2-73 in Alzheimer’s disease commenced in August 2018, which is independent of the ongoing
Phase 2a extension study. The Phase 2b/3 study will enroll approximately 450 patients for 48 weeks, randomized 1:1:1 to two different
ANAVEX<sup>®</sup>2-73 doses or placebo. The trial is currently taking place in Australia; however, additional regions are
being added. The ANAVEX<sup>®</sup>2-73 Phase 2b/3 study design incorporates genomic precision medicine biomarkers identified
in the ANAVEX<sup>®</sup>2-73 Phase 2a study. Primary and secondary endpoints will assess safety and both cognitive and functional
efficacy, measured through Alzheimer’s Disease Assessment Scale – Cognition (ADAS-Cog), ADCS-ADL and Clinical Dementia
Rating – Sum of Boxes for cognition and function (CDR-SB).</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In October 2019, we initiated a long-term
open label extension study, entitled the ATTENTION-AD study, for patients who have completed the 48-week Phase 2b/3 placebo-controlled
trial. This study is expected to last two years and will give patients the opportunity to continue their treatment.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Rett Syndrome </i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In February 2016, we presented positive
preclinical data for ANAVEX<sup>®</sup>2-73 in Rett syndrome, a rare neurodevelopmental disease. The study was funded by the
International Rett Syndrome Foundation (“Rettsyndrome.org”). In January 2017, we were awarded a financial grant from
Rettsyndrome.org of a minimum of $0.6 million to cover some of the costs of a multicenter Phase 2 clinical trial of ANAVEX<sup>®</sup>2-73
for the treatment of Rett syndrome. This award is being received in quarterly instalments which commenced during fiscal 2018.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In March 2019, we commenced the first Phase
2 clinical trial in a planned Rett syndrome program of ANAVEX<sup>®</sup>2-73 for the treatment of Rett syndrome. The studies
will be conducted in a range of patient age demographics and geographic regions.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The first Phase 2 study, which commenced
in March 2019, is taking place in the United States and is a randomized double-blind, placebo-controlled safety, tolerability,
pharmacokinetic and efficacy study of oral liquid ANAVEX<sup>®</sup>2-73 formulation to treat Rett syndrome. Pharmacokinetic
and dose findings will be investigated in a total of 21 patients over a 7-week treatment period including ANAVEX<sup>®</sup>2-73-specific
genomic precision medicine biomarkers. All patients who participate in the study will be eligible to receive ANAVEX<sup>®</sup>2-73
under a voluntary open label extension protocol. Primary and secondary endpoints include safety as well as Rett syndrome conditions
such as cognitive impairment, motor impairment, behavioral symptoms and seizure activity. The ANAVEX<sup>®</sup>2-73 Phase
2 Rett syndrome study designs incorporate genomic precision medicine biomarkers identified in the ANAVEX<sup>®</sup>2-73 Phase
2a Alzheimer’s disease study.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In June 2019, we commenced the second Phase
2 study of ANAVEX<sup>®</sup>2-73 for the treatment of Rett syndrome, called the AVATAR study. This study is taking place in
Australia using a convenient once-daily oral liquid ANAVEX<sup>®</sup>2-73 formulation. Similar to the United States-based
Phase 2 study for Rett syndrome, the study will evaluate the safety and efficacy of ANAVEX<sup>®</sup>2-73 in approximately
33 patients over a 7-week treatment period including ANAVEX<sup>®</sup>2-73 specific precision medicine biomarkers. All patients
who participate in the study will be eligible to receive ANAVEX<sup>®</sup>2-73 under a voluntary open label extension protocol.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In September 2019, we announced approval
from the Australian Human Research Ethics Committee to commence the third study of ANAVEX<sup>®</sup>2-73 for the treatment
of Rett syndrome, called the EXCELLENCE study. Similar to the AVATAR study, this study is taking place in Australia and is using
a convenient once-daily oral liquid ANAVEX<sup>®</sup>2-73 formulation. The study will evaluate the safety and efficacy of
ANAVEX<sup>®</sup>2-73 in approximately 69 pediatric patients, aged 5 to 18, over a 12-week treatment period incorporating
ANAVEX<sup>®</sup>2-73 specific precision medicine biomarkers. All patients who participate in the study will be eligible to
receive ANAVEX<sup>®</sup>2-73 under a voluntary open label extension protocol.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
<!-- Field: Page; Sequence: 7; Value: 1 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Parkinson’s Disease</i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In September 2016, we presented positive
preclinical data for ANAVEX<sup>®</sup>2-73 in Parkinson’s disease, which demonstrated significant improvements on all
measures: behavioral, histopathological, and neuroinflammatory endpoints. The study was funded by the Michael J. Fox Foundation.
Additional data was announced in October 2017 from the model for experimental parkinsonism. The data presented indicates that ANAVEX<sup>®</sup>2-73
induces robust neurorestoration in experimental parkinsonism. The encouraging results we have gathered in this model, coupled with
the favorable profile of this compound in the Alzheimer’s disease trial, support the notion that ANAVEX<sup>®</sup>2-73
is a promising clinical candidate drug for Parkinson’s disease.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In October 2018, we initiated a double-blind,
randomized, placebo-controlled Phase 2 trial with ANAVEX<sup>®</sup>2-73 in Parkinson’s Disease Dementia (PDD), which
will study the effect of the compound on both the cognitive and motor impairment of Parkinson’s disease. The Phase 2 study
will enroll approximately 120 patients for 14 weeks, randomized 1:1:1 to two different ANAVEX<sup>®</sup>2-73 doses or placebo.
The ANAVEX<sup>®</sup>2-73 Phase 2 PDD study design incorporates genomic precision medicine biomarkers identified in the ANAVEX<sup>®</sup>2-73
Phase 2a study. The study is currently taking place in Spain and Australia.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our Pipeline</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our research and development pipeline includes
ANAVEX<sup>®</sup>2-73 currently in three different clinical studies, and several other compounds in different stages of pre-clinical
study.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our proprietary SIGMACEPTOR™ Discovery
Platform produced small molecule drug candidates with unique modes of action, based on our understanding of sigma receptors. Sigma
receptors may be targets for therapeutics to combat many human diseases, both of neurodegenerative nature, including Alzheimer’s
disease, as well as of neurodevelopmental nature, like Rett syndrome. When bound by the appropriate ligands, sigma receptors influence
the functioning of multiple biochemical signals that are involved in the pathogenesis (origin or development) of disease.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Compounds that have been subjects of our
research include the following:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ANAVEX<sup>®</sup>2-73</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ANAVEX<sup>®</sup>2-73 may offer a
disease-modifying approach in neurodegenerative and neurodevelopmental diseases by activation of sigma-1 receptors.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In Rett syndrome, administration of ANAVEX<sup>®</sup>2-73
resulted in both significant and dose related improvements in an array of behavioral paradigms in the MECP2 HET Rett syndrome disease
model. In addition, in a further experiment sponsored by Rettsyndrome.org, ANAVEX<sup>®</sup>2-73 was evaluated in automatic
visual response and respiration tests in 7-month old mice, an age at which advanced pathology is evident. Vehicle-treated MECP2
mice demonstrated fewer automatic visual responses than wild-type mice. Treatment with ANAVEX<sup>®</sup>2-73 for four weeks
significantly increased the automatic visual response in the MECP2 Rett syndrome disease mouse. Additionally, chronic oral dosing
daily for 6.5 weeks of ANAVEX<sup>®</sup>2-73 starting at ~5.5 weeks of age was conducted in the MECP2 HET Rett syndrome disease
mouse model assessed the different aspects of muscular coordination, balance, motor learning and muscular strengths, some of the
core deficits observed in Rett syndrome. Administration of ANAVEX<sup>®</sup>2-73 resulted in both significant and dose related
improvements in an array of these behavioral paradigms in the MECP2 HET Rett syndrome disease model.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In March 2019, we commenced the first Phase
2 clinical trial in a planned Rett syndrome program of ANAVEX<sup>®</sup>2-73 for the treatment of Rett syndrome. The studies
will be conducted in a range of patient age demographics and geographic regions, as more fully described above under <i>Clinical
Studies Overview – Rett Syndrome</i>.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<!-- Field: Page; Sequence: 8; Value: 1 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 2016 and June 2016, the FDA granted
Orphan Drug Designation to ANAVEX<sup>®</sup>2-73 for the treatment of Rett syndrome and infantile spasms, respectively. Further,
in November 2019, the FDA granted to ANAVEX<sup>®</sup>2-73 the Rare Pediatric Disease (RPD) designation for the treatment
of Rett syndrome. The RPD designation provides priority review by the FDA to encourage the development of treatments for rare pediatric
diseases.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For Parkinson’s disease, data demonstrates
significant improvements and restoration of function in a disease modifying animal model of Parkinson’s disease. Significant
improvements were seen on all measures tested: behavioral, histopathological, and neuroinflammatory endpoints. In July 2018 the
Company received approval from the Spanish Agency for Medicinal Products and Medical Devices (AEMPS), to initiate its Phase 2,
double-blind, placebo-controlled 14-week trial of the safety and efficacy of ANAVEX<sup>®</sup>2-73 for the treatment of Parkinson’s
disease dementia. The Phase 2 study commenced in October 2018 and will enroll 120 patients, randomized 1:1:1 to two different ANAVEX<sup>®</sup>2-73
doses or placebo, in up to 24 clinical study sites across Spain and Australia.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In Alzheimer’s disease (AD) animal
models, ANAVEX<sup>®</sup>2-73 has shown pharmacological, histological and behavioral evidence as a potential neuroprotective,
anti-amnesic, anti-convulsive and anti-depressive therapeutic agent, due to its potent affinity to sigma-1 receptors and moderate
affinities to M1-4 type muscarinic receptors. In addition, ANAVEX<sup>®</sup>2-73 has shown a potential dual mechanism which
may impact both amyloid and tau pathology. In a transgenic AD animal model Tg2576, ANAVEX<sup>®</sup>2-73 induced a statistically
significant neuroprotective effect against the development of oxidative stress in the mouse brain, as well as significantly increased
the expression of functional and synaptic plasticity markers that is apparently amyloid-beta independent. It also statistically
alleviated the learning and memory deficits developed over time in the animals, regardless of sex, both in terms of spatial working
memory and long-term spatial reference memory.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based on the results of pre-clinical testing,
we initiated and completed a Phase 1 single ascending dose (SAD) clinical trial of ANAVEX<sup>®</sup>2-73. In this Phase 1
SAD trial, the maximum tolerated single dose was defined per protocol as 55-60 mg. This dose is above the equivalent dose shown
to have positive effects in mouse models of AD. There were no significant changes in laboratory or electrocardiogram (ECG) parameters.
ANAVEX<sup>®</sup>2-73 was well tolerated below the 55-60 mg dose with only mild adverse events in some subjects. Observed
adverse events at doses above the maximum tolerated single dose included headache and dizziness, which were moderate in severity
and reversible. These side effects are often seen with drugs that target CNS conditions, including AD.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The ANAVEX<sup>®</sup>2-73 Phase 1
SAD trial was conducted as a randomized, placebo-controlled study. Healthy male volunteers between the ages of 18 and 55 received
single, ascending oral doses over the course of the trial. Study endpoints included safety and tolerability together with pharmacokinetic
parameters. Pharmacokinetics includes the absorption and distribution of a drug, the rate at which a drug enters the blood and
the duration of its effect, as well as chemical changes of the substance in the body. This study was conducted in Germany in collaboration
with ABX-CRO, a clinical research organization that has conducted several Alzheimer’s disease studies, and the Technical
University of Dresden.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2014, a Phase 2a clinical trial
was initiated for ANAVEX<sup>®</sup>2-73, for the treatment of Alzheimer’s disease. The open-label randomized trial was
designed to assess the safety and exploratory efficacy of ANAVEX<sup>®</sup>2-73 in 32 patients with mild-to-moderate Alzheimer’s
disease. ANAVEX<sup>®</sup>2-73 targets sigma-1 and muscarinic receptors, which have been shown in preclinical studies to reduce
stress levels in the brain believed to restore cellular homeostasis and to reverse the pathological hallmarks observed in Alzheimer’s
disease.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<!-- Field: Page; Sequence: 9; Value: 1 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Phase 2a study met both primary and
secondary objectives of the study. The 31-week preliminary exploratory safety and efficacy data from the Phase
2a study of ANAVEX<sup>®</sup>2-73 in Alzheimer’s patients, with most receiving also donepezil, the current standard
of care, demonstrated favorable safety, maximum tolerated dose, positive dose response, sustained efficacy response
through 31 weeks for both cognitive and functional measures, as well as positive unexpected therapeutic response events. ANAVEX<sup>®</sup>2-73
continued to demonstrate a favorable adverse event (AE) profile through 31 weeks in a patient population of elderly Alzheimer’s
patients with varying degrees of physical fragility. The most common side effects across all AE categories tended to be of
mild severity grade 1 and were resolved with dose reductions that were anticipated within the adaptive design of the study
protocol.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Through 57 weeks,
Alzheimer’s patients taking a daily oral dose between 10mg and 50mg of ANAVEX<sup>®</sup>2-73 was well tolerated. There
were no clinically significant treatment-related adverse events and no serious adverse events. Despite non-optimized dosing of
ANAVEX<sup>®</sup>2-73 throughout the 57-week study, continued significant improvements from baseline of cognitive, functional
and behavioral scores in a group of patients were observed, respectively. This data was analyzed using refined mathematical modeling
methods in conjunction with the detailed pharmacokinetic (PK) information.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In October 2017,
we presented positive PK and PD data from the Phase 2a study, which established a concentration-effect relationship between ANAVEX<sup>®</sup>2-73
and study measurements. These measures, obtained from all patients who participated in the entire 57 weeks, include exploratory
cognitive and functional scores as well as biomarker signals of brain activity. Additionally, the study appears to show that ANAVEX<sup>®</sup>2-73
activity is enhanced by its active metabolite (ANAVEX19-144), which also targets the sigma-1 receptor and has a half-life approximately
twice as long as the parent molecule.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Pre-specified
exploratory analyses included the cognitive (MMSE) and the functional (ADCS-ADL) changes from baseline. A continued stabilization
of both cognitive and functional measures in patients treated with ANAVEX<sup>®</sup>2-73 was observed. This correlation was
positive within all measured scores (MMSE, ADCS-ADL, Cogstate, HAM-D and EEG/ERP).</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In July 2018,
we presented the results of a genomic DNA and RNA evaluation of the participants in the Phase 2a study. More than 33,000 genes
were analyzed using unbiased, data driven, machine learning, artificial intelligence (AI) system for analyzing DNA &amp; RNA data
in patients exposed to ANAVEX<sup>®</sup>2-73. The analysis identified genetic variants that impacted response to ANAVEX<sup>®</sup>2-73,
among them variants related to the Sigma-1 receptor (SIGMAR1), the target for ANAVEX<sup>®</sup>2-73. Results showed that study
participants without the SIGMAR1 (rs1800866) variants, which is about 80 percent of the population worldwide, demonstrated improved
cognitive (MMSE) and the functional (ADCS-ADL) scores. The results from this evaluation may enable a precision medicine approach,
since these signatures can now be applied to neurological indications tested in clinical studies with ANAVEX<sup>®</sup>2-73
including Alzheimer’s disease, Parkinson’s disease dementia and Rett syndrome.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">ANAVEX<sup>®</sup>2-73
data presented met prerequisite information in order to progress into a Phase 2b/3 placebo-controlled study. On July 2, 2018, the
Human Research Ethics Committee in Australia approved the initiation of our Phase 2b/3, double-blind, randomized, placebo-controlled
48-week safety and efficacy trial of ANAVEX<sup>®</sup>2-73 for the treatment of early Alzheimer’s disease. This Phase
2b/3 study design incorporates inclusion of genomic precision medicine biomarkers identified in the ANAVEX<sup>®</sup>2-73
Phase 2a study. The Phase 2b/3 study, which is expected to enroll approximately 450 patients, randomized 1:1:1 to either two different
ANAVEX<sup>®</sup>2-73 doses or placebo, commenced in October 2018.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Preclinical data also validates ANAVEX<sup>®</sup>2-73
as a prospective platform drug for other neurodegenerative diseases beyond Alzheimer’s disease, Parkinson’s disease
or Rett syndrome, more specifically, epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis and,
more recently, tuberous sclerosis complex (TSC). ANAVEX<sup>®</sup>2-73 demonstrated significant improvements in all of these
indications in the respective preclinical animal models.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<!-- Field: Page; Sequence: 10; Value: 1 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In a study sponsored by the Foundation
for Angelman Syndrome, ANAVEX<sup>®</sup>2-73 was assessed in a mouse model for the development of audiogenic seizures.  The
results indicated that ANAVEX<sup>®</sup>2-73 administration significantly reduced audiogenic-induced seizures. In a study
sponsored by FRAXA Research Foundation regarding Fragile X syndrome, data demonstrated that ANAVEX<sup>®</sup>2-73 restored
hippocampal brain-derived neurotrophic factor (BDNF) expression to normal levels. BDNF under-expression has been observed in many
neurodevelopmental and neurodegenerative pathologies. BDNF signaling promotes maturation of both excitatory and inhibitory synapses.
ANAVEX<sup>®</sup>2-73 normalization of BDNF expression could be a contributing factor for the positive data observed in both
neurodevelopmental and neurodegenerative disorders like Angelman and Fragile X syndromes.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Preclinical data presented also indicates
that ANAVEX<sup>®</sup>2-73 demonstrates protective effects of mitochondrial enzyme complexes during pathological conditions,
which, if impaired, are believed to play a role in the pathogenesis of neurodegenerative and neurodevelopmental diseases.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Preclinical data on ANAVEX<sup>®</sup>2-73
related to multiple sclerosis indicates that ANAVEX<sup>®</sup>2-73 may promote remyelination in multiple sclerosis disease.
Further, data also demonstrates that ANAVEX<sup>®</sup>2-73 provides protection for oligodendrocytes (“OL’s”)
and oligodendrocyte precursor cells (“OPC’s”), as well as central nervous system neurons in addition to helping
repair by increasing OPC proliferation and maturation in tissue culture.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In March 2018, we presented preclinical
data of ANAVEX<sup>®</sup>2-73 in a genetic mouse model of tuberous sclerosis complex (“TSC”). TSC is a rare genetic
disorder characterized by the growth of numerous benign tumors in many parts of the body with a high incidence of seizures. The
new preclinical data demonstrates that treatment with ANAVEX<sup>®</sup>2-73 significantly increases survival and reduces seizures.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ANAVEX<sup>®</sup>3-71</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ANAVEX<sup>®</sup>3-71 is a preclinical
drug candidate with a novel mechanism of action via sigma-1 receptor activation and M1 muscarinic allosteric modulation, which
has been shown to enhance neuroprotection and cognition in Alzheimer’s disease models. ANAVEX<sup>®</sup>3-71 is a CNS-penetrable
mono-therapy that bridges treatment of both cognitive impairments with disease modifications. It is highly effective in very small
doses against the major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau
pathologies, and also has beneficial effects on inflammation and mitochondrial dysfunctions. ANAVEX<sup>®</sup>3-71 indicates
extensive therapeutic advantages in Alzheimer’s and other protein-aggregation-related diseases given its ability to enhance
neuroprotection and cognition via sigma-1 receptor activation and M1 muscarinic allosteric modulation.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A preclinical study examined the response
of ANAVEX<sup>®</sup>3-71 in aged transgenic animal models and showed a significant reduction in the rate of cognitive deficit,
amyloid beta pathology and inflammation with the administration of ANAVEX 3-71. In April 2016, the FDA granted Orphan Drug Designation
to ANAVEX<sup>®</sup>3-71 for the treatment of Frontotemporal dementia (FTD).</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During pathological conditions ANAVEX<sup>®</sup>3-71
demonstrated the formation of new synapses between neurons (synaptogenesis) without causing an abnormal increase in the number
of astrocytes. In neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease, synaptogenesis is believed
to be impaired. Additional preclinical data presented also indicates that in addition to reducing oxidative stress, ANAVEX<sup>®</sup>3-71
demonstrates protective effects of mitochondrial enzyme complexes during pathological conditions, which, if impaired, are believed
to play a role in the pathogenesis of neurodegenerative and neurodevelopmental diseases.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ANAVEX<sup>®</sup>1-41</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ANAVEX<sup>®</sup>1-41 is a sigma-1
agonist. Pre-clinical tests revealed significant neuroprotective benefits (i.e., protects nerve cells from degeneration or death)
through the modulation of endoplasmic reticulum, mitochondrial and oxidative stress, which damages and impairs cell viability.
In addition, in animal models, ANAVEX<sup>®</sup>1-41 prevented the expression of caspase-3, an enzyme that plays a key role
in apoptosis (programmed cell death) and loss of cells in the hippocampus, the part of the brain that regulates learning, emotion
and memory. These activities involve both muscarinic and sigma-1 receptor systems through a novel mechanism of action.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<!-- Field: Page; Sequence: 11; Value: 1 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Preclinical data presented also indicates
that ANAVEX<sup>®</sup>1-41 demonstrates protective effects of mitochondrial enzyme complexes during pathological conditions,
which, if impaired, are believed to play a role in the pathogenesis of neurodegenerative and neurodevelopmental diseases.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ANAVEX<sup>®</sup>1066</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ANAVEX<sup>®</sup>1066, a mixed sigma-1/sigma-2
ligand is designed for the potential treatment of neuropathic and visceral pain. ANAVEX<sup>®</sup>1066 was tested in two preclinical
models of neuropathic and visceral pain that have been extensively validated in rats. In the chronic constriction injury model
of neuropathic pain, a single oral administration of ANAVEX<sup>®</sup>1066 dose-dependently restored the nociceptive threshold
in the affected paw to normal levels while leaving the contralateral healthy paw unchanged. Efficacy was rapid and remained significant
for two hours. In a model of visceral pain, chronic colonic hypersensitivity was induced by injection of an inflammatory agent
directly into the colon and a single oral administration of ANAVEX<sup>®</sup>1066 returned the nociceptive threshold to control
levels in a dose-dependent manner. Companion studies in rats demonstrated the lack of any effects on normal gastrointestinal transit
with ANAVEX<sup>®</sup>1066 and a favorable safety profile in a battery of behavioral measures.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our compounds are in the pre-clinical and
clinical testing stages of development, and there is no guarantee that the activity demonstrated in pre-clinical models will be
shown in human testing.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ANAVEX<sup>®</sup>1037 </b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ANAVEX<sup>®</sup>1037 is designed
for the treatment of prostate and pancreatic cancer. It is a low molecular weight, synthetic compound exhibiting high affinity
for sigma-1 receptors at nanomolar levels and moderate affinity for sigma-2 receptors and sodium channels at micromolar levels.
In advanced pre-clinical studies, this compound revealed antitumor potential. It has also been shown to selectively kill human
cancer cells without affecting normal/healthy cells and also to significantly suppress tumor growth in immune-deficient mice models.
Scientific publications highlight the possibility that these ligands may stop tumor growth and induce selective cell death in various
tumor cell lines. Sigma receptors are highly expressed in different tumor cell types. Binding by appropriate sigma-1 and/or sigma-2
ligands can induce selective apoptosis. In addition, through tumor cell membrane reorganization and interactions with ion channels,
our drug candidates may play an important role in inhibiting the processes of metastasis (spreading of cancer cells from the original
site to other parts of the body), angiogenesis (the formation of new blood vessels) and tumor cell proliferation.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We continue to identify and initiate discussions
with potential strategic and commercial partners to most effectively advance our programs and realize maximum shareholder value.
Further, we may acquire or develop new intellectual property and assign, license, or otherwise transfer our intellectual property
to further our goals.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our Target Indications</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have developed compounds with potential
application to two broad categories and several specific indications. including:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Central Nervous System Diseases</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">Alzheimer’s disease – In 2019,
an estimated 5.8 million Americans were suffering from Alzheimer’s disease. The Alzheimer’s Association<sup>®</sup>
reports that by 2025, 7.2 million Americans will be afflicted by the disease, about a 24 percent increase from currently affected
patients. Medications on the market today treat only the symptoms of Alzheimer’s disease and do not have the ability to stop
its onset or its progression. There is an urgent and unmet need for both a disease modifying cure for Alzheimer’s disease
as well as for better symptomatic treatments. </font></td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p>
<!-- Field: Page; Sequence: 12; Value: 1 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">Parkinson’s disease – Parkinson’s
disease is a progressive disease of the nervous system marked by tremors, muscular rigidity, and slow, imprecise movement. It is
associated with degeneration of the basal ganglia of the brain and a deficiency of the neurotransmitter dopamine. Parkinson’s
disease afflicts more than 10 million people worldwide, typically middle-aged and elderly people. The Parkinson’s disease
market is set to expand to $3.2 billion by 2021, according to business intelligence provider GBI Research.</font></td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">Rett syndrome - Rett syndrome is a rare
X-linked genetic neurological and developmental disorder that affects the way the brain develops, including protein transcription,
which is altered and as a result leads to severe disruptions in neuronal homeostasis. It is considered a rare, progressive neurodevelopmental
disorder and is caused by a single mutation in the MECP2 gene. Because males have a different chromosome combination from females,
boys who have the genetic MECP2 mutation are affected in devastating ways. Most of them die before birth or in early infancy. For
females who survive infancy, Rett syndrome leads to severe impairments, affecting nearly every aspect of the child’s life;
severe mental retardation, their ability to speak, walk and eat, sleeping problems, seizures and even the ability to breathe easily.
Rett syndrome affects approximately 1 in every 10,000-15,000 females.</font></td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">Depression - Depression is a major cause
of morbidity worldwide according to the World Health Organization. Pharmaceutical treatment for depression is dominated by blockbuster
brands, with the leading nine brands accounting for approximately 75% of total sales. However, the dominance of the leading brands
is waning, largely due to the effects of patent expiration and generic competition. </font></td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">Epilepsy - Epilepsy is a common chronic
neurological disorder characterized by recurrent unprovoked seizures. These seizures are transient signs and/or symptoms of abnormal,
excessive or synchronous neuronal activity in the brain. According to the Centers for Disease Control and Prevention, epilepsy
affects 3.4 million Americans. Today, epilepsy is often controlled, but not cured, with medication that is categorized as older
traditional anti-epileptic drugs and second generation anti-epileptic drugs. Because epilepsy afflicts sufferers in different ways,
there is a need for drugs used in combination with both traditional anti-epileptic drugs and second generation anti-epileptic drugs.</font></td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">Neuropathic Pain – We define neuralgia,
or neuropathic pain, as pain that is not related to activation of pain receptor cells in any part of the body. Neuralgia is more
difficult to treat than some other types of pain because it does not respond well to normal pain medications. Special medications
have become more specific to neuralgia and typically fall under the category of membrane stabilizing drugs or antidepressants.</font></td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cancer</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">Malignant Melanoma - Predominantly a skin
cancer, malignant melanoma can also occur in melanocytes found in the bowel and the eye. Malignant melanoma accounts for 75% of
all deaths associated with skin cancer. The treatment includes surgical removal of the tumor, adjuvant treatment, chemo and immunotherapy,
or radiation therapy. According to IMS Health the worldwide malignant melanoma market is expected to grow to $4.4 billion by 2022.</font></td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">Prostate Cancer – Specific to men,
prostate cancer is a form of cancer that develops in the prostate, a gland in the male reproductive system. The cancer cells may
metastasize from the prostate to other parts of the body, particularly the bones and lymph nodes. Drug therapeutics for prostate
cancer are expected to increase to nearly $13.5 billion in 2024 according to Datamonitor Healthcare.</font></td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p>
<!-- Field: Page; Sequence: 13; Value: 1 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">Pancreatic Cancer - Pancreatic cancer
is a malignant neoplasm of the pancreas. In the United States, approximately 55,000 new cases of pancreatic cancer will be diagnosed
this year and approximately 44,000 patients will die as a result of their cancer, according to the American Cancer Society. Sales
predictions by GBI Research forecast that the market for the pharmaceutical treatment of pancreatic cancer in the United States
and five largest European countries will increase to $2.9 billion by 2021.</font></td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Competition</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The pharmaceutical industry is intensely
competitive.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At this time, our competitors are other
biomedical development companies that are trying to discover and develop compounds to be used in the treatment of Alzheimer’s
disease and other CNS diseases, and those companies already doing so. Those companies include Biogen (NASDAQ:BIIB), Perrigo Company
Plc (NYSE:PRGO), Pfizer Inc. (NYSE:PFE), Allergan Plc (NYSE:AGN), Novartis AG (NYSE:NVS), GlaxoSmithKline Plc (NYSE:GSK), Merck
&amp; Co. Inc. (NYSE:MRK), Eli Lilly &amp; Co. (NYSE: LLY), Johnson &amp; Johnson (NYSE:JNJ) and Roche Holding AG (VTX:ROG). For
additional discussion of the risks related to competition, see Item 1A “Risk Factors.”</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Patents, Trademarks and Intellectual
Property </i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We hold ownership or exclusive rights to
eight U.S. patents, eight U.S. patent applications, and various PCT or ex-U.S. patent applications relating to our drug candidates,
methods associated therewith, and to our research programs.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We own one issued U.S. patent entitled
“ANAVEX<sup>®</sup>2-73 and certain anticholinesterase inhibitors composition and method for neuroprotection” claims
a composition of matter of ANAVEX®2-73 directed to a novel and synergistic neuroprotective compound combined with donepezil
and other cholinesterase inhibitors.  This patent is expected to expire in June 2034, absent any patent term extension for
regulatory delays. We own two issued U.S. patents each with claims directed to crystalline forms of ANAVEX®2-73. The first
of these two patents claims crystalline forms of ANAVEX®2-73, dosage forms and compositions containing crystalline ANAVEX®2-73,
and methods of treatment for Alzheimer’s disease using them. This patent is expected to expire in July 2036, absent any patent
term extension for regulatory delays. The second of these two patents claims pharmaceutical compositions containing a crystalline
form of ANAVEX®2-73, and methods of treatment for Alzheimer’s disease using the compositions. This patent is expected
to expire in June 2037, absent any patent term extension for regulatory delays. We also own an issued U.S. patent that claims methods
and dosage forms for treating seizures, the dosage forms containing a low-dose anti-epilepsy drug combined with either: (i) ANAVEX®2-73
and its active metabolite ANAVEX®19-144; or (ii) ANAVEX®19-144. This patent is expected to expire in October 2035, absent
any patent term extension for regulatory delays. In addition, we own one issued U.S. Patent with claims directed to methods of
treating melanoma with a compound related to ANAVEX<sup>®</sup>2-73. This patent is expected to expire in February 2030, absent
any patent term extension for regulatory delays.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also own one issued patent with claims
directed to methods for treating or preventing pain with ANAVEX<sup>®</sup>1066. This patent is expected to expire in November
2036, absent any patent term extension for regulatory delays.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With regard to ANAVEX<sup>®</sup>3-71,
we own exclusive rights to two issued U.S. patents with claims respectively directed to the ANAVEX<sup>®</sup>3-71 compound
and methods of treating various diseases including Alzheimer’s with the same. These patents are expected to expire in April
2030, and January 2030, respectively, absent any patent term extension for regulatory delays. We also own exclusive rights to related
patents or applications that are granted or pending in Australia, Canada, China, Europe, Japan, Korea, New Zealand, Russia, and
South Africa, and are expected to expire in January 2030.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<!-- Field: Page; Sequence: 14; Value: 1 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also own other patent applications directed
to enantiomers, formulations and uses that may provide additional protection for one or more of our product candidates.  </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We regard patents and other intellectual
property rights as corporate assets. Accordingly, we attempt to optimize the value of intellectual property in developing our business
strategy including the selective development, protection, and exploitation of our intellectual property rights. In addition to
filings made with intellectual property authorities, we protect our intellectual property and confidential information by means
of carefully considered processes of communication and the sharing of information, and by the use of confidentiality and non-disclosure
agreements and provisions for the same in contractor’s agreements. While no agreement offers absolute protection, such agreements
provide some form of recourse in the event of disclosure, or anticipated disclosure.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our intellectual property position, like
that of many biomedical companies, is uncertain and involves complex legal and technical questions for which important legal principles
are unresolved. For more information regarding challenges to our existing or future patents, see Item 1A “Risk Factors.”</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Government Approval</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Regulation by governmental authorities
in the United States and foreign countries is a significant factor in the development, manufacture, and expected marketing of our
potential drug compounds and in potential future research and development activities. The nature and extent to which such regulation
will apply to us will vary depending on the nature of any potential drug compounds developed. We anticipate that all of our potential
drug compounds will require regulatory approval by governmental agencies prior to commercialization.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The process of obtaining these approvals
and the subsequent compliance with the appropriate federal statutes and regulations requires substantial time and financial resources.
For more information regarding the risks related to obtaining government approvals, see Item 1A “Risk Factors.”</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The steps ordinarily required before a
new drug may be marketed in the United States, which are similar to steps required in most other countries, include:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">non-clinical laboratory tests, non-clinical
studies in animals, formulation studies and the submission to the FDA of an IND;</font></td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">adequate and well-controlled clinical
trials to establish the safety and efficacy of the drug;</font></td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">the submission of a new drug application,
or NDA, or biologic license application, or BLA, to the FDA; and</font></td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">FDA review and approval of the New Drug
Application (NDA) or <font style="background-color: white">biologics license application (</font>BLA).</font></td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Non-clinical tests include laboratory evaluation
of potential drug compound chemistry, formulation and toxicity, as well as animal studies. The results of non-clinical testing
are submitted to the FDA as part of an IND. A 30-day waiting period after the filing of each IND is required prior to commencement
of clinical testing in humans. At any time during the 30-day period or at any time thereafter, the FDA may halt proposed or ongoing
clinical trials until the FDA authorizes trials under specified terms. The FDA may require additional animal testing after an initial
IND is approved and prior to Phase III trials.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Clinical trials to support NDAs are typically
conducted in three sequential phases, although the phases may overlap. During Phase I, clinical trials are conducted with a small
number of subjects to assess metabolism, pharmacokinetics, and pharmacological actions and safety, including side effects associated
with increasing doses. Phase II usually involves studies in a limited patient population to assess the efficacy of the drug in
specific, targeted indications; assess dosage tolerance and optimal dosage; and identify possible adverse effects and safety risks.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<!-- Field: Page; Sequence: 15; Value: 1 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If a compound is found to be potentially
effective and to have an acceptable safety profile in Phase I and II evaluations, Phase III trials are undertaken to further demonstrate
clinical efficacy and to further test for safety within an expanded patient population at geographically dispersed clinical trial
sites.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">After successful completion of the required
clinical trials, a NDA is generally submitted. The FDA may request additional information before accepting the NDA for filing,
in which case the NDA must be resubmitted with the additional information. Once the submission has been accepted for filing, the
FDA reviews the NDA and responds to the applicant. The FDA’s requests for additional information or clarification often significantly
extends the review process. The FDA may refer the NDA to an appropriate advisory committee for review, evaluation, and recommendation
as to whether the NDA should be approved, although the FDA is not bound by the recommendation of an advisory committee.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the United States Orphan Drug Act,
a sponsor may request that the FDA designate a drug intended to treat a “rare disease or condition” as an “orphan
drug.” A “rare disease or condition” is one which affects less than 200,000 people in the United States, or which
affects more than 200,000 people, but for which the cost of developing and making available the product is not expected to be recovered
from sales of the product in the United States. Upon the approval of the first NDA or BLA for a drug designated as an orphan drug
for a specified indication, the sponsor of that NDA or BLA is entitled to seven years of exclusive marketing rights in the United
States unless the sponsor cannot assure the availability of sufficient quantities to meet the needs of persons with the disease.
However, orphan drug status is particular to the approved indication and does not prevent another company from seeking approval
of an off-patent drug that has other labeled indications that are not under orphan or other exclusivities. Orphan drugs may also
be eligible for federal income tax credits for costs associated with the drugs’ development. In order to increase the development
and marketing of drugs for rare disorders, regulatory bodies outside the United States have enacted regulations similar to the
Orphan Drug Act.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sales outside the United States of potential
drug compounds we develop will also be subject to foreign regulatory requirements governing human clinical trials and marketing
for drugs. The requirements vary widely from country to country, but typically the registration and approval process takes several
years and requires significant resources. In most cases, if the FDA has not approved a potential drug compound for sale in the
United States, the potential drug compound may be exported for sale outside of the United States, only if it has been approved
in any one of the following: the European Union, Canada, Australia, New Zealand, Japan, Israel, Switzerland and South Africa. There
are specific FDA regulations that govern this process.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Research and Development Expenses</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Historically, a significant portion of
our operating expenses has related to research and development. See our Consolidated Financial Statements contained elsewhere in
this Annual Report for costs and expenses related to research and development, and other financial information for fiscal years
2019 and 2018.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Scientific Advisors </i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are advised by scientists and physicians
with experience relevant to our Company and our product candidates. Our scientific advisors include clinicians and scientists who
are affiliated with a number of highly regarded medical institutions.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<!-- Field: Page; Sequence: 16; Value: 1 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Employees</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We currently have sixteen full-time employees,
and we retain several independent contractors on a regular or as-needed basis. We believe that we have good relations with our
employees.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Available Information</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our internet website address is www.anavex.com.
Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed
or furnished pursuant to section 13(a) or 15(d) of the Exchange Act are available free of charge through our website. We include
our website address in this report only as an inactive textual reference and do not intend it to be an active link to our website.
The contents of our website are not incorporated into this report.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-style: normal"><a name="main_003"></a></section><section class="edgaug_item1a" id="edgaug_item1a_id">ITEM 1A. RISK FACTORS</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to other information in this
Annual Report on Form 10-K, the following risk factors should be carefully considered in evaluating our business because such factors
may have a significant impact on our business, operating results, liquidity and financial condition. As a result of the risk factors
set forth below, actual results could differ materially from those projected in any forward-looking statements. Additional risks
and uncertainties not presently known to us, or that we currently consider to be immaterial, may also impact our business, operating
results, liquidity and financial condition. If any such risks occur, our business, operating results, liquidity and financial condition
could be materially affected in an adverse manner. Under such circumstances, the trading price of our securities could decline,
and you may lose all or part of your investment.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Risks Related to our Company</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>
<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have had a history of losses and no revenue, and we are dependent on financing cash flows to support our research and development
activities.</i></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">Since inception through September 30,
2019, we have an accumulated a deficit of over $133 million. We can offer no assurance that we will ever operate profitably or
that we will generate positive cash flow in the future. To date, we have not generated any revenues from our operations. As a
result, our management expects the business to continue to experience negative cash flows for the foreseeable future and cannot
predict when, if ever, our business might become profitable. We believe that our existing cash and cash equivalents, along with
existing financial commitments from third parties, will be sufficient to meet our cash commitments for in excess of two years
after the date of this filing. The assumptions upon which we have based our estimates are routinely evaluated and may be subject
to change. The actual amount of our expenditures will vary depending upon a number of factors including but not limited to
the design, timing and duration of future clinical trials, the progress of our research and development programs and the level
of financial resources available. We have the ability to adjust our operating plan spending levels based on the timing of future
clinical trials. We will need to raise additional funds, and such funds may not be available on commercially acceptable terms,
if at all. If we are unable to raise funds on acceptable terms, we may not be able to execute our business plan, take advantage
of future opportunities, or respond to competitive pressures or unanticipated requirements. This may seriously harm our business,
financial condition and results of operations.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are an early stage pharmaceutical
research and development company and may never be able to successfully develop marketable products or generate any revenue. We
have a very limited relevant operating history upon which an evaluation of our performance and prospects can be made. There is
no assurance that our future operations will result in profits. If we cannot generate sufficient revenues, we may suspend or cease
operations.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are an early stage company and have
not generated any revenues to date and have no operating history. All of our potential drug compounds are in the concept stage
or early clinical development stage. Moreover, we cannot be certain that our research and development efforts will be successful
or, if successful, that our potential drug compounds will ever be approved for sales to pharmaceutical companies or generate commercial
revenues. We have no relevant operating history upon which an evaluation of our performance and prospects can be made. We are subject
to all of the business risks associated with a new enterprise, including, but not limited to, risks of unforeseen capital requirements,
failure of potential drug compounds either in non-clinical testing or in clinical trials, failure to establish business relationships
and competitive disadvantages against larger and more established companies. If we fail to become profitable, we may suspend or
cease operations.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<!-- Field: Page; Sequence: 17; Value: 1 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We will need additional funding and
may be unable to raise additional capital when needed, which would force us to delay, reduce or eliminate our research and development
activities.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will need to raise additional funding
and the current economic conditions may have a negative impact on our ability to raise additional needed capital on terms that
are favorable to our Company or at all. We may not be able to generate significant revenues for several years, if at all. Until
we can generate significant revenues, if ever, we expect to satisfy our future cash needs through equity or debt financing. We
cannot be certain that additional funding will be available on acceptable terms, or at all. If adequate funds are not available,
we may be required to delay, reduce the scope of, or eliminate one or more of our research and development activities.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>
<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><b><i>We have identified a material
weakness in our internal control over financial reporting related to accounting for the Australian research and development incentive
program</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the preparation of our financial statements
for the year ended September 30, 2019, we identified an adjustment regarding our accounting for research and development incentive
income associated with the Australian research and development incentive program. Specifically, previously the Company accounted
for research and development incentive income when received in cash. During the preparation of our financial statements for the
year ended September 30, 2019, we determined, based on a continuing assessment of the Company’s eligibility for the incentive
programs under which it was receiving such income, that the income should have been accrued and recorded earlier, specifically
in the period in which the qualifying research and development expenditures were incurred. The cumulative impact of adjusting the
above noted historical amounts resulted in a decrease in our reported net loss for the year ended September 30, 2018, as well as
an increase in the reported assets as of September 30, 2018. As a result of the adjustment, we identified a material weakness in
our internal control over financial reporting related to the accounting of the Australian research and development incentive program
during the year ended September 30, 2019. Please refer to Item 9A <i>Controls and Procedures</i>.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><b><i>Risks Related to our Business</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Even if we are able to develop our
potential drug compounds, we may not be able to receive regulatory approval, or if approved, we may not be able to generate significant
revenues or successfully commercialize our products, which will adversely affect our financial results and financial condition
and we will have to delay or terminate some or all of our research and development plans which may force us to cease operations.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All of our potential drug compounds will
require extensive additional research and development, including non-clinical testing and clinical trials, as well as regulatory
approvals, before we can market them. In particular, human therapeutic products are subject to rigorous non-clinical and clinical
testing and other approval procedures of the FDA and similar regulatory authorities in other countries. Various federal statutes
and regulations also govern or influence testing, manufacturing, safety, labeling, storage, and record-keeping related to such
products and their marketing. We cannot predict if or when any of the potential drug compounds we intend to develop will be approved
for marketing. There are many reasons that we may fail in our efforts to develop our potential drug compounds. These include:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">the possibility that non-clinical testing
or clinical trials may show that our potential drug compounds are ineffective and/or cause harmful side effects;</font></td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">regulators may not authorize us to commence
or continue a clinical trial or may impose a clinical hold or may limit the conduct of a clinical trial through the imposition
of a partial clinical hold;</font></td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">the number of patients required for clinical
trials for our drug candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate,
participants may drop out of these clinical trials at a higher rate than we anticipate or the duration of these clinical trials
may be longer than we anticipate;</font></td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">our third-party contractors, including
investigators, may fail to meet their contractual obligations to us in a timely manner, or at all, or may fail to comply with regulatory
requirements;</font></td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">our potential drug compounds may prove
to be too expensive to manufacture or administer to patients;</font></td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">our potential drug compounds may fail
to receive necessary regulatory approvals from the United States Food and Drug Administration or foreign regulatory authorities
in a timely manner, or at all;</font></td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">even if our potential drug compounds are
approved, we may not be able to produce them in commercial quantities or at reasonable costs;</font></td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">even if our potential drug compounds are
approved, they may not achieve commercial acceptance;</font></td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">regulatory or governmental authorities
may apply restrictions to any of our potential drug compounds, which could adversely affect their commercial success; and</font></td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">the proprietary rights of other parties
may prevent us or our potential collaborative partners from marketing our potential drug compounds.</font></td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"> </p>
<!-- Field: Page; Sequence: 18; Value: 1 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we fail to develop our potential drug
compounds, our financial results and financial condition will be adversely affected, we will have to delay or terminate some or
all of our research and development plans and may be forced to cease operations.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our research and development plans
will require substantial additional future funding which could impact our operations and financial condition. Without the required
additional funds, we will likely cease operations.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">It will take several years before we can
develop potentially marketable products, if at all. Our research and development plans will require substantial additional capital,
arising from costs to:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">conduct research, non-clinical testing
and human studies;</font></td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">establish pilot scale and commercial scale
manufacturing processes and facilities; and</font></td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">establish and develop quality control,
regulatory, marketing, sales, finance and administrative capabilities to support these programs.</font></td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our future operating and capital needs
will depend on many factors, including:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">the pace of scientific progress in our
research and development programs and the magnitude of these programs;</font></td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">the scope and results of pre-clinical
testing and human studies;</font></td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">the time and costs involved in obtaining
regulatory approvals;</font></td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">the time and costs involved in preparing,
filing, prosecuting, securing, maintaining and enforcing patents;</font></td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">competing technological and market developments;</font></td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">our ability to establish additional collaborations;</font></td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">changes in our existing collaborations;</font></td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">the cost of manufacturing scale-up; and</font></td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">the effectiveness of our commercialization
activities.</font></td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We base our outlook regarding the need
for funds on many uncertain variables. Such uncertainties include the success of our research initiatives, regulatory approvals,
the timing of events outside our direct control such as negotiations with potential strategic partners and other factors. Any of
these uncertain events can significantly change our cash requirements as they determine such one-time events as the receipt or
payment of major milestones and other payments.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additional funds will be required to support
our operations and if we are unable to obtain them on favorable terms, we may be required to cease or reduce further research and
development of our drug product programs, sell some or all our intellectual property, merge with another entity or cease operations.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we fail to demonstrate efficacy
in our non-clinical studies and clinical trials our future business prospects, financial condition and operating results will be
materially adversely affected.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The success of our research and development
efforts will be greatly dependent upon our ability to demonstrate potential drug compound efficacy in non-clinical studies, as
well as in clinical trials. Non-clinical studies involve testing potential drug compounds in appropriate non-human disease models
to demonstrate efficacy and safety. Regulatory agencies evaluate these data carefully before they will approve clinical testing
in humans. If certain non-clinical data reveals potential safety issues or the results are inconsistent with an expectation of
the potential drug compound’s efficacy in humans, the regulatory agencies may require additional more rigorous testing before
allowing human clinical trials. This additional testing will increase program expenses and extend timelines. We may decide to suspend
further testing on our potential drug compounds if, in the judgment of our management and advisors, the non-clinical test results
do not support further development.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<!-- Field: Page; Sequence: 19; Value: 1 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Moreover, success in non-clinical testing
and early clinical trials does not ensure that later clinical trials will be successful, and we cannot be sure that the results
of later clinical trials will replicate the results of prior clinical trials and non-clinical testing. The clinical trial process
may fail to demonstrate that our potential drug compounds are safe for humans and effective for indicated uses. This failure would
cause us to abandon a drug candidate and may delay development of other potential drug compounds. Any delay in, or termination
of, our non-clinical testing or clinical trials will delay the filing of an IND and NDA with the Food and Drug Administration or
the equivalent applications with pharmaceutical regulatory authorities outside the United States and, ultimately, our ability to
commercialize our potential drug compounds and generate product revenues. In addition, we expect that our early clinical trials
will involve small patient populations. Because of the small sample size, the results of these early clinical trials may not be
indicative of future results. Also, the IND process may be extremely costly and may substantially delay the development of our
potential drug compounds. Moreover, positive results of non-clinical tests will not necessarily indicate positive results in subsequent
clinical trials.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Following successful non-clinical testing,
potential drug compounds will need to be tested in a clinical development program to provide data on safety and efficacy prior
to becoming eligible for product approval and licensure by regulatory agencies. From the first human trial through to regulatory
approval can take many years and 10-12 years is not unusual for certain compounds.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If any of our future clinical development
potential drug compounds become the subject of problems, our ability to sustain our development programs will become critically
compromised. For example, efficacy or safety concerns may arise, whether or not justified, that could lead to the suspension or
termination of our clinical programs. Examples of problems that could arise include, among others:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">efficacy or safety concerns with the potential
drug compounds, even if not justified;</font></td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">manufacturing difficulties or concerns;</font></td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">regulatory proceedings subjecting the
potential drug compounds to potential recall;</font></td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">publicity affecting doctor prescription
or patient use of the potential drug compounds;</font></td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">pressure from competitive products; or</font></td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">introduction of more effective treatments.</font></td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each clinical phase is designed to test
attributes of the drug and problems that might result in the termination of the entire clinical plan can be revealed at any time
throughout the overall clinical program. The failure to demonstrate efficacy in our clinical trials would have a material adverse
effect on our future business prospects, financial condition and operating results.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we do not obtain the support of
qualified scientific collaborators, our revenue, growth and profitability will likely be limited, which would have a material adverse
effect on our business.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will need to establish relationships
with leading scientists and research institutions. We believe that such relationships are pivotal to establishing products using
our technologies as a standard of care for various indications. Additionally, although in discussion, there is no assurance that
our current research partners will continue to work with us or that we will be able to attract additional research partners. If
we are not able to establish scientific relationships to assist in our research and development, we may not be able to successfully
develop our potential drug compounds. If this happens, our business will be adversely affected.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<!-- Field: Page; Sequence: 20; Value: 1 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may not be able to develop, market
or generate sales of our products to the extent anticipated. Our business may fail and investors could lose all their investment
in our Company.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Assuming that we are successful in developing
our potential drug compounds and receiving regulatory clearances to market our products, our ability to successfully penetrate
the market and generate sales of those products may be limited by a number of factors, including the following:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">If our competitors receive regulatory
approvals for and begin marketing similar products in the United States, the European Union, Japan and other territories before
we do, greater awareness of their products as compared to ours will cause our competitive position to suffer;</font></td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">Information from our competitors or the
academic community indicating that current products or new products are more effective or offer compelling other benefits than
our future products could impede our market penetration or decrease our future market share; and</font></td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">The pricing and reimbursement environment
for our future products, as well as pricing and reimbursement decisions by our competitors and by payers, may have an effect on
our revenues.</font></td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this happens, our business will be adversely
affected.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>None of our potential drug compounds
may reach the commercial market for a number of reasons and our business may fail.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Successful research and development of
pharmaceutical products is high risk. Most products and development candidates fail to reach the market. Our success depends on
the discovery of new drug compounds that we can commercialize. It is possible that our products may never reach the market for
a number of reasons. They may be found ineffective or may cause harmful side-effects during non-clinical testing or clinical trials
or fail to receive necessary regulatory approvals. We may find that certain products cannot be manufactured at a commercial scale
and, therefore, they may not be economical to produce. Our potential products could also fail to achieve market acceptance or be
precluded from commercialization by proprietary rights of third parties. Our patents, patent applications, trademarks and other
intellectual property may be challenged, and this may delay or prohibit us from effectively commercializing our products. Furthermore,
we do not expect our potential drug compounds to be commercially available for a number of years, if at all. If none of our potential
drug compounds reach the commercial market, our business will likely fail and investors will lose all of their investment in our
Company. If this happens, our business will be adversely affected.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If our competitors succeed in developing
products and technologies faster or that are more effective or with a better profile than our own, or if scientific developments
change our understanding of the potential scope and utility of our potential products, then our technologies and future products
may be rendered undesirable or obsolete.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We face significant competition from industry
participants that are pursuing technologies in similar disease states to those that we are pursuing and are developing pharmaceutical
products that are competitive with our products. Nearly all of our industry competitors have greater capital resources, larger
overall research and development staffs and facilities, and a longer history in drug discovery and development, obtaining regulatory
approval and pharmaceutical product manufacturing and marketing than we do. With these additional resources, our competitors may
be able to respond to the rapid and significant technological changes in the biotechnology and pharmaceutical industries faster
than we can. Our future success will depend in large part on our ability to maintain a competitive position with respect to these
technologies. Rapid technological development, as well as new scientific developments, may result in our products becoming obsolete
before we can recover any of the expenses incurred to develop them. For example, changes in our understanding of the appropriate
population of patients who should be treated with a targeted therapy like we are developing may limit the drug’s market potential
if it is subsequently demonstrated that only certain subsets of patients should be treated with the targeted therapy.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<!-- Field: Page; Sequence: 21; Value: 1 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our reliance on third parties, such
as university laboratories, contract manufacturing organizations and contract or clinical research organizations, may result in
delays in completing, or a failure to complete, non-clinical testing or clinical trials if they fail to perform under our agreements
with them.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the course of product development, we
may engage university laboratories, other biotechnology companies or contract or clinical manufacturing organizations to manufacture
drug material for us to be used in non-clinical and clinical testing and contract research organizations to conduct and manage
non-clinical and clinical studies. If we engage these organizations to help us with our non-clinical and clinical programs, many
important aspects of this process have been and will be out of our direct control. If any of these organizations we may engage
in the future fail to perform their obligations under our agreements with them or fail to perform non-clinical testing and/or clinical
trials in a satisfactory manner, we may face delays in completing our clinical trials, as well as commercialization of any of our
potential drug compounds. Furthermore, any loss or delay in obtaining contracts with such entities may also delay the completion
of our clinical trials, regulatory filings and the potential market approval of our potential drug compounds.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we fail to compete successfully
with respect to partnering, licensing, mergers, acquisitions, joint venture and other collaboration opportunities, we may be limited
in our ability to research and develop our potential drug compounds.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our competitors compete with us to attract
established biotechnology and pharmaceutical companies or organizations for partnering, licensing, mergers, acquisitions, joint
ventures or other collaborations. Collaborations include contracting with academic research institutions for the performance of
specific scientific testing. If our competitors successfully enter into partnering arrangements or license agreements with academic
research institutions, we will then be precluded from pursuing those specific opportunities. Since each of these opportunities
is unique, we may not be able to find a substitute. Other companies have already begun many drug development programs, which may
target diseases that we are also targeting, and have already entered into partnering and licensing arrangements with academic research
institutions, reducing the pool of available opportunities.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Universities and public and private research
institutions also compete with us. While these organizations primarily have educational or basic research objectives, they may
develop proprietary technology and acquire patent applications and patents that we may need for the development of our potential
drug compounds. In some instances, we will attempt to license this proprietary technology, if available. These licenses may not
be available to us on acceptable terms, if at all. If we are unable to compete successfully with respect to acquisitions, joint
venture and other collaboration opportunities, we may be limited in our ability to develop new products.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The use of any of our products in
clinical trials may expose us to liability claims, which may cost us significant amounts of money to defend against or pay out,
causing our business to suffer.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The nature of our business exposes us to
potential liability risks inherent in the testing, manufacturing and marketing of our products. We currently have one drug compound
in clinical trials, however, when any of our products enter clinical trials or become marketed products, they could potentially
harm people or allegedly harm people possibly subjecting us to costly and damaging product liability claims. Some of the patients
who participate in clinical trials are already ill when they enter a trial or may intentionally or unintentionally fail to meet
the exclusion criteria. The waivers we obtain may not be enforceable and may not protect us from liability or the costs of product
liability litigation. Although we intend to obtain product liability insurance, which we believe is adequate, we are subject to
the risk that our insurance will not be sufficient to cover claims. The insurance costs along with the defense or payment of liabilities
above the amount of coverage could cost us significant amounts of money and management distraction from other elements of the business,
causing our business to suffer.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<!-- Field: Page; Sequence: 22; Value: 1 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we are unable to safeguard against
security breaches with respect to our information systems, our business may be adversely affected.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the course of our business, we gather,
transmit and retain confidential information through our information systems. Although we endeavor to protect confidential information
through the implementation of security technologies, processes and procedures, it is possible that an individual or group could
defeat security measures and access sensitive information about our business and employees. Any misappropriation, loss or other
unauthorized disclosure of confidential information gathered, stored or used by us could have a material impact on the operation
of our business, including damaging our reputation with our employees, third parties and investors. We could also incur significant
costs implementing additional security measures and organizational changes, implementing additional protection technologies, training
employees or engaging consultants. In addition, we could incur increased litigation as a result of any potential cyber-security
breach. We are not aware that we have experienced any material misappropriation, loss or other unauthorized disclosure of confidential
or personally identifiable information as a result of a cyber-security breach or other act, however, a cyber-security breach or
other act and/or disruption to our information technology systems could have a material adverse effect on our business, prospects,
financial condition or results of operations.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Risks Related to our Common Stock</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>A decline in the price of our common
stock could affect our ability to raise further working capital and adversely impact our operations and would severely dilute existing
or future investors if we were to raise funds at lower prices.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A prolonged decline in the price of our
common stock could result in a reduction in our ability to raise capital. Because our operations have been financed through the
sale of equity securities, a decline in the price of our common stock could be especially detrimental to our continued operations.
Any reduction in our ability to raise equity capital in the future would force us to reallocate funds from other planned uses and
would have a significant negative effect on our business plans and operations, including our ability to develop new products and
continue our current operations. If our stock price declines, there can be no assurance that we can raise additional capital or
generate funds from operations sufficient to meet our obligations. We believe the following factors could cause the market price
of our common stock to continue to fluctuate widely and could cause our common stock to trade at a price below the price at which
you purchase your shares of common stock:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">actual or anticipated variations in our
quarterly operating results;</font></td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">announcements of new services, products,
acquisitions or strategic relationships by us or our competitors;</font></td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">changes in accounting treatments or principles;</font></td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">changes in earnings estimates by securities
analysts and in analyst recommendations; and</font></td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">general political, economic, regulatory
and market conditions.</font></td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The market price for our common stock may
also be affected by our ability to meet or exceed expectations of analysts or investors. Any failure to meet these expectations,
even if minor, could materially adversely affect the market price of our common stock.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we issue additional shares of
common stock in the future, it will result in the dilution of our existing stockholders.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our articles of incorporation authorize
the issuance of 10,000,000 shares of preferred stock and 100,000,000 shares of common stock. Our board of directors has the authority
to issue additional shares of preferred and common stock up to the authorized capital stated in the articles of incorporation.
Our board of directors may choose to issue some or all such shares of common stock to acquire one or more businesses or to provide
additional financing in the future. The issuance of any such shares of common stock will result in a reduction of the book value
or market price of the outstanding shares of our common stock. If we do issue any such additional shares of common stock, such
issuance also will cause a reduction in the proportionate ownership and voting power of all other stockholders. Further, any such
issuance may result in a change of control of our corporation.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<!-- Field: Page; Sequence: 23; Value: 1 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Trading of our common stock may be
volatile and sporadic, which could depress the market price of our common stock and make it difficult for our stockholders to resell
their shares.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is currently a limited market for
our common stock and the volume of our common stock traded on any day may vary significantly from one period to another. Trading
in our stock is often thin and characterized by wide fluctuations in trading prices, due to many factors that may have little to
do with our operations or business prospects. The availability of buyers and sellers represented by this volatility could lead
to a market price for our common stock that is unrelated to operating performance. There is no assurance that a sufficient market
will develop in the stock, in which case it could be difficult for our stockholders to resell their stock.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The sale or issuance of our common
stock to Lincoln Park may cause dilution and the sale of the shares of common stock acquired by Lincoln Park, or the perception
that such sales may occur, could cause the price of our common stock to fall.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 7, 2019, we entered into a Purchase
Agreement (the “Purchase Agreement”) with Lincoln Park Capital Fund, LLC (“Lincoln Park”), pursuant to
which Lincoln Park committed to purchase up to $50 million of our common stock. Concurrently with the execution of the 2019 Purchase
Agreement, we issued 324,383 shares of our common stock to Lincoln Park as a commitment fee and shall issue up to 162,191 shares
pro rata, when and if, Lincoln Park purchases at our discretion the $50 million aggregate commitment. The purchase shares sold
pursuant to the 2019 Purchase Agreement may be sold by us to Lincoln Park at our discretion from time to time over a 36-month period.
The purchase price for shares that we may sell to Lincoln Park under the 2019 Purchase Agreement will fluctuate based on the price
of our common stock. Depending on market liquidity at the time, sales of such shares may cause the trading price of our common
stock to fall.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have the right to control the timing
and amount of any sales of our shares to Lincoln Park in our sole discretion, subject to certain limits on the amount of shares
that can be sold on a given date. Sales of shares of our common stock, if any, to Lincoln Park will depend upon market conditions
and other factors to be determined by us. Therefore, Lincoln Park may ultimately purchase all, some or none of the shares of our
common stock that may be sold pursuant to the 2019 Purchase Agreement and, after it has acquired shares, Lincoln Park may sell
all, some or none of those shares. Sales to Lincoln Park by us could result in substantial dilution to the interests of other holders
of our common stock. Additionally, the sale of a substantial number of shares of our common stock to Lincoln Park, or the anticipation
of such sales, could make it more difficult for us to sell equity or equity-related securities in the future at a time and at a
price that we might otherwise wish to effect sales, which could have a materially adverse effect on our business and operations.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may not be able to access sufficient
funds under the Purchase Agreement when needed.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our ability to sell shares to Lincoln Park
and obtain funds under the 2019 Purchase Agreement is limited by the terms and conditions in the 2019 Purchase Agreement, including
restrictions on the amounts we may sell to Lincoln Park at any one time, and a limitation on our ability to sell shares to Lincoln
Park to the extent that it would cause Lincoln Park to beneficially own more than 4.99% of our outstanding shares of common stock.
Additionally, we have only registered approximately $15.5 million of shares of our common stock, and we will only be able to sell
or issue to Lincoln Park a number of shares equal to 19.99% of the shares of common stock outstanding on the date of the 2019 Purchase
Agreement unless we obtain shareholder approval or the average price of such sales exceeds the price of our common stock on June
7, 2019 as determined under NASDAQ rules. Therefore, we currently do not, and may not in the future, have access to the full amount
available to us under the 2019 Purchase Agreement. In addition, any amounts we sell under the Purchase Agreement may not satisfy
all of our funding needs, even if we are able and choose to sell and issue all of our common stock currently registered.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p>
<!-- Field: Page; Sequence: 24; Value: 1 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Future sales of our common stock
may cause our share price to fall.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 6, 2018, we entered into a Controlled
Equity Offering Sales Agreement with Cantor Fitzgerald &amp; Co. to offer shares of our common stock from time to time through
“at-the-market” offerings, pursuant to which we offer and sell shares of our common stock for an aggregate offering
price of up to $50 million. To date, no offerings have occurred under this agreement. We are not obligated to make or continue
to make any sale of shares of our common stock under the “at-the-market” offerings. Although any sale of securities
pursuant to the “at-the-market” offerings will result in an increase in cash for each share sold, it may result in
shareholder dilution and may cause our share price to fall.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Risks Related to our Intellectual
Property</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we are unable to obtain and maintain
sufficient intellectual property protection for our product candidates, or if the scope of the intellectual property protection
obtained is not sufficiently broad, our competitors could develop and commercialize product candidates similar or identical to
ours, and our ability to successfully commercialize our product candidates that we may pursue may be impaired. </i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our success depends in large part on our
ability to obtain and maintain protection of our intellectual property, particularly patents, in the United States and other countries
with respect to our product candidates and technology. We seek to protect our proprietary position by filing patent applications
in the United States and abroad related to our product candidates or by in-licensing intellectual property. U.S. patents related
to ANAVEX<sup>®</sup>2-73 are directed to a dosage form comprising certain doses of ANAVEX®2-73 and donepezil, and the
coverage is limited to the United States only. We may not be able to obtain patent protection for ANAVEX<sup>®</sup>2-73 as
a single drug or in other jurisdictions.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Moreover, we may be subject to a third-party
preissuance submission of prior art to the United States Patent and Trademark Office, or the USPTO, or become involved in opposition,
derivation, reexamination, inter partes review, post-grant review or interference proceedings challenging our patent rights or
the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of,
or invalidate, our patent rights, allow third parties to commercialize our product candidates and compete directly with us, without
payment to us, or result in our inability to manufacture or commercialize drugs without infringing on third-party patent rights.
In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, regardless
of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product
candidates.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the issuance of a patent is
not conclusive as to its inventorship, scope, validity or enforceability, and our patents may be challenged in the courts or patent
offices in the United States and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims
being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using
or commercializing similar or identical product candidates, or limit the duration of the patent protection of our product candidates.
Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting
such candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may
not provide us with sufficient rights to exclude others from commercializing drugs similar or identical to ours.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<!-- Field: Page; Sequence: 25; Value: 1 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We hold ownership or exclusive rights to
eight issued U.S. patent, eight U.S. patent applications, and various PCT or ex-U.S. patent applications relating to our drug candidates,
methods associated therewith, and to our research programs. Neither patents nor patent applications ensure the protection of our
intellectual property for a number of reasons, including the following:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
<td style="width: 5%; text-align: justify"> </td>
<td style="vertical-align: top; width: 5%; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</font></td>
<td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Competitors may interfere with our patenting process in a variety of ways. Competitors may claim that Anavex is not entitled to an issued patent for a variety of legal reasons. Competitors may also claim that we are infringing their patents and restrict our freedom to operate. If a court or, in some circumstances, a board of a national patent authority, agrees, we would lose some or all of our patent protection. As a company, we have no meaningful experience with competitors interfering with our patents or patent applications.</font></td></tr>
<tr>
<td style="text-align: justify"> </td>
<td style="vertical-align: top; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</font></td>
<td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because of the time, money and effort involved in obtaining and enforcing patents, our management may spend less time and resources on developing potential drug compounds than they otherwise would, which could increase our operating expenses and delay product programs.</font></td></tr>
<tr>
<td style="text-align: justify"> </td>
<td style="vertical-align: top; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</font></td>
<td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance of a patent may not provide significant practical protection. If we receive a patent of narrow scope, then it may be possible for competitors to design products that do not infringe our patent(s).</font></td></tr>
<tr>
<td style="text-align: justify"> </td>
<td style="vertical-align: top; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</font></td>
<td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex is seeking patent protection for a number of indications, combination products and drug regimens. The lack of patent protection in global markets for a specific end product or indication may inhibit our ability to advance our compounds and may make Anavex less attractive to potential partners.</font></td></tr>
<tr>
<td style="text-align: justify"> </td>
<td style="vertical-align: top; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</font></td>
<td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Defending a patent lawsuit takes significant time and can be very expensive.</font></td></tr>
<tr>
<td style="text-align: justify"> </td>
<td style="vertical-align: top; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</font></td>
<td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If a court decides that an Anavex compound, its method of manufacture or use, infringes on the competitor’s patent, we may have to pay substantial damages for infringement.</font></td></tr>
<tr>
<td style="text-align: justify"> </td>
<td style="vertical-align: top; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</font></td>
<td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A court may prohibit us from making, selling or licensing the potential drug compound unless the patent holder grants a license. A patent holder is not required to grant a license. If a license is available, we may have to pay substantial royalties or grant cross licenses to our patents, and the license terms may be unacceptable.</font></td></tr>
<tr>
<td style="text-align: justify"> </td>
<td style="vertical-align: top; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</font></td>
<td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Redesigning our potential drug compounds so that they do not infringe on other patents may not be possible or could require substantial funds and time.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">It is also unclear whether our trade secrets
are adequately protected. While we use reasonable efforts to protect our trade secrets, our employees or consultants may unintentionally
or willfully disclose our information to competitors. Enforcing a claim that someone illegally obtained and is using our trade
secrets, like patent litigation, is expensive and time consuming, and the outcome is unpredictable. In addition, courts outside
the United States are sometimes less willing to protect trade secrets. Our competitors may independently develop equivalent knowledge,
methods and know-how.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may also support and collaborate in
research conducted by government organizations, hospitals, universities or other educational institutions. These research partners
may be unable or unwilling to grant us exclusive rights to technology or products derived from these collaborations.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we do not obtain required intellectual
property licenses or rights, we could encounter delays in our product development efforts while we attempt to design around other
patents or even be prohibited from developing, manufacturing or selling potential drug compounds requiring these rights or licenses.
There is also a risk that legal disputes may arise as to the rights to technology or potential drug compounds developed in collaboration
with other parties, all with attendant risk, distraction, expense, and lack of predictability.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we fail to comply with our obligations
in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to
our business relationships with our licensors, we could lose intellectual property rights that are important to our business.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are party to an exclusive license agreement
with Life Science Research Israel Ltd., with respect to certain in-licensed intellectual property related to our ANAVEX®3-71
product candidate, and we may need to obtain additional licenses from others in the future. Our license agreement with Life Science
Research Israel Ltd. imposes, and we expect that future license agreements will impose, various development, diligence, commercialization,
and other obligations on us. In spite of our efforts, our licensors might conclude that we have materially breached our obligations
under such license agreements and might therefore terminate the license agreements, thereby removing or limiting our ability to
develop and commercialize products and technology covered by these license agreements. If these in-licenses are terminated, or
if the underlying patents fail to provide the intended exclusivity, competitors or other third parties would have the freedom to
seek regulatory approval of, and to market, products identical to ours and we may be required to cease our development and commercialization
of ANAVEX<sup>®</sup>3-71 or other product candidates covered by any such future licenses. Any of the foregoing could have
a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<!-- Field: Page; Sequence: 26; Value: 1 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Moreover, disputes may arise regarding
intellectual property subject to a licensing agreement, including:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">the scope of rights granted under the
license agreement and other interpretation-related issues;</font></td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">the extent to which our product candidates,
technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</font></td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">the sublicensing of patent and other rights
under our collaborative development relationships;</font></td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">our diligence obligations under the license
agreement and what activities satisfy those diligence obligations;</font></td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">the inventorship and ownership of inventions
and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and</font></td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">the priority of invention of patented
technology.</font></td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the agreements under which
we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements
may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could
narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe
to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on
our business, financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property that
we have licensed prevent or impair our ability to maintain our licensing arrangements on commercially acceptable terms, we may
be unable to successfully develop and commercialize the affected product candidates, which could have a material adverse effect
on our business, financial conditions, results of operations, and prospects.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we do not obtain required intellectual
property licenses or rights, we could encounter delays in our product development efforts while we attempt to design around other
patents or even be prohibited from developing, manufacturing or selling potential drug compounds requiring these rights or licenses.
There is also a risk that legal disputes may arise as to the rights to technology or potential drug compounds developed in collaboration
with other parties, all with attendant risk, distraction, expense, and lack of predictability.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Third-party claims of intellectual
property infringement may prevent or delay our development and commercialization efforts.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our success will also depend in part on
our ability to commercialize our compounds without infringing the proprietary rights of others. We have not conducted extensive
freedom of use patent searches and no assurance can be given that patents do not exist or could be issued which would have an adverse
effect on our ability to market our technology or maintain our competitive position with respect to our technology. If our compounds
or other subject matter are claimed under other United States patents or other international patents or are otherwise protected
by third party proprietary rights, we may be subject to infringement actions. In such event, we may challenge the validity of such
patents or other proprietary rights or we may be required to obtain licenses from such companies in order to develop, manufacture
or market our technology. There can be no assurances that we would be successful in a challenge or be able to obtain such licenses
or that such licenses, if available, could be obtained on commercially reasonable terms. Furthermore, the failure to succeed in
a challenge, develop a commercially viable alternative or obtain needed licenses could be materially adverse. Adverse consequences
include delays in marketing some or all of our potential drug compounds based on our drug technology or the inability to proceed
with the development, manufacture or sale of potential drug compounds requiring such licenses. If we defend ourselves against charges
of patent infringement or to protect our proprietary rights against third parties, substantial costs will be incurred regardless
of whether we are successful. Such proceedings are typically protracted with no certainty of success. An adverse outcome could
subject us to significant liabilities to third parties and force us to curtail or cease the research and development of our technology.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<!-- Field: Page; Sequence: 27; Value: 1 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Parties making claims against us may obtain
injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize ANAVEX®2-73
or our other product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense
and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement
against us, we may have to pay substantial damages, including treble damages and attorneys’ fees for willful infringement,
pay royalties, redesign our infringing products or obtain one or more licenses from third parties, which may be impossible or require
substantial time and monetary expenditure. Additionally, parties making claims against us may be able to sustain the costs of complex
patent litigation more effectively than we can because they have substantially greater resources. Furthermore, because of the substantial
amount of discovery required in connection with intellectual property litigation or administrative proceedings, there is a risk
that some of our confidential information could be compromised by disclosure. In addition, any uncertainties resulting from the
initiation and continuation of any litigation could have material adverse effect on our ability to raise additional funds or otherwise
have a material adverse effect on our business, results of operations, financial condition and prospects.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we are unable to protect the confidentiality
of our trade secrets, the value of our technology could be materially adversely affected and our business would be harmed.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">While we use reasonable efforts to protect
our trade secrets, our employees or consultants may unintentionally or willfully disclose our information to competitors. Enforcing
a claim that someone illegally obtained and is using our trade secrets, like patent litigation, is expensive and time consuming,
and the outcome is unpredictable. In addition, courts outside the United States are sometimes less willing to protect trade secrets.
Our competitors may independently develop equivalent knowledge, methods and know-how.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We seek to protect our confidential proprietary
information, in part, by confidentiality agreements and invention assignment agreements with our employees, consultants, scientific
advisors, contractors and collaborators. These agreements are designed to protect our proprietary information. However, we cannot
be certain that such agreements have been entered into with all relevant parties, and we cannot be certain that our trade secrets
and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our
trade secrets or independently develop substantially equivalent information and techniques. For example, any of these parties may
breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate
remedies for such breaches. We also seek to preserve the integrity and confidentiality of our confidential proprietary information
by maintaining physical security of our premises and physical and electronic security of our information technology systems, but
it is possible that these security measures could be breached. If any of our confidential proprietary information were to be lawfully
obtained or independently developed by a competitor, we would have no right to prevent such competitor from using that technology
or information to compete with us, which could harm our competitive position.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<!-- Field: Page; Sequence: 28; Value: 1 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Although we are not currently involved
in any litigation, we may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could
be expensive, time consuming and unsuccessful.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Competitors may infringe our patents or
other intellectual property. Although we are not currently involved in any litigation, if we were to initiate legal proceedings
against a third party to enforce a patent covering ANAVEX®2-73 or our other product candidates, the defendant could counterclaim
that the patent covering our product candidate is invalid and/or unenforceable. In patent litigation in the United States, defendant
counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged
failure to meet any of several statutory requirements, including lack of novelty, obviousness, written description or non-enablement.
Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld
relevant information from the USPTO, or made a misleading statement, during prosecution. The outcome following legal assertions
of invalidity and unenforceability is unpredictable.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Interference or derivation proceedings
provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with
respect to our patents or patent applications. An unfavorable outcome could require us to cease using the related technology or
to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer
us a license on commercially reasonable terms or at all, or if a non-exclusive license is offered and our competitors gain access
to the same technology. Our defense of litigation or interference or derivation proceedings may fail and, even if successful, may
result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with litigation
could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our
research programs, license necessary technology from third parties, or enter into development partnerships that would help us bring
ANAVEX®2-73 or our other product candidates to market.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be subject to claims challenging
the inventorship of our patents and other intellectual property.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We or our licensors may be subject to claims
that former employees, collaborators or other third parties have an interest in our owned or in-licensed patents, trade secrets,
or other intellectual property as an inventor or co-inventor. For example, we or our licensors may have inventorship disputes arise
from conflicting obligations of employees, consultants or others who are involved in developing our product candidates. Litigation
may be necessary to defend against these and other claims challenging inventorship or our or our licensors’ ownership of
our owned or in-licensed patents, trade secrets or other intellectual property. If we or our licensors fail in defending any such
claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership
of, or right to use, intellectual property that is important to our product candidates. Even if we are successful in defending
against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of
the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Obtaining and maintaining our patent
protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental
patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Periodic maintenance fees, renewal fees,
annuity fees and various other governmental fees on patents and/or applications will be due to be paid to the USPTO and various
governmental patent agencies outside of the United States in several stages over the lifetime of the patents and/or applications.
We have systems in place to remind us to pay these fees, and we employ an outside firm and rely on our outside counsel to pay these
fees due to non-U.S. patent agencies. The USPTO and various non-U.S. governmental patent agencies require compliance with a number
of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable
law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late
fee or by other means in accordance with the applicable rules. However, there are situations in which non-compliance can result
in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant
jurisdiction. In such an event, our competitors might be able to enter the market and this circumstance would have a material adverse
effect on our business.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<!-- Field: Page; Sequence: 29; Value: 1 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may not be able to protect our
intellectual property rights throughout the world.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Filing, prosecuting and defending patents
on our product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property
rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws
of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United
States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United
States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors
may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and may also
export infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United
States. These products may compete with our products and our patents or other intellectual property rights may not be effective
or sufficient to prevent them from competing.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-style: normal"><a name="main_004"></a></section><section class="edgaug_item1b" id="edgaug_item1b_id">ITEM 1B. UNRESOLVED
STAFF COMMENTS</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">None.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-style: normal"><a name="main_005"></a></section><section class="edgaug_item2" id="edgaug_item2_id">ITEM 2. PROPERTIES</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We do not own any real property. We maintain
several offices of which the office at 7th Floor, 51 West 52nd Street, New York, NY, USA is our main office. Our lease costs are
approximately $16,000 per month. We believe our offices are suitable and adequate to operate our business now as they provide us
with sufficient space to conduct our operations. We fully utilize our current premises.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-style: normal"><a name="main_006"></a></section><section class="edgaug_item3" id="edgaug_item3_id">ITEM 3. LEGAL PROCEEDINGS</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We know of no
material pending legal proceedings, other than ordinary routine litigation incidental to our business, to which our Company or
our subsidiary is a party or of which any of their property is subject. There are no proceedings in which any of our directors,
officers or affiliates, or any registered or beneficial stockholder holding more than 5% of our shares, is an adverse party or
has a material interest adverse to our or our subsidiary’s interest. </p>
<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-style: normal"> </font></p>
<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-style: normal"><a name="main_007"></a></section><section class="edgaug_item4" id="edgaug_item4_id">ITEM 4. MINE SAFETY
DISCLOSURES</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not applicable.</p>
<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><a name="main_008"></a>PART II</p>
<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-style: normal"> </font></p>
<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-style: normal"><a name="main_009"></a></section><section class="edgaug_item5" id="edgaug_item5_id">ITEM 5. MARKET
FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Market information</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our common stock is quoted on the NASDAQ
Stock Market LLC (“NASDAQ”) under the symbol “AVXL.”</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Holders of Common Stock </i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>
<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 12, 2019, there were approximately 53 holders of record and 56,123,076 shares of our common stock were issued and
outstanding.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<!-- Field: Page; Sequence: 30; Value: 1 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b><i>Dividends
</i></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt">We have not paid any cash dividends
on our common stock and have no intention of paying any dividends on the shares of our common stock. Our current policy is to
retain earnings, if any, for use in our operations and in the development of our business. Our future dividend policy will be
determined from time to time by our board of directors.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b><i>Securities
Authorized for Issuance under Equity Compensation Plans or Individual Compensation Arrangements </i></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">The following
table summarizes certain information regarding our equity compensation plan or individual compensation arrangements as at September
30, 2019:</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td colspan="13" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 10pt">Equity Compensation
    Plan Information</font></td></tr>
<tr style="vertical-align: bottom">
<td style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 10pt">Plan Category</font></td><td style="font-weight: bold"><font style="font-size: 10pt"> </font></td>
<td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 10pt">Number of
    securities to<br/> be issued upon exercise<br/> of outstanding options,<br/> warrants and rights <br/> (a)</font></td><td style="font-weight: bold"><font style="font-size: 10pt"> </font></td>
<td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 10pt">Weighted-average<br/>
    exercise price of<br/> outstanding options,<br/> warrants and rights<br/> (b)</font></td><td style="font-weight: bold"><font style="font-size: 10pt"> </font></td>
<td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 10pt">Number of
    securities<br/> remaining available for<br/> future issuances under<br/> equity compensation<br/> plans (excluding<br/> securities
    reflected in<br/> column (a))<br/> (c)</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 31%; text-align: left"><font style="font-size: 10pt">Equity compensation plans approved by security holders</font></td><td style="width: 1%"><font style="font-size: 10pt"> </font></td>
<td style="width: 1%; text-align: left"><font style="font-size: 10pt"> </font></td><td style="width: 20%; text-align: right"><font style="font-size: 10pt">12,050,553</font></td><td style="width: 1%; text-align: left"><font style="font-size: 10pt"> </font></td><td style="width: 1%"><font style="font-size: 10pt"> </font></td>
<td style="width: 1%; text-align: left"><font style="font-size: 10pt"> </font></td><td style="width: 20%; text-align: right"><font style="font-size: 10pt">4.02</font></td><td style="width: 1%; text-align: left"><font style="font-size: 10pt"> </font></td><td style="width: 1%"><font style="font-size: 10pt"> </font></td>
<td style="width: 1%; text-align: left"><font style="font-size: 10pt"> </font></td><td style="width: 20%; text-align: right"><font style="font-size: 10pt">4,934,704</font></td><td style="width: 1%; text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left"><font style="font-size: 10pt">Equity compensation plans not approved by security holders</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">-</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">-</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">-</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font-weight: bold"><font style="font-size: 10pt">Total</font></td><td style="font-weight: bold"><font style="font-size: 10pt"> </font></td>
<td style="font-weight: bold; text-align: left"><font style="font-size: 10pt"> </font></td><td style="font-weight: bold; text-align: right"><font style="font-size: 10pt">12,050,553</font></td><td style="font-weight: bold; text-align: left"><font style="font-size: 10pt"> </font></td><td style="font-weight: bold"><font style="font-size: 10pt"> </font></td>
<td style="font-weight: bold; text-align: left"><font style="font-size: 10pt"> </font></td><td style="font-weight: bold; text-align: right"><font style="font-size: 10pt">4.02</font></td><td style="font-weight: bold; text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">4,934,704</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b><i> </i></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b><i>Stock
Option Plan </i></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">2019 Stock
Option Plan</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">On January
15, 2019, the Board approved the 2019 Omnibus Incentive Plan (the “2019 Plan”), which provides for the grant of stock
options and restricted stock awards to directors, officers, employees, consultants and advisors of the Company. The 2019 Plan
was approved by our stockholders on April 5, 2019.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">Under the
terms of the 2019 Plan, 6,000,000 shares of Common Stock are available for issuance, in addition to the shares available under
the 2015 Plan. Any awards outstanding under the Company’s 2015 Omnibus Incentive Plan (the “2015 Plan”) or the
Company’s 2007 Stock Option Plan (the “2007 Plan”) will remain subject to and be paid under the 2015 Plan or
the 2007 Plan, respectively, and any shares subject to outstanding awards under the 2015 Plan or the 2007 Plan that subsequently
cease to be subject to such awards (other than by reason of settlement of the awards in shares) will automatically become available
for issuance under the 2019 Plan.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">The 2019
Plan provides that it may be administered by the Board, or the Board may delegate such responsibility to a committee. The exercise
price will be determined by the board of directors at the time of grant shall be at least equal to the fair market value on such
date. If the grantee is a 10% stockholder on the grant date, then the exercise price shall not be less than 110% of fair market
value of the Company’s shares of common stock on the grant date. Stock options may be granted under the 2019 Plan for an
exercise period of up to ten years from the date of grant of the option or such lesser periods as may be determined by the board,
subject to earlier termination in accordance with the terms of the 2019 Plan.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<!-- Field: Page; Sequence: 31; Value: 1 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">The purpose
of the 2019 Plan is to retain the services of valued key employees and consultants of our Company and such other persons, and
to encourage such persons to acquire a greater proprietary interest in our Company, thereby strengthening their incentive to achieve
the objectives of the shareholders of our Company. The purpose is also to serve as an aid and inducement in the hiring of new
employees and to provide an equity incentive to consultants.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b><i>Recent
Sales of Unregistered Securities </i></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">Since the
beginning of our fiscal year ended September 30, 2019, we have not sold any equity securities that were not registered under the
Securities Act of 1933 that were not previously reported in a quarterly report on Form 10-Q or in a current report on Form 8-K.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b><i>Repurchases
of Equity Securities by Our Company and Affiliated Purchasers</i></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt">None.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt; font-style: normal"><a name="main_010"></a></section><section class="edgaug_item6" id="edgaug_item6_id">ITEM 6 SELECTED FINANCIAL DATA</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt">Not applicable.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt; font-style: normal"><a name="main_011"></a></section><section class="edgaug_item7" id="edgaug_item7_id">ITEM 7 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt">The following discussion should
be read in conjunction with our audited consolidated financial statements and notes thereto for the fiscal year ended September
30, 2019, included elsewhere in this Annual Report on Form 10-K.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b><i> </i></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b><i>Financial
Highlights</i></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b><i> </i></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">During fiscal
2019, we make significant progress in the advancement of clinical studies for ANAVEX®2-73, including commencement of a Phase
2b/3 Alzheimer’s disease trial in August 2018, a Phase 2 Parkinson’s disease dementia trial in October 2018, and a
multi-regional Phase 2 clinical program for the treatment of Rett syndrome in March 2019. As a result, our operating expenses
for fiscal 2019 increased to $29.1 million, from $19.3 million in fiscal 2018. The increase is attributable to an increase in
research and development expenses of $9.0 million in 2019, from $13.3 million in fiscal 2018 to $22.3 million in fiscal 2019.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">During fiscal
2019, we utilized $18.5 million to fund our operations, compared to $12.6 million during fiscal 2018. Our cash position decreased
only slightly by $0.7 million during fiscal 2019, to $22.2 million. The majority of our operations were financed through the issuance
of shares of common stock under the purchase agreements by and between the Company and Lincoln Park Capital Fund, LLC (“Lincoln
Park”).</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">We expect
our research and development expenses will continue to increase as we advance our ANAVEX<sup>®</sup>2-73 clinical studies,
including adding extension studies to allow us to continue to gather longer term data, and adding additional staffing to advance
the clinical studies currently underway. We will continue to target potential research partners to further advance our pipeline
compounds. </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">Net loss
for fiscal 2019 was $26.3 million, or $0.54 per share, as compared to $17.3 million, or $0.39 per share in fiscal 2018.</font></p>
<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<!-- Field: Page; Sequence: 32; Value: 1 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">Results
of Operations</font></p>
<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">Revenue</font></p>
<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt; font-style: normal"> </font></p>
<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt; font-style: normal">We
are in the development stage and have not earned any revenues since our inception in 2004. We do not anticipate earning any revenues
until we can establish an alliance with other companies to develop, co-develop, license, acquire or market our products.</font></p>
<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt; font-style: normal"><b> </b></font></p>
<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt; font-style: normal"><b>Year
ended September 30, 2019 compared to year ended September 30, 2018</b></font></p>
<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">Operating
Expenses</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">Total operating
expenses for the year ended September 30, 2019 were $29.1 million, compared to $19.3 million in fiscal 2018, which was an increase
of approximately $9.8 million from fiscal 2018.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">Research
and development expenses for fiscal 2019 were $22.3 million, as compared to $13.3 million fiscal 2018, an increase of $9.0 million.
During fiscal 2019, research and development expenses included approximately $0.4 million spent in connection with the Phase 2a
extension trial for Alzheimer’s Disease, compared to approximately $0.4 million in fiscal 2018. In addition, in August 2018,
we initiated a Phase 2b/3 clinical trial in Alzheimer’s Disease and during fiscal 2019 research and development expenses
included approximately $6.2 million spent in connection with this trial, as compared to approximately $2.4 million in fiscal 2018.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">In October
2018, we initiated a Phase 2 clinical trial for Parkinson’s Disease Dementia and during fiscal 2019 research and development
expenses included approximately $3.3 million spent in connection with this trial, as compared to approximately $0.9 million in
fiscal 2018.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">Additionally,
research and development expenses during fiscal 2019 included approximately $3.0 million in connection with the Phase 2 clinical
studies for the treatment of Rett syndrome, as compared to approximately $0.6 million in fiscal 2018.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">During fiscal
2019, we spent approximately $2.3 million on preclinical development activities for ANAVEX®2-73 and ANAVEX®3-71, as compared
to approximately $3.9 million in fiscal 2018.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">The remainder
of research and development expenses consisted primarily of personnel costs, including non-cash stock option compensation charges
of $3.2 million, as compared to $2.8 million in fiscal 2018.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">During fiscal
2019 our general and administrative expenses were $6.8 million as compared to $6.0 million in fiscal 2018, an increase of $0.8
million, primarily related to salaries and wages, including stock-option compensation charges associated with an increase in staffing
and personnel.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><i> </i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><i>Other
income </i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">The net
amount of other income for the year ended September 30, 2019 was $2.9 million as compared to $2.2 million for the comparable period
of fiscal 2018. During fiscal 2019, we recorded $2.5 million in the research and development incentive income, including the Australian
research and development incentive credit administered through the Australian Tax Office, and the New York City Biotechnology
Tax Credit from the City of New York, in connection with fiscal 2019 eligible expenditures. In comparison, research and development
incentive income for fiscal 2018 was $1.8 million in connection with fiscal 2018 eligible expenditures.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">We received
$0.3 million in connection with a financial grant from the Rettsyndrome.org foundation, which was awarded to cover some of the
costs of the Phase 2 clinical trial of ANAVEX<sup>®</sup>2-73 for the treatment of Rett syndrome, as compared to $0.15 million
received during fiscal 2018 in connection with the same award, which is being received in quarterly instalments over a two year
period.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<!-- Field: Page; Sequence: 33; Value: 1 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">Net loss
for fiscal 2019 was $26.3 million, or $0.54 per share, compared to a net loss of approximately $17.3 million, or $0.39 per share
for fiscal 2018.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b> </b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b>Liquidity
and Capital Resources </b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b> </b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b>Working
Capital</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b> </b></font></p>
<table align="CENTER" cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal">
<tr style="vertical-align: bottom">
<td style="white-space: nowrap; text-align: justify"><font style="font-size: 10pt"> </font></td><td style="font-weight: bold; padding-bottom: 1pt"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 10pt">2019</font></td><td style="border-bottom: Black 1pt solid; font-weight: bold"><font style="font-size: 10pt"> </font></td><td style="font-weight: bold; border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 10pt">2018</font></td><td style="padding-bottom: 1pt; font-weight: bold"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 60%; text-align: justify"><font style="font-size: 10pt">Current Assets</font></td><td style="width: 1%"><font style="font-size: 10pt"> </font></td>
<td style="width: 1%; text-align: left"><font style="font-size: 10pt">$</font></td><td style="width: 12%; text-align: right"><font style="font-size: 10pt">25,329,373</font></td><td style="width: 1%; text-align: left"><font style="font-size: 10pt"> </font></td><td style="width: 1%"><font style="font-size: 10pt"> </font></td>
<td style="width: 1%; text-align: left"><font style="font-size: 10pt">$</font></td><td style="width: 12%; text-align: right"><font style="font-size: 10pt">26,052,793</font></td><td style="width: 1%; text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: justify; padding-bottom: 1pt"><font style="font-size: 10pt">Current Liabilities</font></td><td style="padding-bottom: 1pt"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 10pt">5,039,674</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 10pt">3,884,626</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify; padding-bottom: 1pt"><font style="font-size: 10pt">Working Capital</font></td><td style="padding-bottom: 1pt"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt">$</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 10pt">20,289,699</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt">$</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 10pt">22,168,167</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 10pt"> </font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">At September
30, 2019, we had $22.2 million in cash and cash equivalents, a decrease of $0.7 million, from $22.9 million at September 30, 2018.
The principal reason for this decrease is an increase in operating expenditures incurred in connection with the clinical trials
for ANAVEX<sup>®</sup>2-73, as more fully described above.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">We intend
to use the majority of our capital resources to advance our clinical trials for ANAVEX<sup>®</sup>2-73, and to perform work
necessary to prepare for future development of our pipeline compounds.</font></p>
<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">Cash
Flows</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td style="white-space: nowrap; text-align: justify; padding-left: 5.4pt"><font style="font-size: 10pt"> </font></td><td style="font-weight: bold"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right"><font style="font-size: 10pt">2019</font></td><td style="font-weight: bold"><font style="font-size: 10pt"> </font></td><td style="font-weight: bold"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right"><font style="font-size: 10pt">2018</font></td><td style="font-weight: bold"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 70%; text-align: justify; padding-left: 5.4pt"><font style="font-size: 10pt">Cash flows used in operating
    activities</font></td><td style="width: 1%"><font style="font-size: 10pt"> </font></td>
<td style="width: 1%; text-align: left"><font style="font-size: 10pt">$</font></td><td style="width: 12%; text-align: right"><font style="font-size: 10pt">(18,527,117</font></td><td style="width: 1%; text-align: left"><font style="font-size: 10pt">)</font></td><td style="width: 1%"><font style="font-size: 10pt"> </font></td>
<td style="width: 1%; text-align: left"><font style="font-size: 10pt">$</font></td><td style="width: 12%; text-align: right"><font style="font-size: 10pt">(12,582,406</font></td><td style="width: 1%; text-align: left"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: justify; padding-left: 5.4pt"><font style="font-size: 10pt">Cash flows provided by financing activities</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">17,782,109</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">8,072,787</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify; padding-left: 5.4pt"><font style="font-size: 10pt">Increase (decrease) in cash</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt">$</font></td><td style="text-align: right"><font style="font-size: 10pt">(745,008</font></td><td style="text-align: left"><font style="font-size: 10pt">)</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt">$</font></td><td style="text-align: right"><font style="font-size: 10pt">(4,509,619</font></td><td style="text-align: left"><font style="font-size: 10pt">)</font></td></tr>
</table>
<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">Cash
flow used in operating activities</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">There was
an increase in cash used in operating activities of $5.9 million during fiscal 2019 as a result of an increase in operating expenditures,
as more fully described above.</font></p>
<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">Cash
flow provided by financing activities</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">Cash provided
by financing activities for fiscal 2019 and 2018 were related to cash received from the issuance of shares under the purchase
agreements with Lincoln Park, including the Purchase Agreement and a prior purchase agreement with Lincoln Park which has expired
pursuant to its terms (see Note 4 to our Consolidated Financial Statements). During fiscal 2019, we issued 6.7 million shares
for gross proceeds of $17.8 million. During fiscal 2018, we issued 2.4 million shares for gross proceeds of $8.2 million.</font></p>
<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">Other
Financings</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b> </b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b>Purchase
Agreement</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">On June
7, 2019, we entered into the 2019 Purchase Agreement (the “2019 Purchase Agreement”) with Lincoln Park Capital Fund,
LLC (“Lincoln Park”), pursuant to which Lincoln Park committed to purchase up to $50,000,000 of our common stock.
Concurrently with the execution of the 2019 Purchase Agreement, we issued 324,383 shares of our common stock to Lincoln Park as
a fee for its commitment to purchase shares of our common stock under the 2019 Purchase Agreement and shall issue up to 162,191
shares pro rata, when and if Lincoln Park purchases, at our discretion, the $50,000,000 aggregate commitment. The purchase shares
that may be sold pursuant to the 2019 Purchase Agreement may be sold by us to Lincoln Park at our discretion from time to time
until July 1, 2022.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<!-- Field: Page; Sequence: 34; Value: 1 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">We may direct
Lincoln Park, at our sole discretion, and subject to certain conditions, to purchase up to 200,000 shares of common stock on any
business day (a “Regular Purchase”). The amount of a Regular Purchase may be increased under certain circumstances
up to 250,000 shares provided that Lincoln Park’s committed obligation for Regular Purchases on any business day shall not
exceed $2,000,000. In the even we purchase the full amount allowed for a Regular Purchase on any given business day, we may also
direct Lincoln Park to purchase additional amounts as accelerated and additional purchases. The purchase price of shares of common
stock related to the future funding will be based on the then prevailing market prices of such shares at the time of sales as
described in the Purchase Agreement.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">At September
30, 2019, approximately $45.3 million in shares of our common stock remained available for purchase by Lincoln Park under the
2019 Purchase Agreement, including $15.4 million of our shares of common stock currently registered under our effective registration
statement.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b>Controlled
Equity Offering Sales Agreement</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">On July
6, 2018, the Company entered into a Controlled Equity Offering Sales Agreement (the “Sales Agreement”) with Cantor
Fitzgerald &amp; Co., as agent (“Cantor Fitzgerald”), pursuant to which the Company may offer and sell shares
of common stock, for aggregate gross sale proceeds of up to $50,000,000 from time to time through Cantor Fitzgerald (the “At-the-Market
Offering”). </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">Upon delivery
of a placement notice based on the Company’s instructions and subject to the terms and conditions of the Sales Agreement,
Cantor Fitzgerald may sell shares of common stock by methods deemed to be an “at the market offering” offering, in
negotiated transactions at market prices prevailing at the time of sale or at prices related to such prevailing market prices,
or by any other method permitted by law, including negotiated transactions, subject to the prior written consent of the Company.
The Company is not obligated to make any sales of shares under the Sales Agreement. The Company or Cantor Fitzgerald may suspend
or terminate the At-the-Market Offering upon notice to the other party, subject to certain conditions.  Cantor Fitzgerald
will act as sales agent on a commercially reasonable efforts basis consistent with its normal trading and sales practices and
applicable state and federal law, rules and regulations and the rules of Nasdaq.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">The Company
has agreed to pay Cantor Fitzgerald commissions for its services of acting as agent of up to 3.0% of the gross proceeds from the
sale of the Shares pursuant to the Sales Agreement.  The Company has also agreed to provide Cantor Fitzgerald with customary
indemnification and contribution rights. To date, no shares of common stock have been sold pursuant to the Sales Agreement.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">We expect
that we will be able to continue to fund our operations through existing cash on hand and through equity and debt financing in
the future. If we raise additional financing by issuing equity securities, our existing stockholders’ ownership will be
diluted. Obtaining commercial loans, assuming these loans would be available, would increase our liabilities and future cash commitments.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b><i> </i></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b><i>Off-Balance
Sheet Arrangements</i></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b><i> </i></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">We have
no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition,
changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources
that are material to our stockholders.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b> </b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt; text-transform: uppercase"><b>Application
of Critical Accounting Policies</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">Our financial
statements and accompanying notes are prepared in accordance with generally accepted accounting principles in the United States.
Preparing financial statements requires management to make estimates and assumptions that affect the reported amounts of assets,
liabilities, revenue and expenses. These estimates and assumptions are affected by management’s application of accounting
policies. We believe that understanding the basis and nature of the estimates and assumptions involved with the following aspects
of our financial statements is critical to an understanding of our financial statements.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<!-- Field: Page; Sequence: 35; Value: 1 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">We base
our assumptions and estimates on historical experience and other sources that we believe to be reasonable at the time. Actual
results may vary from our estimates due to changes in circumstances, politics, global economics, general business conditions and
other factors. Our significant estimates are related to the valuation of warrants and options.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">There are
accounting policies that we believe are significant to the presentation of our financial statements. The most significant of these
accounting policies relates to the accounting for our research and development expenses and stock-based compensation expense.</font></p>
<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">Research
and Development Expenses</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">Research
and development costs are expensed as incurred. These expenses are comprised of the costs of the Company’s proprietary research
and development efforts, including preclinical studies, clinical trials, manufacturing costs, employee salaries and benefits and
stock based compensation expense, contract services including external research and development expenses incurred under arrangements
with third parties such as contract research organizations (“CROs”), facilities costs, overhead costs and other related
expenses. Milestone payments made by the Company to third parties are expensed when the specific milestone has been achieved.
Manufacturing costs are expensed as incurred in accordance with Accounting Standard Codification (“ASC”) 730, Research
and Development, as these materials have no alternative future use outside of their intended use.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">Nonrefundable
advance payments for goods or services that will be used or rendered for future research and development activities are deferred
and amortized over the period that the goods are delivered, or the related services are performed, subject to an assessment of
recoverability. The Company makes estimates of costs incurred in relation to external CROs, and clinical site costs. The Company
analyzes the progress of clinical trials, including levels of patient enrollment, invoices received and contracted costs when
evaluating the adequacy of the amount expensed and the related prepaid asset and accrued liability. Significant judgments and
estimates must be made and used in determining the accrued balance and expense in any accounting period. The Company reviews and
accrues CRO expenses and clinical trial study expenses based on work performed and relies upon estimates of those costs applicable
to the stage of completion of a study. Accrued CRO costs are subject to revisions as such trials progress to completion. Revisions
are charged to expense in the period in which the facts that give rise to the revision become known. With respect to clinical
site costs, the financial terms of these agreements are subject to negotiation and vary from contract to contract. Payments under
these contracts may be uneven and depend on factors such as the achievement of certain events, the successful recruitment of patients,
the completion of portions of the clinical trial or similar conditions. The objective of our policy is to match the recording
of expenses in our financial statements to the actual services received and efforts expended. As such, expense accruals related
to clinical site costs are recognized based on our estimate of the degree of completion of the event or events specified in the
specific clinical study or trial contract.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">In addition,
we incur expenses in respect of the acquisition of intellectual property relating to patents and trademarks. The probability of
success and length of time to developing commercial applications of the drugs subject to the acquired patents and trademarks is
difficult to determine and numerous risks and uncertainties exist with respect to the timely completion of the development projects.
There is no assurance the acquired patents and trademarks will ever be successfully commercialized. Due to these risks and uncertainties,
we expense the acquisition of patents and trademarks.</font></p>
<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">Stock-based
Compensation</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">We account
for all stock-based payments and awards under the fair value-based method.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<!-- Field: Page; Sequence: 36; Value: 1 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">Stock-based
payments to non-employees are measured at the fair value of the consideration received, or the fair value of the equity instruments
issued, or liabilities incurred, whichever is more reliably measurable. The fair value of stock-based payments to non-employees
is periodically re-measured until the counterparty performance is complete, and any change therein is recognized over the vesting
period of the award and in the same manner as if we had paid cash instead of paying with or using equity-based instruments. Compensation
costs for stock-based payments with graded vesting are recognized on a straight-line basis. The cost of the stock-based payments
to non-employees that are fully vested and non-forfeitable at the grant date is measured and recognized at that date, unless there
is a contractual term for services in which case such compensation would be amortized over the contractual term.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">We account
for the granting of share purchase options to employees using the fair value method whereby all awards to employees will be recorded
at fair value on the date of the grant. The fair value of all share purchase options are expensed over their vesting period with
a corresponding increase to additional paid in capital.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">We use the
Black-Scholes option valuation model to calculate the fair value of share purchase options at the date of the grant. Option pricing
models require the input of highly subjective assumptions, including the expected price volatility. Changes in assumptions can
materially affect the fair value estimate and therefore the Black-Scholes model does not necessarily provide a reliable single
measure of the fair value of our share purchase options.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">For a discussion
of recent accounting pronouncements and their possible effect on our results, see Note 2(n) to our Consolidated Financial Statements
found elsewhere in this Annual Report.</font></p>
<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt; font-style: normal"> </font></p>
<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt; font-style: normal"><a name="main_012"></a></section><section class="edgaug_item7a" id="edgaug_item7a_id">ITEM 7A QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">Not Applicable.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>
<!-- Field: Page; Sequence: 37; Options: NewSection; Value: 34 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt; font-style: normal"><a name="main_013"></a></section><section class="edgaug_item8" id="edgaug_item8_id">ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"><b> </b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-size: 10pt"><b>ANAVEX
LIFE SCIENCES CORP.</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-size: 10pt">CONSOLIDATED
FINANCIAL STATEMENTS</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-size: 10pt">September
30, 2019</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<!-- Field: Page; Sequence: 38 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="margin: 0pt"> </p></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Report
of Independent Registered Public Accounting Firm</b></font></p>
<p style="font: 10.5pt Trebuchet MS, Times, Serif; margin: 12pt 0 0; text-align: justify; color: fuchsia"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></font></p>
<p style="font: 10.5pt Trebuchet MS, Times, Serif; margin: 12pt 0 0; text-align: justify; color: fuchsia"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Shareholders
and Board of Directors</font></p>
<p style="font: 10.5pt Trebuchet MS, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Anavex
Life Sciences Corp.</font></p>
<p style="font: 10.5pt Trebuchet MS, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">New
York, New York</font></p>
<p style="font: 10.5pt Trebuchet MS, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0in; color: fuchsia"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Opinion
on the Consolidated Financial Statements </b></font></p>
<p style="font: 10.5pt Trebuchet MS, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0in; color: fuchsia"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
have audited the accompanying consolidated balance sheets of Anavex Life Sciences Corp. (the “Company”) and subsidiaries
as of September 30, 2019 and 2018, the related consolidated statements of operations, stockholders’ equity, and cash flows
for each of the two years in the period ended September 30, 2019 and the related notes (collectively referred to as the “consolidated
financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects,
the financial position of the Company and subsidiaries at September 30, 2019 and 2018, and the results of its operations and its
cash flows for each of the two years in the period ended September 30, 2019<b>,</b> in conformity with accounting principles generally
accepted in the United States of America.</font></p>
<p style="font: 10.5pt Trebuchet MS, Times, Serif; margin: 12pt 0 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (“PCAOB”),
the Company's internal control over financial reporting as of September 30, 2019, based on criteria established in <i>Internal
Control – Integrated Framework (2013)</i> issued by the Committee of Sponsoring Organizations of the Treadway Commission
(“COSO”) and our report dated December 16, 2019 expressed an adverse opinion thereon.</font></p>
<p style="font: 10.5pt Trebuchet MS, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0in; color: fuchsia"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Basis
for Opinion</b></font></p>
<p style="font: 10.5pt Trebuchet MS, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0in; color: fuchsia"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">These
consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an
opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered
with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities
laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</font></p>
<p style="font: 10.5pt Trebuchet MS, Times, Serif; margin: 12pt 0 0; text-align: justify; color: fuchsia"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit
to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether
due to error or fraud.</font></p>
<p style="font: 10.5pt Trebuchet MS, Times, Serif; margin: 12pt 0 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Our
audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether
due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis,
evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the
accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the
consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</font></p>
<p style="font: 10.5pt Trebuchet MS, Times, Serif; margin: 0; text-align: justify; color: fuchsia"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </font></p>
<p style="font: 10.5pt Trebuchet MS, Times, Serif; margin: 0; text-align: justify; color: fuchsia"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">/S/
BDO USA, LLP </font></p>
<p style="font: 10.5pt Trebuchet MS, Times, Serif; margin: 0; text-align: justify; color: fuchsia"><font style="font: 10pt Times New Roman, Times, Serif; color: Black"></font></p>
<p style="font: 10.5pt Trebuchet MS, Times, Serif; margin: 12pt 0 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
have served as the Company's auditor since 2013</font></p>
<p style="font: 10.5pt Trebuchet MS, Times, Serif; margin: 0; text-align: justify; color: fuchsia"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </font></p>
<p style="font: 10.5pt Trebuchet MS, Times, Serif; margin: 0; text-align: justify; color: fuchsia"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </font></p>
<p style="font: 10.5pt Trebuchet MS, Times, Serif; margin: 0; text-align: justify; color: fuchsia"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">New
York, New York</font></p>
<p style="font: 10.5pt Trebuchet MS, Times, Serif; margin: 0; text-align: justify; color: fuchsia"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">December
16, 2019</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"><b> </b></font></p>
<!-- Field: Page; Sequence: 39 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="margin: 0pt"> </p></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"><b> </b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: fuchsia"><font style="color: Black"><b>Report
of Independent Registered Public Accounting Firm </b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; color: fuchsia"><font style="color: Black">Shareholders
and Board of Directors</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="color: Black">Anavex Life Sciences
Corp.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="color: Black">New York, New York</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; color: fuchsia"><font style="color: Black"><b>Opinion
on Internal Control over Financial Reporting</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; color: fuchsia"><font style="color: Black">We
have audited Anavex Life Sciences Corp.’s (the “Company’s”) internal control over financial reporting
as of September 30, 2019, based on criteria established in <i>Internal Control – Integrated Framework (2013)</i> issued
by the Committee of Sponsoring Organizations of the Treadway Commission (the “COSO criteria”). In our opinion, the
Company did not maintain, in all material respects, effective internal control over financial reporting as of September 30, 2019,
based on the COSO criteria.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 6pt; text-align: justify; color: fuchsia"><font style="color: Black">We
do not express an opinion or any other form of assurance on management’s statements referring to any corrective actions
taken by the Company after the date of management’s assessment.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 6pt; text-align: justify">We also have audited, in accordance
with the standards of the Public Company Accounting Oversight Board (United States) (“PCAOB”), the consolidated balance
sheets of the Company and subsidiaries as of September 30, 2019 and 2018, the related consolidated statements of operations, stockholders’
equity, and cash flows for each of the two years in the period ended September 30, 2019, and the related notes (collectively referred
to as “the financial statements”) and our report dated December 16, 2019 expressed an unqualified opinion thereon.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; color: fuchsia"><font style="color: Black"><b>Basis
for Opinion</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><font style="color: Black">The Company’s
management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness
of internal control over financial reporting, included in the accompanying Item 9A, Management’s Report on Internal Control
over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting
based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect
to the Company in accordance with U.S. federal securities laws and the applicable rules and regulations of the Securities and
Exchange Commission and the PCAOB.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify; color: fuchsia"><font style="color: Black">We
conducted our audit of internal control over financial reporting in accordance with the standards of the PCAOB. Those standards
require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial
reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial
reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness
of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary
in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; color: fuchsia"><font style="color: Black">A
material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there
is a reasonable possibility that a material misstatement of the company’s annual or interim financial statements will not
be prevented or detected on a timely basis. A material weakness regarding management’s failure to design and maintain effective
internal controls over the accuracy of accounting for the Australian research and development  incentive program has been identified and described in management’s assessment.
This material weakness was considered in determining the nature, timing, and extent of audit tests applied in our audit of the
2019 financial statements, and this report does not affect our report dated December 16, 2019 on those financial statements.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify; color: fuchsia"><font style="color: Black"><b>Definition
and Limitations of Internal Control over Financial Reporting</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify; color: fuchsia"><font style="color: Black">A
company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures
that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and
dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit
preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures
of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide
reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s
assets that could have a material effect on the financial statements.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; color: fuchsia"><font style="color: Black">Because
of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections
of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes
in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; color: fuchsia"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">/S/
BDO USA, LLP <br/>
 </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: fuchsia"><font style="color: Black"></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: fuchsia"><font style="color: Black">New
York, New York</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="color: Black">December 16, 2019</font></p>
<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="color: Black"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"><b> </b></font></p>
<!-- Field: Page; Sequence: 39 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="margin: 0pt"> </p></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"><b> </b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-size: 10pt"><b>ANAVEX
LIFE SCIENCES CORP.</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-size: 10pt">CONSOLIDATED
BALANCE SHEETS</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-size: 10pt">As at September
30, 2019 and 2018</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-size: 10pt"><b> </b></font></p>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td style="white-space: nowrap; border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td><td style="font-weight: bold; border-bottom: Black 1pt solid; white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 10pt">2019</font></td><td style="border-bottom: Black 1pt solid; font-weight: bold; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 10pt">2018</font></td><td style="border-bottom: Black 1pt solid; white-space: nowrap"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom">
<td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td><font style="font-size: 10pt">Assets</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td><font style="font-size: 10pt">Current</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 70%; text-align: left; padding-left: 9pt"><font style="font-size: 10pt">Cash and cash equivalents</font></td><td style="width: 1%; font-weight: bold"><font style="font-size: 10pt"> </font></td>
<td style="width: 1%; font-weight: bold; text-align: left"><font style="font-size: 10pt">$</font></td><td style="width: 12%; font-weight: bold; text-align: right"><font style="font-size: 10pt">22,185,630</font></td><td style="width: 1%; font-weight: bold; text-align: left"><font style="font-size: 10pt"> </font></td><td style="width: 1%"><font style="font-size: 10pt"> </font></td>
<td style="width: 1%; text-align: left"><font style="font-size: 10pt">$</font></td><td style="width: 12%; text-align: right"><font style="font-size: 10pt">22,930,638</font></td><td style="width: 1%; text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; padding-left: 9pt"><font style="font-size: 10pt">Incentive and tax receivables</font></td><td style="font-weight: bold"><font style="font-size: 10pt"> </font></td>
<td style="font-weight: bold; text-align: left"><font style="font-size: 10pt"> </font></td><td style="font-weight: bold; text-align: right"><font style="font-size: 10pt">2,642,745</font></td><td style="font-weight: bold; text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">1,870,357</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; border-bottom: Black 1pt solid; padding-left: 9pt"><font style="font-size: 10pt">Prepaid expenses
    and deposits</font></td><td style="font-weight: bold; border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><font style="font-size: 10pt">500,998</font></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 10pt">1,251,798</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left"><font style="font-size: 10pt">Total Current Assets</font></td><td style="font-weight: bold"><font style="font-size: 10pt"> </font></td>
<td style="font-weight: bold; text-align: left"><font style="font-size: 10pt"> </font></td><td style="font-weight: bold; text-align: right"><font style="font-size: 10pt">25,329,373</font></td><td style="font-weight: bold; text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">26,052,793</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left"><font style="font-size: 10pt">Deferred costs</font></td><td style="font-weight: bold"><font style="font-size: 10pt"> </font></td>
<td style="font-weight: bold; text-align: left"><font style="font-size: 10pt"> </font></td><td style="font-weight: bold; text-align: right"><font style="font-size: 10pt">-</font></td><td style="font-weight: bold; text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">101,133</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt">Deposits</font></td><td style="font-weight: bold; border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><font style="font-size: 10pt">-</font></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 10pt">52,396</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; border-bottom: Black 2.5pt double"><font style="font-size: 10pt">Total Assets</font></td><td style="font-weight: bold; border-bottom: Black 2.5pt double"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><font style="font-size: 10pt">$</font></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><font style="font-size: 10pt">25,329,373</font></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 2.5pt double"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 10pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 10pt">26,206,322</font></td><td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left"><font style="font-size: 10pt">Liabilities and Stockholders' Equity</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left"><font style="font-size: 10pt">Current Liabilities</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-left: 9pt"><font style="font-size: 10pt">Accounts payable</font></td><td style="font-weight: bold"><font style="font-size: 10pt"> </font></td>
<td style="font-weight: bold; text-align: left"><font style="font-size: 10pt">$</font></td><td style="font-weight: bold; text-align: right"><font style="font-size: 10pt">3,523,332</font></td><td style="font-weight: bold; text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt">$</font></td><td style="text-align: right"><font style="font-size: 10pt">2,955,293</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; border-bottom: Black 1pt solid; padding-left: 9pt"><font style="font-size: 10pt">Accrued liabilities</font></td><td style="font-weight: bold; border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><font style="font-size: 10pt">1,516,342</font></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 10pt">929,333</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; border-bottom: Black 1pt solid"><font style="font-size: 10pt">Total Liabilities</font></td><td style="font-weight: bold; border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><font style="font-size: 10pt">5,039,674</font></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 10pt">3,884,626</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left"><font style="font-size: 10pt">Commitments - Note 5</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left"><font style="font-size: 10pt">Capital stock</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-left: 0.125in"><font style="font-size: 10pt">Authorized:</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding-left: 0.25in"><font style="font-size: 10pt">10,000,000 preferred stock, par value $0.001 per share</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-left: 0.25in"><font style="font-size: 10pt">100,000,000 common stock, par value $0.001 per share</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-left: 0.125in"><font style="font-size: 10pt">Issued and outstanding:</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-left: 0.25in"><font style="font-size: 10pt">52,650,251 common shares (2018 - 45,933,472)</font></td><td style="font-weight: bold"><font style="font-size: 10pt"> </font></td>
<td style="font-weight: bold; text-align: left"><font style="font-size: 10pt"> </font></td><td style="font-weight: bold; text-align: right"><font style="font-size: 10pt">52,652</font></td><td style="font-weight: bold; text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">45,935</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left"><font style="font-size: 10pt">Additional paid-in capital</font></td><td style="font-weight: bold"><font style="font-size: 10pt"> </font></td>
<td style="font-weight: bold; text-align: left"><font style="font-size: 10pt"> </font></td><td style="font-weight: bold; text-align: right"><font style="font-size: 10pt">153,633,807</font></td><td style="font-weight: bold; text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">129,377,542</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; border-bottom: Black 1pt solid"><font style="font-size: 10pt">Accumulated deficit</font></td><td style="font-weight: bold; border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><font style="font-size: 10pt">(133,396,760</font></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><font style="font-size: 10pt">)</font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 10pt">(107,101,781</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; border-bottom: Black 1pt solid"><font style="font-size: 10pt">Total Stockholders' Equity</font></td><td style="font-weight: bold; border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><font style="font-size: 10pt">20,289,699</font></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 10pt">22,321,696</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; border-bottom: Black 2.5pt double; padding-left: 0.125in"><font style="font-size: 10pt">Total
    Liabilities and Stockholders' Equity</font></td><td style="font-weight: bold; border-bottom: Black 2.5pt double"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><font style="font-size: 10pt">$</font></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><font style="font-size: 10pt">25,329,373</font></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 2.5pt double"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 10pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 10pt">26,206,322</font></td><td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 10pt"> </font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-size: 10pt">See Accompanying
Notes to Consolidated Financial Statements</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-size: 10pt"> </font></p>
<!-- Field: Page; Sequence: 40; Options: NewSection; Value: 1 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-size: 10pt"><b>ANAVEX
LIFE SCIENCES CORP.</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-size: 10pt">CONSOLIDATED
STATEMENTS OF OPERATIONS</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-size: 10pt">For the years
ended September 30, 2019 and 2018</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-size: 10pt"> </font></p>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td style="white-space: nowrap; border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td><td style="font-weight: bold; border-bottom: Black 1pt solid; white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 10pt">2019</font></td><td style="border-bottom: Black 1pt solid; font-weight: bold; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 10pt">2018</font></td><td style="border-bottom: Black 1pt solid; white-space: nowrap"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left"><font style="font-size: 10pt">Operating expenses</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="width: 70%; text-align: left"><font style="font-size: 10pt">General and administrative</font></td><td style="width: 1%; font-weight: bold"><font style="font-size: 10pt"> </font></td>
<td style="width: 1%; font-weight: bold; text-align: left"><font style="font-size: 10pt">$</font></td><td style="width: 12%; font-weight: bold; text-align: right"><font style="font-size: 10pt">6,846,599</font></td><td style="width: 1%; font-weight: bold; text-align: left"><font style="font-size: 10pt"> </font></td><td style="width: 1%"><font style="font-size: 10pt"> </font></td>
<td style="width: 1%; text-align: left"><font style="font-size: 10pt">$</font></td><td style="width: 12%; text-align: right"><font style="font-size: 10pt">5,989,170</font></td><td style="width: 1%; text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; border-bottom: Black 1pt solid"><font style="font-size: 10pt">Research and development</font></td><td style="font-weight: bold; border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td>
<td style="font-weight: bold; text-align: left; border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td><td style="font-weight: bold; text-align: right; border-bottom: Black 1pt solid"><font style="font-size: 10pt">22,260,349</font></td><td style="font-weight: bold; text-align: left; border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td><td style="text-align: right; border-bottom: Black 1pt solid"><font style="font-size: 10pt">13,344,421</font></td><td style="text-align: left; border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left"><font style="font-size: 10pt">Total operating expenses</font></td><td style="font-weight: bold"><font style="font-size: 10pt"> </font></td>
<td style="font-weight: bold; text-align: left"><font style="font-size: 10pt"> </font></td><td style="font-weight: bold; text-align: right"><font style="font-size: 10pt">(29,106,948</font></td><td style="font-weight: bold; text-align: left"><font style="font-size: 10pt">)</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">(19,333,591</font></td><td style="text-align: left"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left"><font style="font-size: 10pt">Other income (expenses)</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left"><font style="font-size: 10pt">Grant income</font></td><td style="font-weight: bold"><font style="font-size: 10pt"> </font></td>
<td style="font-weight: bold; text-align: left"><font style="font-size: 10pt"> </font></td><td style="font-weight: bold; text-align: right"><font style="font-size: 10pt">298,943</font></td><td style="font-weight: bold; text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">149,055</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left"><font style="font-size: 10pt">Research and development incentive income</font></td><td style="font-weight: bold"><font style="font-size: 10pt"> </font></td>
<td style="font-weight: bold; text-align: left"><font style="font-size: 10pt"> </font></td><td style="font-weight: bold; text-align: right"><font style="font-size: 10pt">2,465,691</font></td><td style="font-weight: bold; text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">1,830,186</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left"><font style="font-size: 10pt">Interest income, net</font></td><td style="font-weight: bold"><font style="font-size: 10pt"> </font></td>
<td style="font-weight: bold; text-align: left"><font style="font-size: 10pt"> </font></td><td style="font-weight: bold; text-align: right"><font style="font-size: 10pt">207,280</font></td><td style="font-weight: bold; text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">255,092</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left"><font style="font-size: 10pt">Gain on settlement of accounts payable</font></td><td style="font-weight: bold"><font style="font-size: 10pt"> </font></td>
<td style="font-weight: bold; text-align: left"><font style="font-size: 10pt"> </font></td><td style="font-weight: bold; text-align: right"><font style="font-size: 10pt">115,758</font></td><td style="font-weight: bold; text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">-</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left"><font style="font-size: 10pt">Financing related charges</font></td><td style="font-weight: bold"><font style="font-size: 10pt"> </font></td>
<td style="font-weight: bold; text-align: left"><font style="font-size: 10pt"> </font></td><td style="font-weight: bold; text-align: right"><font style="font-size: 10pt">(151,133</font></td><td style="font-weight: bold; text-align: left"><font style="font-size: 10pt">)</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">(30,943</font></td><td style="text-align: left"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; border-bottom: Black 1pt solid"><font style="font-size: 10pt">Foreign exchange gain (loss), net</font></td><td style="font-weight: bold; border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><font style="font-size: 10pt">(42,389</font></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><font style="font-size: 10pt">)</font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 10pt">(49,789</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; border-bottom: Black 1pt solid"><font style="font-size: 10pt">Total other income, net</font></td><td style="font-weight: bold; border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><font style="font-size: 10pt">2,894,150</font></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 10pt">2,153,601</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left"><font style="font-size: 10pt">Net loss before provision for income taxes</font></td><td style="font-weight: bold"><font style="font-size: 10pt"> </font></td>
<td style="font-weight: bold; text-align: left"><font style="font-size: 10pt"> </font></td><td style="font-weight: bold; text-align: right"><font style="font-size: 10pt">(26,212,798</font></td><td style="font-weight: bold; text-align: left"><font style="font-size: 10pt">)</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">(17,179,990</font></td><td style="text-align: left"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; border-bottom: Black 1pt solid"><font style="font-size: 10pt">Income tax expense, current</font></td><td style="font-weight: bold; border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><font style="font-size: 10pt">(82,181</font></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><font style="font-size: 10pt">)</font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 10pt">(72,746</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; border-bottom: Black 2.5pt double"><font style="font-size: 10pt">Net loss and comprehensive loss</font></td><td style="font-weight: bold; border-bottom: Black 2.5pt double"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><font style="font-size: 10pt">$</font></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><font style="font-size: 10pt">(26,294,979</font></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><font style="font-size: 10pt">)</font></td><td style="border-bottom: Black 2.5pt double"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 10pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 10pt">(17,252,736</font></td><td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td><font style="font-size: 10pt">Net Loss per share</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; border-bottom: Black 2.5pt double; padding-left: 9pt"><font style="font-size: 10pt">Basic and
    diluted</font></td><td style="font-weight: bold; border-bottom: Black 2.5pt double"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><font style="font-size: 10pt">$</font></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><font style="font-size: 10pt">(0.54</font></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><font style="font-size: 10pt">)</font></td><td style="border-bottom: Black 2.5pt double"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 10pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 10pt">(0.39</font></td><td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td><font style="font-size: 10pt">Weighted average number of shares outstanding</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; border-bottom: Black 2.5pt double; padding-left: 9pt"><font style="font-size: 10pt">Basic and
    diluted</font></td><td style="border-bottom: Black 2.5pt double"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 10pt">48,906,470</font></td><td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 2.5pt double"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 10pt">44,655,725</font></td><td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 10pt"> </font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-size: 10pt">See Accompanying
Notes to Consolidated Financial Statements</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-size: 10pt"> </font></p>
<!-- Field: Page; Sequence: 41; Value: 1 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-size: 10pt"><b>ANAVEX
LIFE SCIENCES CORP.</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF CASH FLOWS</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-size: 10pt">For the years
ended September 30, 2019 and 2018</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-size: 10pt"> </font></p>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td style="white-space: nowrap; border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td><td style="font-weight: bold; border-bottom: Black 1pt solid; white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 10pt">2019</font></td><td style="border-bottom: Black 1pt solid; font-weight: bold; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="font-weight: bold; border-bottom: Black 1pt solid; white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 10pt">2018</font></td><td style="border-bottom: Black 1pt solid; font-weight: bold; white-space: nowrap"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom">
<td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left"><font style="font-size: 10pt">Cash Flows used in Operating Activities</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="width: 70%; text-align: left"><font style="font-size: 10pt">Net loss</font></td><td style="width: 1%; font-weight: bold"><font style="font-size: 10pt"> </font></td>
<td style="width: 1%; font-weight: bold; text-align: left"><font style="font-size: 10pt">$</font></td><td style="width: 12%; font-weight: bold; text-align: right"><font style="font-size: 10pt">(26,294,979</font></td><td style="width: 1%; font-weight: bold; text-align: left"><font style="font-size: 10pt">)</font></td><td style="width: 1%"><font style="font-size: 10pt"> </font></td>
<td style="width: 1%; text-align: left"><font style="font-size: 10pt">$</font></td><td style="width: 12%; text-align: right"><font style="font-size: 10pt">(17,252,736</font></td><td style="width: 1%; text-align: left"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left"><font style="font-size: 10pt">Adjustments to reconcile net loss to net cash used in operations:</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; padding-left: 9pt"><font style="font-size: 10pt">Stock-based compensation</font></td><td style="font-weight: bold"><font style="font-size: 10pt"> </font></td>
<td style="font-weight: bold; text-align: left"><font style="font-size: 10pt"> </font></td><td style="font-weight: bold; text-align: right"><font style="font-size: 10pt">6,430,873</font></td><td style="font-weight: bold; text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">5,517,004</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-left: 9pt"><font style="font-size: 10pt">Deferred costs</font></td><td style="font-weight: bold"><font style="font-size: 10pt"> </font></td>
<td style="font-weight: bold; text-align: left"><font style="font-size: 10pt"> </font></td><td style="font-weight: bold; text-align: right"><font style="font-size: 10pt">151,133</font></td><td style="font-weight: bold; text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">-</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; padding-left: 9pt"><font style="font-size: 10pt">Gain on settlement of accounts payable</font></td><td style="font-weight: bold"><font style="font-size: 10pt"> </font></td>
<td style="font-weight: bold; text-align: left"><font style="font-size: 10pt"> </font></td><td style="font-weight: bold; text-align: right"><font style="font-size: 10pt">(115,758</font></td><td style="font-weight: bold; text-align: left"><font style="font-size: 10pt">)</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">-</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left"><font style="font-size: 10pt">Changes in non-cash working capital balances related to operations:</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; padding-left: 9pt"><font style="font-size: 10pt">Incentive and tax receivables</font></td><td style="font-weight: bold"><font style="font-size: 10pt"> </font></td>
<td style="font-weight: bold; text-align: left"><font style="font-size: 10pt"> </font></td><td style="font-weight: bold; text-align: right"><font style="font-size: 10pt">(772,388</font></td><td style="font-weight: bold; text-align: left"><font style="font-size: 10pt">)</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">(231,096</font></td><td style="text-align: left"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-left: 9pt"><font style="font-size: 10pt">Prepaid expenses and deposits</font></td><td style="font-weight: bold"><font style="font-size: 10pt"> </font></td>
<td style="font-weight: bold; text-align: left"><font style="font-size: 10pt"> </font></td><td style="font-weight: bold; text-align: right"><font style="font-size: 10pt">803,196</font></td><td style="font-weight: bold; text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">(915,870</font></td><td style="text-align: left"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; padding-left: 9pt"><font style="font-size: 10pt">Accounts payable</font></td><td style="font-weight: bold"><font style="font-size: 10pt"> </font></td>
<td style="font-weight: bold; text-align: left"><font style="font-size: 10pt"> </font></td><td style="font-weight: bold; text-align: right"><font style="font-size: 10pt">683,797</font></td><td style="font-weight: bold; text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">38,233</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; border-bottom: Black 1pt solid; padding-left: 9pt"><font style="font-size: 10pt">Accrued liabilities</font></td><td style="font-weight: bold; border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><font style="font-size: 10pt">587,009</font></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 10pt">262,059</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left"><font style="font-size: 10pt">Net cash used in operating activities</font></td><td style="font-weight: bold"><font style="font-size: 10pt"> </font></td>
<td style="font-weight: bold; text-align: left"><font style="font-size: 10pt"> </font></td><td style="font-weight: bold; text-align: right"><font style="font-size: 10pt">(18,527,117</font></td><td style="font-weight: bold; text-align: left"><font style="font-size: 10pt">)</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">(12,582,406</font></td><td style="text-align: left"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left"><font style="font-size: 10pt">Cash Flows provided by Financing Activities</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td><font style="font-size: 10pt">Issuance of common shares</font></td><td style="font-weight: bold"><font style="font-size: 10pt"> </font></td>
<td style="font-weight: bold; text-align: left"><font style="font-size: 10pt"> </font></td><td style="font-weight: bold; text-align: right"><font style="font-size: 10pt">17,832,109</font></td><td style="font-weight: bold; text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">8,173,920</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; border-bottom: Black 1pt solid"><font style="font-size: 10pt">Deferred financing charges</font></td><td style="font-weight: bold; border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><font style="font-size: 10pt">(50,000</font></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><font style="font-size: 10pt">)</font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 10pt">(101,133</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left"><font style="font-size: 10pt">Net cash provided by financing activities</font></td><td style="font-weight: bold"><font style="font-size: 10pt"> </font></td>
<td style="font-weight: bold; text-align: left"><font style="font-size: 10pt"> </font></td><td style="font-weight: bold; text-align: right"><font style="font-size: 10pt">17,782,109</font></td><td style="font-weight: bold; text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">8,072,787</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left"><font style="font-size: 10pt">Decrease in cash and cash equivalents during the period</font></td><td style="font-weight: bold"><font style="font-size: 10pt"> </font></td>
<td style="font-weight: bold; text-align: left"><font style="font-size: 10pt"> </font></td><td style="font-weight: bold; text-align: right"><font style="font-size: 10pt">(745,008</font></td><td style="font-weight: bold; text-align: left"><font style="font-size: 10pt">)</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">(4,509,619</font></td><td style="text-align: left"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; border-bottom: Black 1pt solid"><font style="font-size: 10pt">Cash and cash equivalents, beginning
    of period</font></td><td style="font-weight: bold; border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><font style="font-size: 10pt">22,930,638</font></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 10pt">27,440,257</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; border-bottom: Black 2.5pt double"><font style="font-size: 10pt">Cash and cash equivalents, end
    of period</font></td><td style="font-weight: bold; border-bottom: Black 2.5pt double"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><font style="font-size: 10pt">$</font></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><font style="font-size: 10pt">22,185,630</font></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 2.5pt double"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 10pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 10pt">22,930,638</font></td><td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 10pt"> </font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><font style="font-size: 10pt">See
Accompanying Notes to Consolidated Financial Statements</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<!-- Field: Page; Sequence: 42; Value: 1 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-size: 10pt"><b>ANAVEX
LIFE SCIENCES CORP.</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-size: 10pt">CONSOLIDATED
STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-size: 10pt">For the years
ended September 30, 2019 and 2018</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td style="white-space: nowrap; text-align: center; padding-bottom: 1pt"><font style="font-size: 10pt"> </font></td><td style="padding-bottom: 1pt; white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td colspan="10" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 10pt">Common
    Stock</font></td><td style="padding-bottom: 1pt; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="padding-bottom: 1pt; white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td colspan="6" style="white-space: nowrap; text-align: center; padding-bottom: 1pt"><font style="font-size: 10pt"> </font></td><td style="padding-bottom: 1pt; white-space: nowrap"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom">
<td style="white-space: nowrap; text-align: center"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 10pt">Additional</font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom">
<td style="white-space: nowrap; text-align: center"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 10pt">Paid-in</font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 10pt">Accumulated</font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom">
<td style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 10pt">Shares</font></td><td style="border-bottom: Black 1pt solid; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 10pt">Par
    Value</font></td><td style="border-bottom: Black 1pt solid; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 10pt">Capital</font></td><td style="border-bottom: Black 1pt solid; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 10pt">Deficit</font></td><td style="border-bottom: Black 1pt solid; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 10pt">Total</font></td><td style="border-bottom: Black 1pt solid; white-space: nowrap"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom">
<td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 35%"><font style="font-size: 10pt">Balance, September 30, 2017</font></td><td style="width: 1%"><font style="font-size: 10pt"> </font></td>
<td style="width: 1%; text-align: left"><font style="font-size: 10pt"> </font></td><td style="width: 10%; text-align: right"><font style="font-size: 10pt">43,330,817</font></td><td style="width: 1%; text-align: left"><font style="font-size: 10pt"> </font></td><td style="width: 1%"><font style="font-size: 10pt"> </font></td>
<td style="width: 1%; text-align: left"><font style="font-size: 10pt">$</font></td><td style="width: 10%; text-align: right"><font style="font-size: 10pt">43,332</font></td><td style="width: 1%; text-align: left"><font style="font-size: 10pt"> </font></td><td style="width: 1%"><font style="font-size: 10pt"> </font></td>
<td style="width: 1%; text-align: left"><font style="font-size: 10pt">$</font></td><td style="width: 10%; text-align: right"><font style="font-size: 10pt">115,689,221</font></td><td style="width: 1%; text-align: left"><font style="font-size: 10pt"> </font></td><td style="width: 1%"><font style="font-size: 10pt"> </font></td>
<td style="width: 1%; text-align: left"><font style="font-size: 10pt">$</font></td><td style="width: 10%; text-align: right"><font style="font-size: 10pt">(89,849,045</font></td><td style="width: 1%; text-align: left"><font style="font-size: 10pt">)</font></td><td style="width: 1%"><font style="font-size: 10pt"> </font></td>
<td style="width: 1%; text-align: left"><font style="font-size: 10pt">$</font></td><td style="width: 10%; text-align: right"><font style="font-size: 10pt">25,883,508</font></td><td style="width: 1%; text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left"><font style="font-size: 10pt">Shares issued under 2015 Purchase Agreement</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding-left: 9pt"><font style="font-size: 10pt">Purchase shares</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">2,383,580</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">2,384</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">8,171,536</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">-</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">8,173,920</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-left: 9pt"><font style="font-size: 10pt">Commitment shares</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">14,681</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">15</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">(15</font></td><td style="text-align: left"><font style="font-size: 10pt">)</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">-</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">-</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left"><font style="font-size: 10pt">Shares issued pursuant to cashless exercise of options</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">78,646</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">78</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">(78</font></td><td style="text-align: left"><font style="font-size: 10pt">)</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">-</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">-</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left"><font style="font-size: 10pt">Shares issued pursuant to cashless exercise of warrants</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">125,748</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">126</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">(126</font></td><td style="text-align: left"><font style="font-size: 10pt">)</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">-</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">-</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td><font style="font-size: 10pt">Share based compensation</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">-</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">-</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">5,517,004</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">-</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">5,517,004</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; border-bottom: Black 1pt solid"><font style="font-size: 10pt">Net loss</font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 10pt">-</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 10pt">-</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 10pt">-</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 10pt">(17,252,736</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt">)</font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 10pt">(17,252,736</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td><font style="font-size: 10pt">Balance, September 30, 2018</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">45,933,472</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt">$</font></td><td style="text-align: right"><font style="font-size: 10pt">45,935</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt">$</font></td><td style="text-align: right"><font style="font-size: 10pt">129,377,542</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt">$</font></td><td style="text-align: right"><font style="font-size: 10pt">(107,101,781</font></td><td style="text-align: left"><font style="font-size: 10pt">)</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt">$</font></td><td style="text-align: right"><font style="font-size: 10pt">22,321,696</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left"><font style="font-size: 10pt">Shares issued under 2015 Purchase Agreement</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-left: 9pt"><font style="font-size: 10pt">Purchase shares</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">4,848,995</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">4,849</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">13,192,755</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">-</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">13,197,604</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding-left: 9pt"><font style="font-size: 10pt">Commitment shares</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">23,701</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">24</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">(24</font></td><td style="text-align: left"><font style="font-size: 10pt">)</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">-</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">-</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left"><font style="font-size: 10pt">Shares issued under 2019 Purchase Agreement</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding-left: 9pt"><font style="font-size: 10pt">Purchase shares</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">1,500,000</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">1,500</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">4,633,005</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">-</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">4,634,505</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-left: 9pt"><font style="font-size: 10pt">Commitment shares</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">339,415</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">339</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">(339</font></td><td style="text-align: left"><font style="font-size: 10pt">)</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">-</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">-</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left"><font style="font-size: 10pt">Shares issued pursuant to cashless exercise of warrants</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">4,938</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">5</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">(5</font></td><td style="text-align: left"><font style="font-size: 10pt">)</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">-</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">-</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td><font style="font-size: 10pt">Share based compensation</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">-</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">-</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">6,430,873</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">-</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">6,430,873</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; border-bottom: Black 1pt solid"><font style="font-size: 10pt">Net loss</font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 10pt">-</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 10pt">-</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 10pt">-</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 10pt">(26,294,979</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt">)</font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 10pt">(26,294,979</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="border-bottom: Black 2.5pt double"><font style="font-size: 10pt">Balance, September 30, 2019</font></td><td style="border-bottom: Black 2.5pt double"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 10pt">52,650,521</font></td><td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 2.5pt double"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 10pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 10pt">52,652</font></td><td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 2.5pt double"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 10pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 10pt">153,633,807</font></td><td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 2.5pt double"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 10pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 10pt">(133,396,760</font></td><td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 10pt">)</font></td><td style="border-bottom: Black 2.5pt double"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 10pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 10pt">20,289,699</font></td><td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 10pt"> </font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><font style="font-size: 10pt">See
Accompanying Notes to Consolidated Financial Statements</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<!-- Field: Page; Sequence: 43; Value: 1 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt">Anavex Life Sciences Corp.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt">Notes to the Consolidated Financial
Statements</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt">September 30, 2019 – Page
1</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.59in; text-align: left"><font style="font-size: 10pt">Note 1</font></td><td style="text-align: justify"><font style="font-size: 10pt"><u>Business
                                         Description and Basis of Presentation</u></font></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="text-indent: 0.59in"><font style="font-size: 10pt">Business </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42pt; text-align: justify"><font style="font-size: 10pt">Anavex
Life Sciences Corp. (the “Company”) is a clinical stage biopharmaceutical company engaged in the development of differentiated
therapeutics by applying precision medicine to central nervous system (“CNS”) diseases with high unmet need. Anavex
analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic
benefit for the treatment of neurodegenerative and neurodevelopmental diseases. The Company’s lead compound ANAVEX®2-73
is being developed to treat Alzheimer’s disease, Parkinson’s disease and potentially other central nervous system
diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in
the X-linked gene, methyl-CpG-binding protein 2 (“MECP2”).</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.59in"><font style="font-size: 10pt">Basis
of Presentation</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt">These
consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission
(“SEC”) and the instructions to Form 10-K and have been prepared under the accounting principles generally accepted
in the United States of America (“U.S. GAAP”).</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt">Liquidity</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt">All
of the Company’s potential drug compounds are in the clinical development stage and the Company cannot be certain that its
research and development efforts will be successful or, if successful, that its potential drug compounds will ever be approved
for sales to pharmaceutical companies or generate commercial revenues. To date, we have not generated any revenues from our operations.
The Company expects the business to continue to experience negative cash flows for the foreseeable future and cannot predict when,
if ever, our business might become profitable.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt">The
Company believes that its existing cash and cash equivalents, along with existing financial commitments from third parties, will
be sufficient to meet its cash commitments for in excess of two years after the date that these consolidated financial statements
are issued. The process of drug development can be costly, and the timing and outcomes of clinical trials is uncertain. The
assumptions upon which the Company has based its estimates are routinely evaluated and may be subject to change. The actual
amount of the Company’s expenditures will vary depending upon a number of factors including but not limited to the design,
timing and duration of future clinical trials, the progress of the Company’s research and development programs and the level
of financial resources available. The Company has the ability to adjust its operating plan spending levels based on the timing
of future clinical trials.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt">Other
than our rights related to the Sales Agreement and the 2019 Purchase Agreement (each as defined below), there can be no assurance
that additional financing will be available to us when needed or, if available, that it can be obtained on commercially reasonable
terms. If we are not able to obtain the additional financing on a timely basis, if and when it is needed, we will be forced to
delay or scale down some or all of our research and development activities.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<!-- Field: Page; Sequence: 44; Value: 1 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt">Anavex Life Sciences Corp.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt">Notes to the Consolidated Financial
Statements</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt">September 30, 2019 – Page
2</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.59in; text-align: left"><font style="font-size: 10pt">Note 1</font></td><td style="text-align: justify"><font style="font-size: 10pt"><u>Business
                                         Description and Basis of Presentation</u> – Continued</font></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt"></p>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjustment
of Prior Period Financial Statements</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font-size: 10pt">The
Company adjusted amounts to previously reported consolidated financial statements which were immaterial. These adjustments were
identified in connection with the preparation of the consolidated financial statements for the year ended September 30, 2019 and
related to the timing of recognition of research and development incentive income. Previously the Company accounted for research
and development incentive income when received in cash. During the year ended September 30, 2019, based on a continuing assessment
regarding the Company’s eligibility for the incentive programs under which it was receiving such income, the Company determined
that the income should have been accrued and recorded in the period in which the qualifying research and development expenditures
were incurred.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt">The
Company evaluated the materiality of these misstatements both qualitatively and quantitatively in accordance with Staff Accounting
Bulletin (“SAB”) No. 99 Materiality and SAB No. 108, Considering the Effects of Prior Year Misstatements When Quantifying
Misstatements in Current Year Financial Statements, and determined that the effect of the adjustment in the period of origination
was not material.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"></p>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company adjusted the accumulated deficit as of the beginning of the earliest year presented in these consolidated financial statements,
resulting in a decrease in the previously reported deficit at October 1, 2017 by $1,629,513 from $(91,478,558) to the adjusted
amount $(89,849,045). In addition, the consolidated financial statements for the year ended September 30, 2018 presented herein
have been adjusted to include an increase in net income and incentives and taxes receivable as noted below.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: 42.55pt"><font style="font-size: 10pt"> </font></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 92%; margin-left: 0.59in">
<tr style="vertical-align: bottom">
<td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 10pt">As Previously</font></td><td><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom">
<td style="white-space: nowrap; padding-bottom: 1pt"><font style="font-size: 10pt"> </font></td><td style="padding-bottom: 1pt"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 10pt">Reported</font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 10pt">Adjustment</font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 10pt">As
    Adjusted</font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font-weight: bold; text-align: left"><font style="font-size: 10pt">Balance Sheet:</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="width: 61%; text-align: left"><font style="font-size: 10pt">Incentive and tax receivables</font></td><td style="width: 1%"><font style="font-size: 10pt"> </font></td>
<td style="width: 1%; text-align: left"><font style="font-size: 10pt">$</font></td><td style="width: 10%; text-align: right"><font style="font-size: 10pt">40,171</font></td><td style="width: 1%; text-align: left"><font style="font-size: 10pt"> </font></td><td style="width: 1%"><font style="font-size: 10pt"> </font></td>
<td style="width: 1%; text-align: left"><font style="font-size: 10pt">$</font></td><td style="width: 10%; text-align: right"><font style="font-size: 10pt">1,830,186</font></td><td style="width: 1%; text-align: left"><font style="font-size: 10pt"> </font></td><td style="width: 1%"><font style="font-size: 10pt"> </font></td>
<td style="width: 1%; text-align: left"><font style="font-size: 10pt">$</font></td><td style="width: 10%; text-align: right"><font style="font-size: 10pt">1,870,357</font></td><td style="width: 1%; text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left"><font style="font-size: 10pt">Total current assets</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt">$</font></td><td style="text-align: right"><font style="font-size: 10pt">24,222,607</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt">$</font></td><td style="text-align: right"><font style="font-size: 10pt">1,830,186</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt">$</font></td><td style="text-align: right"><font style="font-size: 10pt">26,052,793</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left"><font style="font-size: 10pt">Total assets</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt">$</font></td><td style="text-align: right"><font style="font-size: 10pt">24,376,136</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt">$</font></td><td style="text-align: right"><font style="font-size: 10pt">1,830,186</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt">$</font></td><td style="text-align: right"><font style="font-size: 10pt">26,206,322</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left"><font style="font-size: 10pt">Accumulated deficit</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt">$</font></td><td style="text-align: right"><font style="font-size: 10pt">(108,931,967</font></td><td style="text-align: left"><font style="font-size: 10pt">)</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt">$</font></td><td style="text-align: right"><font style="font-size: 10pt">1,830,186</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt">$</font></td><td style="text-align: right"><font style="font-size: 10pt">(107,101,781</font></td><td style="text-align: left"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left"><font style="font-size: 10pt">Total Stockholders' Equity</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt">$</font></td><td style="text-align: right"><font style="font-size: 10pt">20,491,510</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt">$</font></td><td style="text-align: right"><font style="font-size: 10pt">1,830,186</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt">$</font></td><td style="text-align: right"><font style="font-size: 10pt">22,321,696</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left"><font style="font-size: 10pt">Total Liabilities and Stockholders' Equity</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt">$</font></td><td style="text-align: right"><font style="font-size: 10pt">24,376,136</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt">$</font></td><td style="text-align: right"><font style="font-size: 10pt">1,830,186</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt">$</font></td><td style="text-align: right"><font style="font-size: 10pt">26,206,322</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-weight: bold"><font style="font-size: 10pt">Statement of Operations:</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left"><font style="font-size: 10pt">Research and development incentive income</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt">$</font></td><td style="text-align: right"><font style="font-size: 10pt">1,629,513</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt">$</font></td><td style="text-align: right"><font style="font-size: 10pt">200,673</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt">$</font></td><td style="text-align: right"><font style="font-size: 10pt">1,830,186</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left"><font style="font-size: 10pt">Total other income, net</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt">$</font></td><td style="text-align: right"><font style="font-size: 10pt">1,952,928</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt">$</font></td><td style="text-align: right"><font style="font-size: 10pt">200,673</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt">$</font></td><td style="text-align: right"><font style="font-size: 10pt">2,153,601</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left"><font style="font-size: 10pt">Net loss before provision for income taxes</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt">$</font></td><td style="text-align: right"><font style="font-size: 10pt">(17,380,663</font></td><td style="text-align: left"><font style="font-size: 10pt">)</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt">$</font></td><td style="text-align: right"><font style="font-size: 10pt">200,673</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt">$</font></td><td style="text-align: right"><font style="font-size: 10pt">(17,179,990</font></td><td style="text-align: left"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left"><font style="font-size: 10pt">Net loss and comprehensive loss</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt">$</font></td><td style="text-align: right"><font style="font-size: 10pt">(17,453,409</font></td><td style="text-align: left"><font style="font-size: 10pt">)</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt">$</font></td><td style="text-align: right"><font style="font-size: 10pt">200,673</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt">$</font></td><td style="text-align: right"><font style="font-size: 10pt">(17,252,736</font></td><td style="text-align: left"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font-weight: bold; text-align: left"><font style="font-size: 10pt">Statement of Cash Flows:</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left"><font style="font-size: 10pt">Net loss</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt">$</font></td><td style="text-align: right"><font style="font-size: 10pt">(17,453,409</font></td><td style="text-align: left"><font style="font-size: 10pt">)</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt">$</font></td><td style="text-align: right"><font style="font-size: 10pt">200,673</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt">$</font></td><td style="text-align: right"><font style="font-size: 10pt">(17,252,736</font></td><td style="text-align: left"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left"><font style="font-size: 10pt">Incentive and tax receivables</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt">$</font></td><td style="text-align: right"><font style="font-size: 10pt">(30,423</font></td><td style="text-align: left"><font style="font-size: 10pt">)</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt">$</font></td><td style="text-align: right"><font style="font-size: 10pt">(200,673</font></td><td style="text-align: left"><font style="font-size: 10pt">)</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt">$</font></td><td style="text-align: right"><font style="font-size: 10pt">(231,096</font></td><td style="text-align: left"><font style="font-size: 10pt">)</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"></p>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">As the Company adjusted the research
and development incentive income for the year ended September 30, 2019 in the Company’s fourth quarter and determined that
amounts were immaterial to previously issued unaudited condensed consolidated financial statements, in future filings, the Company
will adjust corresponding quarterly amounts included in previously issued unaudited condensed consolidated financial statements
for the first, second and third quarter to increase research and development incentive income and reduce net loss by $413,682,
$510,990, and $552,335, respectively.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"></p>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<!-- Field: Page; Sequence: 45; Value: 1 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt">Anavex Life Sciences Corp.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt">Notes to the Consolidated Financial
Statements</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt">September 30, 2019 – Page
3</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.59in; text-align: left"><font style="font-size: 10pt">Note 2</font></td><td style="text-align: justify"><font style="font-size: 10pt"><u>Summary
                                         of Significant Accounting Policies</u></font></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 42.55pt"></td><td style="width: 18pt"><font style="font-size: 10pt; font-style: normal">a)</font></td><td style="text-align: justify"><font style="font-size: 10pt; font-style: normal">Use
                                         of Estimates</font></td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"></p>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and
expenses in the reporting period. The Company regularly evaluates estimates and assumptions related to accounting for research
and development costs, valuation and recoverability of deferred tax assets, asset impairment, stock-based compensation and loss
contingencies. The Company bases its estimates and assumptions on current facts, historical experience and various other factors
that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the
carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources.
The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent
there are material differences between the estimate s and the actual results, future results of operations will be affected.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.5pt; text-align: justify; text-indent: -0.25in"></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 42.5pt"></td><td style="width: 18pt"><font style="font-size: 10pt; font-style: normal">b)</font></td><td style="text-align: justify"><font style="font-size: 10pt; font-style: normal">Principles
                                         of Consolidation</font></td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt">These
consolidated financial statements include the accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex
Australia Pty Limited, a company incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated under the
laws of Germany, and Anavex Canada Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company
transactions and balances have been eliminated.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.55pt; text-align: justify; text-indent: -0.25in"><font style="font-size: 10pt; font-style: normal"> </font></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 42.55pt"></td><td style="width: 18pt"><font style="font-size: 10pt; font-style: normal">c)</font></td><td style="text-align: justify"><font style="font-size: 10pt; font-style: normal">Cash
                                         and equivalents</font></td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt; font-style: normal"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt">The
Company considers only those investments which are highly liquid, readily convertible to cash and that mature within three months
from the date of purchase to be cash equivalents.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<!-- Field: Page; Sequence: 46; Value: 1 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt">Anavex Life Sciences Corp.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt">Notes to the Consolidated Financial
Statements</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt">September 30, 2019 – Page
4</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.59in; text-align: left"><font style="font-size: 10pt">Note 2</font></td><td style="text-align: justify"><font style="font-size: 10pt"><u>Summary
                                         of Significant Accounting Policies</u> – (continued)</font></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 42.55pt"></td><td style="width: 18pt"><font style="font-size: 10pt">d)</font></td><td style="text-align: justify"><font style="font-size: 10pt">Research
                                         and Development Expenses</font></td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt"><i> </i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt">Research
and development costs are expensed as incurred. These expenses are comprised of the costs of the Company’s proprietary research
and development efforts, including preclinical studies, clinical trials, manufacturing costs, employee salaries and benefits and
stock based compensation expense, contract services including external research and development expenses incurred under arrangements
with third parties such as contract research organizations (“CROs”), facilities costs, overhead costs and other related
expenses. Milestone payments made by the Company to third parties are expensed when the specific milestone has been achieved.
Manufacturing costs are expensed as incurred in accordance with Accounting Standard Codification (“ASC”) 730, Research
and Development, as these materials have no alternative future use outside of their intended use.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt">Nonrefundable
advance payments for goods or services that will be used or rendered for future research and development activities are deferred
and amortized over the period that the goods are delivered, or the related services are performed, subject to an assessment of
recoverability. The Company makes estimates of costs incurred in relation to external CROs, and clinical site costs. The Company
analyzes the progress of clinical trials, including levels of patient enrollment, invoices received and contracted costs when
evaluating the adequacy of the amount expensed and the related prepaid asset and accrued liability. Significant judgments and
estimates must be made and used in determining the accrued balance and expense in any accounting period. The Company reviews and
accrues CRO expenses and clinical trial study expenses based on work performed and relies upon estimates of those costs applicable
to the stage of completion of a study. Accrued CRO costs are subject to revisions as such trials progress to completion. Revisions
are charged to expense in the period in which the facts that give rise to the revision become known. With respect to clinical
site costs, the financial terms of these agreements are subject to negotiation and vary from contract to contract. Payments under
these contracts may be uneven and depend on factors such as the achievement of certain events, the successful recruitment of patients,
the completion of portions of the clinical trial or similar conditions. The objective of our policy is to match the recording
of expenses in our financial statements to the actual services received and efforts expended. As such, expense accruals related
to clinical site costs are recognized based on our estimate of the degree of completion of the event or events specified in the
specific clinical study or trial contract.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt">In
addition, the Company incurs expenses in respect of the acquisition of intellectual property relating to patents and trademarks.
The probability of success and length of time to develop commercial applications of the drugs subject to the acquired patents
and trademarks is difficult to determine and numerous risks and uncertainties exist with respect to the timely completion of the
development projects. There is no assurance the acquired patents and trademarks will ever be successfully commercialized. Due
to these risks and uncertainties, the acquisition of patents and trademarks does not meet the definition of an asset and thus
are expensed as incurred within general and administrative expenses.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<!-- Field: Page; Sequence: 47; Value: 1 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt">Anavex Life Sciences Corp.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt">Notes to the Consolidated Financial
Statements</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt">September 30, 2019 – Page
5</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.59in; text-align: left"><font style="font-size: 10pt">Note 2</font></td><td style="text-align: justify"><font style="font-size: 10pt"><u>Summary
                                         of Significant Accounting Policies</u> – (continued)</font></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 42.55pt"></td><td style="width: 18pt"><font style="font-size: 10pt">e)</font></td><td style="text-align: justify"><font style="font-size: 10pt">Research
                                         and Development Incentive Income</font></td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt"><i> </i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"></p>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">The Company is eligible to obtain
certain research and development tax credits, including the New York City Biotechnology Tax Credit (“NYC Biotech credit”),
and the Australian research and development tax incentive credit (the “Australia R&amp;D credit”) through a program
administered through the Australian Tax Office (the “ATO”), which provides for a cash refund based on a percentage
of certain research and development activities undertaken in Australia by the Company’s wholly owned subsidiary, Anavex Australia
Pty Ltd. (“Anavex Australia”). The cash refund is available to eligible companies with annual aggregate revenue of
less than $20.0 million (Australian) during the reimbursable period.</p>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></p>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
tax incentives are available on the basis of specific criteria with which the Company must comply. Although the tax incentive
may be administered through the local tax authority, the Company has accounted for the incentives outside of the scope of ASC
Topic 740, Income Taxes, since the incentives are not linked to the Company’s taxable income and can be realized regardless
of whether the Company has generated taxable income in the respective jurisdictions.</font></p>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></p>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
respect to the Australia R&amp;D credit, Anavex Australia may be eligible to receive the cash refund for certain research and
development expenses incurred by Anavex Australia outside of Australia, to the extent such expenses are pre-approved by the Australian
authority pursuant to an advanced overseas finding application. The Company accrues for the amount of cash refund it expects to
receive in relation to research and development expenses outside of Australia only to the extent it has received advanced approval
from the Department of Industry, Innovation and Science in Australia, pursuant to an approved advanced overseas finding application.</font></p>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></p>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes the amount of cash refund it expects to receive related to the NYC Biotech credit and Australian research and
development tax incentive program when there is reasonable assurance that the cash refund will be received, when the relevant
expenditures have been incurred, and when the amount can be reliability measured. This amount is included in Incentive and tax
receivables in the accompanying consolidated balance sheets.</font></p>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></p>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, Anavex Australia incurs Goods and Services Tax (“GST”) on services provided by Australian vendors. As an
Australian entity, Anavex Australia is entitled to a refund of the GST paid. The Company’s estimate of the amount of cash
refund it expects to receive related to GST incurred is included in “Incentive and tax receivables” in the accompanying
consolidated balance sheets.</font><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt"></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 42.55pt"></td><td style="width: 18pt"><font style="font-size: 10pt; font-style: normal">f)</font></td><td style="text-align: justify"><font style="font-size: 10pt; font-style: normal">Basic
                                         and Diluted Loss per Share</font></td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt">Basic
loss per common share is computed by dividing net loss available to common stockholders by the weighted average number of common
shares outstanding during the period. Diluted loss per common share is computed similar to basic loss per common share except
that the denominator is increased to include the weighted average number of all potentially dilutive securities convertible into
shares of common stock that were outstanding during the period.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt">As
of September 30, 2019, loss per share excludes 8,812,933 (2018 – 7,185,296) potentially dilutive common shares related to
outstanding options and warrants, as their effect was anti-dilutive.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt; font-style: normal"> </font></p>
<!-- Field: Page; Sequence: 48; Value: 1 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt">Anavex Life Sciences Corp.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt">Notes to the Consolidated Financial
Statements</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt">September 30, 2019 – Page
6</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.59in; text-align: left"><font style="font-size: 10pt">Note 2</font></td><td style="text-align: justify"><font style="font-size: 10pt"><u>Summary
                                         of Significant Accounting Policies</u> – (continued)</font></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 42.55pt"></td><td style="width: 18pt"><font style="font-size: 10pt; font-style: normal">g)</font></td><td style="text-align: justify"><font style="font-size: 10pt; font-style: normal">Financial
                                         Instruments</font></td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt">The
carrying value of the Company’s financial instruments, consisting of cash and equivalents, incentive and tax receivables,
accounts payable and accrued liabilities approximate their fair value due to the short-term maturity of such instruments. Unless
otherwise noted, it is management’s opinion that the Company is not exposed to significant interest, currency or credit
risks arising from these financial instruments.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.55pt; text-align: justify; text-indent: -0.25in"><font style="font-size: 10pt; font-style: normal"> </font></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 42.55pt"></td><td style="width: 18pt"><font style="font-size: 10pt; font-style: normal">h)</font></td><td style="text-align: justify"><font style="font-size: 10pt; font-style: normal">Foreign
                                         Currency Translation</font></td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt">The
functional currency of the Company is the US dollar. Monetary items denominated in a foreign currency are translated into US dollars
at exchange rates prevailing at the balance sheet date and non-monetary items are translated at exchange rates prevailing when
the assets were acquired, or obligations incurred. Foreign currency denominated expense items are translated at exchange rates
prevailing on the transaction date. Unrealized gains or losses arising from the translations are credited or charged to income
in the period in which they occur.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt">The
Company has determined that the functional currency of Anavex Australia Pty Limited is the US dollar. The Company has determined
that the functional currency of Anavex Germany GmbH is the US dollar. The functional currency of Anavex Canada Ltd. is the Canadian
dollar.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.55pt; text-indent: -0.25in"><font style="font-size: 10pt"> </font></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 42.55pt"></td><td style="width: 18pt"><font style="font-size: 10pt">i)</font></td><td><font style="font-size: 10pt">Segment
                                         and Geographic Reporting</font></td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt">Operating
segments are defined as components of an enterprise for which separate discrete information is available for evaluation by the
chief operating decision maker or decision-making group, in deciding how to allocate resources and in assessing performance. The
Company views its operations and manages its business as one operating segment, which is the business of developing novel therapies
for the management of CNS diseases.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.55pt; text-align: justify; text-indent: -0.25in"><font style="font-size: 10pt"> </font></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 42.55pt"></td><td style="width: 18pt"><font style="font-size: 10pt">j)</font></td><td style="text-align: justify"><font style="font-size: 10pt">Grant
                                         Income</font></td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt">Research
and development incentive income is recognized when the research and development activities have been undertaken and the Company
has completed its assessment of whether such activities meet the relevant qualifying criteria. The Company recognizes such income
at the fair value of the grant when it is received, and all substantive conditions have been satisfied. Grants received from government
and other agencies in advance of the specific research and development costs to which they relate are deferred and recognized
in the consolidated statement of operations in the period they are earned and when the related research and development costs
are incurred.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 42.55pt"></td><td style="width: 18pt"><font style="font-size: 10pt; font-style: normal">k)</font></td><td style="text-align: justify"><font style="font-size: 10pt; font-style: normal">Income
                                         Taxes</font></td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt">The
Company has adopted the provisions of Financial Accounting Standards Board (FASB) ASC 740, Income Taxes, (“ASC 740”)
which requires the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax
assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial
statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities
are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are
expected to be recovered or settled.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<!-- Field: Page; Sequence: 49; Value: 1 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt">Anavex Life Sciences Corp.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt">Notes to the Consolidated Financial
Statements</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt">September 30, 2019 – Page
7</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.59in; text-align: left"><font style="font-size: 10pt">Note 2</font></td><td style="text-align: justify"><font style="font-size: 10pt"><u>Summary
                                         of Significant Accounting Policies</u> – (continued)</font></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 42.55pt"></td><td style="width: 18pt"><font style="font-size: 10pt; font-style: normal">k)</font></td><td style="text-align: justify"><font style="font-size: 10pt; font-style: normal">Income
                                         Taxes – (Continued) </font></td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt">The
Company follows the provisions of ASC 740 regarding accounting for uncertainty in income taxes. The Company initially recognizes
tax positions in the financial statements when it is more likely than not the position will be sustained upon examination by the
tax authorities. Such tax positions are initially and subsequently measured as the largest amount of tax benefit that is greater
than 50% likely of being realized upon ultimate settlement with the tax authority assuming full knowledge of the position and
all relevant facts. Application requires numerous estimates based on available information. The Company considers many factors
when evaluating and estimating its tax positions and tax benefits, and its recognized tax positions and tax benefits may not accurately
anticipate actual outcomes. As additional information is obtained, there may be a need to periodically adjust the recognized tax
positions and tax benefits. These periodic adjustments may have a material impact on the consolidated statements of operations.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.55pt; text-align: justify; text-indent: -0.25in"><font style="font-size: 10pt; font-style: normal"> </font></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 42.55pt"></td><td style="width: 18pt"><font style="font-size: 10pt; font-style: normal">l)</font></td><td style="text-align: justify"><font style="font-size: 10pt; font-style: normal">Stock-based
                                         Compensation</font></td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt">The
Company accounts for all stock-based payments and awards under the fair value method.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt">Stock-based
payments to non-employees are measured at the fair value of the consideration received, or the fair value of the equity instruments
issued, or liabilities incurred, whichever is more reliably measurable. The fair value of stock-based payments to non-employees
is periodically re-measured until the counterparty performance is complete, and any change therein is recognized over the vesting
period of the award and in the same manner as if the Company had paid cash instead of paying with or using equity based instruments.
Compensation costs for stock-based payments with graded vesting are recognized on a straight-line basis. The cost of stock-based
payments to non-employees that are fully vested and non-forfeitable at the grant date are measured and recognized at that date,
unless there is a contractual term for services in which case such compensation would be amortized over the contractual term.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt">The
Company accounts for the granting of share purchase options to employees using the fair value method whereby all awards to employees
will be recorded at fair value on the date of the grant. The fair value of all share purchase options are expensed over their
contractual vesting period, or over the expected performance period for only the portion of awards expected to vest, in the case
of milestone-based vesting, with a corresponding increase to additional paid-in capital.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt">The
Company uses the Black-Scholes option valuation model to calculate the fair value of share purchase options at the date of the
grant. Option pricing models require the input of highly subjective assumptions, including the expected price volatility. Changes
in these assumptions can materially affect the fair value estimates.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.55pt; text-align: justify; text-indent: -0.25in"><font style="font-size: 10pt; font-style: normal"> </font></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 42.55pt"></td><td style="width: 18pt"><font style="font-size: 10pt; font-style: normal">m)</font></td><td style="text-align: justify"><font style="font-size: 10pt; font-style: normal">Fair
                                         Value Measurements</font></td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.55pt"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt">Fair
value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in
the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at
the measurement date. Assets and liabilities that are measured at fair value are reported using a three-level fair value hierarchy
that prioritizes the inputs used to measure fair value. This hierarchy maximizes the use of observable inputs and minimizes the
use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<!-- Field: Page; Sequence: 50; Value: 1 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt">Anavex Life Sciences Corp.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt">Notes to the Consolidated Financial
Statements</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt">September 30, 2019 – Page
8</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.59in; text-align: left"><font style="font-size: 10pt">Note 2</font></td><td style="text-align: justify"><font style="font-size: 10pt"><u>Summary
                                         of Significant Accounting Policies</u> – (continued)</font></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.55pt; text-align: justify; text-indent: -0.25in"><font style="font-size: 10pt; font-style: normal"> </font></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 42.55pt"></td><td style="width: 18pt"><font style="font-size: 10pt">m)</font></td><td style="text-align: justify"><font style="font-size: 10pt">Fair
                                         Value Measurements – (continued)</font></td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.59in"><font style="font-size: 10pt">Level 1 - 	quoted
prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at the measurement
date;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.59in"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.59in; text-align: justify"><font style="font-size: 10pt">Level
2 - observable inputs other than Level 1, quoted prices for similar assets or liabilities in active 		markets, quoted prices
for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable
or whose significant value drivers are observable; and</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.59in"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.59in; text-align: justify"><font style="font-size: 10pt">Level
3 - 	assets and liabilities whose significant value drivers are unobservable by little or no market activity and that are significant
to the fair value of the assets or liabilities.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.59in"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.59in; text-align: justify"><font style="font-size: 10pt">The
book value of cash and cash equivalents and accounts payable and accrued liabilities approximate their fair values due to the
short-term maturity of those instruments.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.59in"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.59in; text-align: justify"><font style="font-size: 10pt">At
September 30, 2019 and 2018, the Company did not have any Level 3 assets or liabilities.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 42.55pt"></td><td style="width: 18pt"><font style="font-size: 10pt; font-style: normal">n)</font></td><td style="text-align: justify"><font style="font-size: 10pt; font-style: normal">Recent
                                         Accounting Pronouncements</font></td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.59in; text-align: justify; background-color: white"><font style="font-size: 10pt"><i>Recently
Adopted Accounting Pronouncements</i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.59in; text-align: justify; background-color: white"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.59in; text-align: justify"><font style="font-size: 10pt">In
May 2014, the FASB and the International Accounting Standards Board (IASB) issued a converged standard on revenue recognition
from contracts with customers, ASU 2014-09 (Topic 606 and IFRS 15). This standard superseded nearly all existing revenue recognition
guidance. ASU 2014-09 is effective for the Company on a prospective basis beginning on October 1, 2018. The adoption of this standard
did not have a material impact for any period presented.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.59in; text-align: justify"><font style="font-size: 10pt"><i> </i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.59in; text-align: justify; background-color: white"><font style="font-size: 10pt">In
May 2017, the FASB issued ASU No. 2017-09, “Compensation–Stock Compensation (Topic 718): Scope of Modification Accounting,”
clarifying when a change to the terms or conditions of a share-based payment award must be accounted for as a modification. The
new guidance requires modification accounting if the fair value, vesting condition or the classification of the award is not the
same immediately before and after a change to the terms and conditions of the award. The new guidance was effective for the Company
on a prospective basis beginning on October 1, 2018. The adoption of this standard did not have a material impact for any period
presented.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.59in; text-align: justify; background-color: white"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.59in; text-align: justify"><font style="font-size: 10pt"><i>Recent
Accounting Pronouncements Not Yet Adopted</i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.59in; text-align: justify; background-color: white"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.59in; text-align: justify; background-color: white"><font style="font-size: 10pt">In
February 2016, the FASB issued Accounting Standards Update No. 2016-02, <i>Leases</i>. The guidance would require lessees to recognize
most leases on their balance sheets as lease liabilities with corresponding right-of-use assets. The guidance is effective for
annual and interim reporting periods beginning on or after December 15, 2018. The new guidance is effective for the Company on
a prospective basis beginning on October 1, 2019. The adoption of this guidance is not expected to have a material impact for
any period presented.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt"><font style="font-size: 10pt"> </font></p>
<!-- Field: Page; Sequence: 51; Value: 1 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt">Anavex Life Sciences Corp.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt">Notes to the Consolidated Financial
Statements</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt">September 30, 2019 – Page
9</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.59in; text-align: left"><font style="font-size: 10pt">Note 2</font></td><td style="text-align: justify"><font style="font-size: 10pt"><u>Summary
                                         of Significant Accounting Policies</u> – (continued)</font></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify; background-color: white"><font style="font-size: 10pt"> </font></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 42.55pt"></td><td style="width: 18pt"><font style="font-size: 10pt">n)</font></td><td style="text-align: justify"><font style="font-size: 10pt">Recent
                                         Accounting Pronouncements – (continued)</font></td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify; background-color: white"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.59in; text-align: justify; background-color: white"><font style="font-size: 10pt">In
June 2018, the FASB issued ASU No. 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based
Payment Accounting, to simplify the accounting for share-based payments to nonemployees by aligning it with the accounting for
share-based payments to employees, with certain exceptions. The new guidance is effective for the Company beginning on October
1, 2019. The new guidance is required to be applied retrospectively with the cumulative effect recognized at the date of initial
application. The Company is currently evaluating the impact this guidance will have on its financial condition, results of operations
and cash flows.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.59in; text-align: justify; background-color: white"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.59in; text-align: justify; background-color: white"><font style="font-size: 10pt">Other
than noted above, the Company does not expect the adoption of recently issued accounting pronouncements to have a significant
impact on its results of operations, financial position or cash flow.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.59in"><font style="font-size: 10pt"> </font></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.59in; text-align: left"><font style="font-size: 10pt">Note 3</font></td><td style="text-align: justify"><font style="font-size: 10pt"><u>Other
                                         Income</u></font></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.59in; text-align: justify; background-color: white; text-indent: 0"><font style="font-size: 10pt">Grant
income</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.59in; text-align: justify; background-color: white; text-indent: 0"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.59in; text-align: justify; background-color: white; text-indent: 0"><font style="font-size: 10pt">During
the year ended September 30, 2017, the Company was awarded grant funding in the amount of $597,886. The grant is being received
in equal quarterly installments over a period of two years beginning during the year ended September 30, 2018, in exchange for
a commitment to complete clinical testing for a therapeutic drug candidate for the treatment of Rett syndrome.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.59in; text-align: justify; background-color: white; text-indent: 0"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.59in; text-align: justify; background-color: white; text-indent: 0"><font style="font-size: 10pt">The
grant income is deferred when received and amortized to other income as the related research and development expenditures are
incurred. During the year ended September 30, 2019, the Company recognized $298,943 (2018: $149,055) of this grant on its statement
of operations as a component of other income.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.59in; text-align: justify; background-color: white; text-indent: 0"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.59in; text-align: justify; background-color: white; text-indent: 0"><font style="font-size: 10pt">Research
and development incentive income</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.59in; text-align: justify; background-color: white; text-indent: 0"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.59in; text-align: justify; background-color: white; text-indent: 0"><font style="font-size: 10pt">Research
and development incentive income represents the receipt by the Company’s Australian subsidiary, of the Australian research
and development incentive credit, (the “ATO R&amp;D Credit”), as well as receipt by the Company of the New York City
Biotechnology Tax Credit (“NYC Biotech credit”).</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.59in; text-align: justify; background-color: white; text-indent: 0"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.59in; text-align: justify; background-color: white; text-indent: 0"><font style="font-size: 10pt">During
the year ended September 30, 2019, the Company recorded research and development incentive income of $2,215,691 (AUD 3,281,300)
(2018: $1,647,219 (AUD 2,344,486)) in respect of the ATO R&amp;D Credit for eligible research and development expenses incurred
during the year.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.59in; text-align: justify; background-color: white; text-indent: 0"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.59in; text-align: justify; background-color: white; text-indent: 0"><font style="font-size: 10pt">During
the year ended September 30, 2019, the Company recorded research and development incentive income of $250,000 (2018: $182,967)
in respect of the NYC Biotech Credit awarded to the Company during the year.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify; background-color: white"><font style="font-size: 10pt"> </font></p>
<!-- Field: Page; Sequence: 52; Value: 1 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt">Anavex Life Sciences Corp.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt">Notes to the Consolidated Financial
Statements</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt">September 30, 2019 – Page
10</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.59in; text-align: left"><font style="font-size: 10pt">Note 4</font></td><td style="text-align: justify"><font style="font-size: 10pt"><u>Equity
                                         Offering Agreements</u></font></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt">Controlled
Equity Offering Sales Agreement</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt">On
July 6, 2018, the Company entered into a Controlled Equity Offering Sales Agreement (the “Sales Agreement”) with
Cantor Fitzgerald &amp; Co., as agent (“Cantor Fitzgerald”), pursuant to which the Company may offer and sell
shares of common stock, for aggregate gross sale proceeds of up to $50,000,000 from time to time through Cantor Fitzgerald (the
“Offering”). </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt">Upon
delivery of a placement notice based on the Company’s instructions and subject to the terms and conditions of the Sales
Agreement, Cantor Fitzgerald may sell the Shares by methods deemed to be an “at the market offering” offering, in
negotiated transactions at market prices prevailing at the time of sale or at prices related to such prevailing market prices,
or by any other method permitted by law, including negotiated transactions, subject to the prior written consent of the Company.
The Company is not obligated to make any sales of Shares under the Sales Agreement. The Company or Cantor Fitzgerald may suspend
or terminate the offering of Shares upon notice to the other party, subject to certain conditions.  Cantor Fitzgerald will
act as sales agent on a commercially reasonable efforts basis consistent with its normal trading and sales practices and applicable
state and federal law, rules and regulations and the rules of Nasdaq.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"></p>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has agreed to pay Cantor Fitzgerald commissions for its services of acting as agent of up to 3.0% of the gross proceeds
from the sale of the Shares pursuant to the Sales Agreement.  The Company also agreed to provide Cantor Fitzgerald with customary
indemnification and contribution rights. The Company incurred $151,133 in legal and accounting fees associated with the Sales
Agreement. This amount was charged to financing related charges on the statement of operations during the year ended September
30, 2019, based on the passage of time. At September 30, 2019, no shares had been sold pursuant to the Offering.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt">2015
Purchase Agreement</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt">On
October 21, 2015, the Company entered into a $50,000,000 purchase agreement (the “2015 Purchase Agreement”) with Lincoln
Park Capital Fund, LLC (“Lincoln Park”), pursuant to which the Company could sell and issue to Lincoln Park, and Lincoln
Park was obligated to purchase, up to $50,000,000 in value of its shares of common stock from time to time over a 36-month period.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt">During
the year ended September 30, 2019, the Company issued to Lincoln Park an aggregate of 4,872,696 (2018: 2,398,261) shares of common
stock under the 2015 Purchase Agreement, including 4,848,995 (2018: 2,383,580) shares of common stock for an aggregate purchase
price of $13,197,604 (2018: $8,173,290) and 23,701 (2018: 14,681) as commitment shares. At September 30, 2019, all remaining purchase
amounts available for issuance under the 2015 Purchase Agreement have been utilized and the 2015 Purchase Agreement has expired
pursuant to its terms. As such, no further shares will be sold under the 2015 Purchase Agreement.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<!-- Field: Page; Sequence: 53; Value: 1 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt">Anavex Life Sciences Corp.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt">Notes to the Consolidated Financial
Statements</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt">September 30, 2019 – Page
11</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.59in; text-align: left"><font style="font-size: 10pt">Note 4</font></td><td style="text-align: justify"><font style="font-size: 10pt"><u>Equity
                                         Offering Agreements</u> – (continued)</font></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt">2019
Purchase Agreement</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt">On
June 7, 2019, the Company entered into a $50,000,000 purchase agreement (the “2019 Purchase Agreement”) with Lincoln
Park, pursuant to which the Company may sell and issue to Lincoln Park, and Lincoln Park is obligated to purchase, up to $50,000,000
in value of its shares of common stock from time to time from June 12, 2019, the date a prospectus supplement under which shares
of common stock issuable under the 2019 Purchase Agreement was filed with the SEC, until July 1, 2022, which is the first day
of the next month following the 36-month anniversary of June 12, 2019.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt">The
Company may direct Lincoln Park, at its sole discretion, and subject to certain conditions, to purchase up to 200,000 shares of
common stock on any business day (a “Regular Purchase”). The amount of a Regular Purchase may be increased under certain
circumstances up to 250,000 shares, provided that Lincoln Park’s committed obligation for Regular Purchases on any business
day shall not exceed $2,000,000. In the event we purchase the full amount allowed for a Regular Purchase on any given business
day, we may also direct Lincoln Park to purchase additional amounts as accelerated and additional accelerated purchases. The purchase
price of shares of common stock related to the future funding will be based on the then prevailing market prices of such shares
at the time of sales as described in the 2019 Purchase Agreement.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt">The
2019 Purchase Agreement limits the Company’s sale of shares of Common Stock to Lincoln Park to 10,076,680 shares of Common
Stock, representing 19.99% of the shares of the Common Stock outstanding on the date of the 2019 Purchase Agreement unless (i)
shareholder approval is obtained to issue more than such amount or (ii) the average price of all applicable sales of Common Stock
to Lincoln Park under the 2019 Purchase Agreement equals or exceeds the lower of (A) the closing price of the Common Stock on
the Nasdaq Capital Market immediately preceding the Execution Date or (B) the average of the closing prices of the Common Stock
on the Nasdaq Capital Market for the five Business Days immediately preceding the Execution Date, and it also limits the Company’s
sale of shares to Lincoln Park to the extent it would cause Lincoln Park to beneficially own more than 4.99% of the Company’s
outstanding shares of Common Stock at any given time.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt">In
consideration for entering into the 2019 Purchase Agreement, the Company issued to Lincoln Park 324,383 shares of common stock
as a commitment fee and agreed to issue up to 162,191 shares pro rata, when and if, Lincoln Park purchases at the Company’s
discretion the $50,000,000 aggregate commitment.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt">During
the year ended September 30, 2019, the Company issued to Lincoln Park an aggregate of 1,839,415 shares of common stock under the
2019 Purchase Agreement, including 1,500,000 shares of common stock for an aggregate purchase price of $4,634,505 and 339,415
commitment shares, inclusive of the 324,383 initial commitment shares described above. At September 30, 2019, an amount of $45,365,495
remained available under the 2019 Purchase Agreement.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<!-- Field: Page; Sequence: 54; Value: 1 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt">Anavex Life Sciences Corp.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt">Notes to the Consolidated Financial
Statements</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt">September 30, 2019 – Page
12</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.59in; text-align: left"><font style="font-size: 10pt">Note 5</font></td><td style="text-align: justify"><font style="font-size: 10pt"><u>Commitments</u></font></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.59in"></td><td style="width: 0.25in"><font style="font-size: 10pt; font-style: normal">a)</font></td><td><font style="font-size: 10pt; font-style: normal">Lease</font></td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt; font-style: normal"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"></p>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; color: gray"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">The Company has entered into an
office lease agreement under which it leases office space on a month-to-month basis until March 2020. During the year ended September
30, 2019 the Company incurred office lease expense of $190,416 (2018: $151,405).</p>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; color: gray"><font style="font: 10pt Times New Roman, Times, Serif; color: Black"></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"> </font></p>
<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.59in"></td><td style="width: 0.25in"><font style="font-size: 10pt; font-style: normal">b)</font></td><td><font style="font-size: 10pt; font-style: normal">Litigation</font></td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.75pt"><font style="font-size: 10pt; font-style: normal"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt">The
Company is subject to claims and legal proceedings that arise in the ordinary course of business. Such matters are inherently
uncertain, and there can be no guarantee that the outcome of any such matter will be decided favorably to the Company or that
the resolution of any such matter will not have a material adverse effect upon the Company's consolidated financial statements.
The Company does not believe that any of such pending claims and legal proceedings will have a material adverse effect on its
consolidated financial statements.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.75pt"><font style="font-size: 10pt; font-style: normal"> </font></p>
<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.59in"></td><td style="width: 0.25in"><font style="font-size: 10pt; font-style: normal">c)</font></td><td><font style="font-size: 10pt; font-style: normal">Share
                                         Purchase Warrants</font></td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt">At
September 30, 2019, the Company had outstanding warrants to purchase 350,000 shares of common stock at $4.19 until June 2021.
The following table summarizes the warrant activity during the years ended September 30, 2019 and 2018:</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.59in">
<tr style="vertical-align: bottom">
<td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 10pt">Weighted Average</font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom">
<td style="white-space: nowrap; border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 10pt">Number
    of Shares</font></td><td style="border-bottom: Black 1pt solid; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 10pt">Exercise
    Price ($)</font></td><td style="border-bottom: Black 1pt solid; white-space: nowrap"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 74%"><font style="font-size: 10pt">Balance, September 30, 2017</font></td><td style="width: 1%"><font style="font-size: 10pt"> </font></td>
<td style="width: 1%; text-align: left"><font style="font-size: 10pt"> </font></td><td style="width: 10%; text-align: right"><font style="font-size: 10pt">1,609,309</font></td><td style="width: 1%; text-align: left"><font style="font-size: 10pt"> </font></td><td style="width: 1%"><font style="font-size: 10pt"> </font></td>
<td style="width: 1%; text-align: left"><font style="font-size: 10pt"> </font></td><td style="width: 10%; text-align: right"><font style="font-size: 10pt">2.66</font></td><td style="width: 1%; text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td><font style="font-size: 10pt">Issued</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">350,000</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">4.19</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td><font style="font-size: 10pt">Exercised</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">(756,143</font></td><td style="text-align: left"><font style="font-size: 10pt">)</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">2.96</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt">Expired</font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 10pt">(524,787</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt">)</font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 10pt">3.00</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td><font style="font-size: 10pt">Balance, September 30, 2018</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">678,379</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">2.87</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td><font style="font-size: 10pt">Exercised</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">(8,750</font></td><td style="text-align: left"><font style="font-size: 10pt">)</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">1.13</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt">Expired</font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 10pt">(319,629</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt">)</font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 10pt">1.46</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="border-bottom: Black 2.5pt double"><font style="font-size: 10pt">Balance, September 30, 2019</font></td><td style="border-bottom: Black 2.5pt double"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 10pt">350,000</font></td><td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 2.5pt double"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 10pt">4.19</font></td><td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 10pt"> </font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt">During
the year ended September 30, 2018, 350,000 options granted to a consultant to the Company were converted to 350,000 warrants with
the same exercise price.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -0.85pt"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -0.8pt"><font style="font-size: 10pt">During
the year ended September 30, 2019, the Company issued 4,938 shares in connection with the exercise of 8,750 warrants on a cashless
basis.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt">During
the year ended September 30, 2018, an aggregate of 737,393 warrants at $3.00 per share and 18,750 warrants at $1.24 per share
were exercised on a cashless basis, pursuant to which the Company issued 125,748 shares of common stock.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<!-- Field: Page; Sequence: 55; Value: 1 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt">Anavex Life Sciences Corp.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt">Notes to the Consolidated Financial
Statements</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt">September 30, 2019 – Page
13</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.59in; text-align: left"><font style="font-size: 10pt">Note 5</font></td><td style="text-align: justify"><font style="font-size: 10pt"><u>Commitments
                                         </u>– (Continued)</font></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 42.75pt"></td><td style="width: 18pt"><font style="font-size: 10pt; font-style: normal">d)</font></td><td style="text-align: justify"><font style="font-size: 10pt; font-style: normal">Stock–based
                                         Compensation Plan</font></td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt">2015
Stock Option Plan</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -1in"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt">On
September 18, 2015, the Company’s board of directors approved a 2015 Omnibus Incentive Plan (the “2015 Plan”),
which provides for the grant of stock options and restricted stock awards to directors, officers, employees and consultants of
the Company.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt">The
maximum number of our common shares reserved for issue under the plan is 6,050,553 shares, subject to adjustment in the event
of a change of the Company’s capitalization. As a result of the adoption of the 2015 Plan, no further option awards will
be granted under any previously existing stock option plan. Stock option awards previously granted under the previously existing
stock option plans remain outstanding in accordance with their terms.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt">The
2015 Plan provides that it may be administered by the board of directors, or the board of directors may delegate such responsibility
to a committee. The exercise price will be determined by the board of directors at the time of grant shall be at least equal to
the fair market value on such date. If the grantee is a 10% stockholder on the grant date, then the exercise price shall not be
less than 110% of fair market value of the Company’s shares of common stock on the grant date. Stock options may be granted
under the 2015 Plan for an exercise period of up to ten years from the date of grant of the option or such lesser periods as may
be determined by the board, subject to earlier termination in accordance with the terms of the 2015 Plan.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt">2019
Stock Option Plan</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt">On
January 15, 2019, the Board approved the 2019 Omnibus Incentive Plan (the “2019 Plan”), which provides for the grant
of stock options and restricted stock awards to directors, officers, employees, consultants and advisors of the Company. Under
the terms of the 2019 Plan, 6,000,000 additional shares of Common Stock are available for issuance under the 2019 Plan, in addition
to the shares available under the 2015 Plan. Any awards outstanding under the 2015 Plan or the Company’s 2007 Stock Option
Plan (the “2007 Plan”) will remain subject to and be paid under the 2015 Plan or the 2007 Plan, respectively, and
any shares subject to outstanding awards under the 2015 Plan or the 2007 Plan that subsequently cease to be subject to such awards
(other than by reason of settlement of the awards in shares) will automatically become available for issuance under the 2019 Plan.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt">The
2019 Plan provides that it may be administered by the Board, or the Board may delegate such responsibility to a committee. The
exercise price will be determined by the board of directors at the time of grant shall be at least equal to the fair market value
on such date. If the grantee is a 10% stockholder on the grant date, then the exercise price shall not be less than 110% of fair
market value of the Company’s shares of common stock on the grant date. Stock options may be granted under the 2019 Plan
for an exercise period of up to ten years from the date of grant of the option or such lesser periods as may be determined by
the board, subject to earlier termination in accordance with the terms of the 2019 Plan.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<!-- Field: Page; Sequence: 56; Value: 1 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt">Anavex Life Sciences Corp.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt">Notes to the Consolidated Financial
Statements</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt">September 30, 2019 – Page
14</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.59in; text-align: left"><font style="font-size: 10pt">Note 5</font></td><td style="text-align: justify"><font style="font-size: 10pt"><u>Commitments
                                         </u>– (Continued)</font></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify; text-indent: -0.25in"><font style="font-size: 10pt"> </font></p>
<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 42.75pt"></td><td style="width: 18pt"><font style="font-size: 10pt">d)</font></td><td style="text-align: justify"><font style="font-size: 10pt">Stock–based
                                         Compensation Plan – (Continued)</font></td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt">A
summary of the status of Company’s outstanding stock purchase options is presented below:</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.85in">
<tr style="vertical-align: bottom">
<td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted</font></td><td style="white-space: nowrap"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom">
<td style="white-space: nowrap"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted</font></td><td style="white-space: nowrap"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Average
    Grant</font></td><td style="white-space: nowrap"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom">
<td style="white-space: nowrap"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
    of</font></td><td style="white-space: nowrap"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Average
    Exercise</font></td><td style="white-space: nowrap"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date
    Fair Value</font></td><td style="white-space: nowrap"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td style="text-align: center; vertical-align: middle"><p style="margin-top: 0; margin-bottom: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aggregate</font></p>
<p style="margin-top: 0; margin-bottom: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">intrinsic</font></p></td></tr>
<tr style="vertical-align: bottom">
<td style="white-space: nowrap; border-bottom: Black 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; white-space: nowrap"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</font></td><td style="border-bottom: Black 1pt solid; white-space: nowrap"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; white-space: nowrap"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Price
    ($)</font></td><td style="border-bottom: Black 1pt solid; white-space: nowrap"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; white-space: nowrap"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">($)</font></td><td style="border-bottom: Black 1pt solid; white-space: nowrap"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td style="border-bottom: Black 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td style="text-align: center; vertical-align: middle; border-bottom: Black 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">value</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 50%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding, September 30,
    2017</font></td><td style="width: 1%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td style="width: 1%; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td><td style="width: 8%; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,092,030</font></td><td style="width: 1%; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td><td style="width: 1%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td style="width: 1%; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td><td style="width: 8%; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13</font></td><td style="width: 1%; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td><td style="width: 1%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td style="width: 1%; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td><td style="width: 8%; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td><td style="width: 1%; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td style="width: 1%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</font></td>
<td style="width: 16%; text-align: right; vertical-align: middle"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,280,544</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</font></td><td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,730,000</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td><td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.71</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td><td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.09</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</font></td><td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(164,280</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</font></td><td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.66</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td><td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="border-bottom: Black 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</font></td><td style="border-bottom: Black 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(150,833</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</font></td><td style="border-bottom: Black 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.18</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td style="border-bottom: Black 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td style="border-bottom: Black 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding, September 30, 2018</font></td><td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,506,917</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td><td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.83</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td><td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</font></td>
<td style="text-align: right; vertical-align: middle"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,353,088</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</font></td><td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,265,399</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td><td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.79</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td><td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.27</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="border-bottom: Black 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</font></td><td style="border-bottom: Black 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(309,383</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</font></td><td style="border-bottom: Black 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.25</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td style="border-bottom: Black 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td style="border-bottom: Black 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="border-bottom: Black 2.5pt double"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding,
    September 30, 2019</font></td><td style="border-bottom: Black 2.5pt double"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,462,933</font></td><td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td><td style="border-bottom: Black 2.5pt double"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.58</font></td><td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td><td style="border-bottom: Black 2.5pt double"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td><td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td style="padding-bottom: 1pt; border-bottom: Black 2.5pt double"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: right; vertical-align: middle"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,115,032</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="border-bottom: Black 2.5pt double"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable,
    September 30, 2019</font></td><td style="border-bottom: Black 2.5pt double"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,727,963</font></td><td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td><td style="border-bottom: Black 2.5pt double"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.85</font></td><td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td><td style="border-bottom: Black 2.5pt double"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td><td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td style="border-bottom: Black 2.5pt double"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</font></td>
<td style="text-align: right; vertical-align: middle; border-bottom: Black 2.5pt double"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,275,500</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt">The
aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted market
price of the Company’s stock for the options that were in-the-money at September 30, 2019.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt">	The
Company recognized stock-based compensation expense of $6,430,873 during the year ended September 30, 2019 (2018: $5,517,004)
in connection with the issuance and vesting 	of stock options and warrants in exchange for services. These amounts have been
included in general and 	administrative expenses and research and development expenses on the Company’s statement of
	operations as follows:</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.59in">
<tr style="vertical-align: bottom">
<td style="white-space: nowrap; padding-bottom: 1pt; text-align: center"><font style="font-size: 10pt"> </font></td><td style="padding-bottom: 1pt; text-align: center"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">2019</font></td><td style="border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">2018</font></td><td style="border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 74%; text-align: left"><font style="font-size: 10pt">General and administrative</font></td><td style="width: 1%"><font style="font-size: 10pt"> </font></td>
<td style="width: 1%; text-align: left"><font style="font-size: 10pt">$</font></td><td style="width: 10%; text-align: right"><font style="font-size: 10pt">3,203,165</font></td><td style="width: 1%; text-align: left"><font style="font-size: 10pt"> </font></td><td style="width: 1%"><font style="font-size: 10pt"> </font></td>
<td style="width: 1%; text-align: left"><font style="font-size: 10pt">$</font></td><td style="width: 10%; text-align: right"><font style="font-size: 10pt">2,699,557</font></td><td style="width: 1%; text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; padding-bottom: 1pt"><font style="font-size: 10pt">Research and development</font></td><td style="padding-bottom: 1pt"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td><td style="text-align: right; border-bottom: Black 1pt solid"><font style="font-size: 10pt">3,227,708</font></td><td style="text-align: left; border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td><td style="text-align: right; border-bottom: Black 1pt solid"><font style="font-size: 10pt">2,817,447</font></td><td style="text-align: left; border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-bottom: 2.5pt"><font style="font-size: 10pt">Total stock-based compensation</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; border-bottom: Black 2.5pt double"><font style="font-size: 10pt">$</font></td><td style="text-align: right; border-bottom: Black 2.5pt double"><font style="font-size: 10pt">6,430,873</font></td><td style="text-align: left; border-bottom: Black 2.5pt double"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 2.5pt double"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; border-bottom: Black 2.5pt double"><font style="font-size: 10pt">$</font></td><td style="text-align: right; border-bottom: Black 2.5pt double"><font style="font-size: 10pt">5,517,004</font></td><td style="text-align: left; border-bottom: Black 2.5pt double"><font style="font-size: 10pt"> </font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt">An
amount of approximately $5,097,281 in stock-based compensation is expected to be recorded over the remaining term 	of such
options through 2022.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt">The
fair value of each option award is estimated on the date of grant using the Black Scholes option pricing model based on the following
weighted average assumptions:</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt"><font style="font-size: 10pt"> </font></p>
<table align="CENTER" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 75%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td style="white-space: nowrap; padding-bottom: 1pt"><font style="font-size: 10pt"> </font></td><td style="padding-bottom: 1pt"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 10pt">2019</font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 10pt">2018</font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 74%; text-align: left"><font style="font-size: 10pt">Risk-free interest rate</font></td><td style="width: 1%"><font style="font-size: 10pt"> </font></td>
<td style="width: 1%; text-align: left"><font style="font-size: 10pt"> </font></td><td style="width: 10%; text-align: right"><font style="font-size: 10pt">2.50</font></td><td style="width: 1%; text-align: left"><font style="font-size: 10pt">%</font></td><td style="width: 1%"><font style="font-size: 10pt"> </font></td>
<td style="width: 1%; text-align: left"><font style="font-size: 10pt"> </font></td><td style="width: 10%; text-align: right"><font style="font-size: 10pt">2.73</font></td><td style="width: 1%; text-align: left"><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left"><font style="font-size: 10pt">Expected life of options (years)</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">6.05</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">5.60</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left"><font style="font-size: 10pt">Annualized volatility</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">104.45</font></td><td style="text-align: left"><font style="font-size: 10pt">%</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">106.45</font></td><td style="text-align: left"><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left"><font style="font-size: 10pt">Dividend rate</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">0.00</font></td><td style="text-align: left"><font style="font-size: 10pt">%</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">0.00</font></td><td style="text-align: left"><font style="font-size: 10pt">%</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"></p>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of stock compensation charges recognized during the years ended September 30, 2019 and 2018 was determined with reference
to the quoted market price of the Company’s shares on the grant date.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-size: 10pt"> </font></p>
<!-- Field: Page; Sequence: 57; Value: 1 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt">Anavex Life Sciences Corp.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt">Notes to the Consolidated Financial
Statements</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt">September 30, 2019 – Page
15</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.59in; text-align: left"><font style="font-size: 10pt">Note 6</font></td><td style="text-align: justify"><font style="font-size: 10pt"><u>Income
                                         Taxes</u></font></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt">The
Company’s U.S. and foreign loss before income taxes are set forth below:</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.59in">
<tr style="vertical-align: bottom">
<td style="white-space: nowrap; border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 10pt">2019</font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 10pt">2018</font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 74%; text-align: left"><font style="font-size: 10pt">United States</font></td><td style="width: 1%"><font style="font-size: 10pt"> </font></td>
<td style="width: 1%; text-align: left"><font style="font-size: 10pt"> </font></td><td style="width: 10%; text-align: right"><font style="font-size: 10pt">(18,031,016</font></td><td style="width: 1%; text-align: left"><font style="font-size: 10pt">)</font></td><td style="width: 1%"><font style="font-size: 10pt"> </font></td>
<td style="width: 1%; text-align: left"><font style="font-size: 10pt"> </font></td><td style="width: 10%; text-align: right"><font style="font-size: 10pt">(14,681,272</font></td><td style="width: 1%; text-align: left"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt">Foreign</font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 10pt">(8,181,782</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt">)</font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 10pt">(2,498,718</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt">Total</font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 10pt">(26,212,798</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt">)</font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 10pt">(17,179,990</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt">)</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt">US
Tax Reform</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt">On
December 22, 2017, the President of the United States signed into law the Tax Cuts and Jobs Act (“Tax Reform Act”).
The legislation significantly changes U.S. tax law by, among other things, lowering corporate income tax rates, implementing a
territorial tax system and imposing a transition tax on deemed repatriated earnings of foreign subsidiaries. The Tax Reform Act
permanently reduces the U.S. corporate income tax rate from a maximum of 35% to a flat 21% rate, effective
January 1, 2018.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt">The
Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities
are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of
existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted
tax rates expected to apply to taxable income in the years in which those temporary differences are expected to reverse.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt">As
a result of the reduction in the U.S. corporate income tax rate from 35% to 21% under the Tax Reform Act, the Company revalued
its ending net deferred tax liabilities at December 31, 2017. The Company did not need to recognize any provisional tax expense
for the year ended September 30, 2018.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt">The
Tax Reform Act also provided for a one-time deemed mandatory repatriation of post – 1986 undistributed foreign subsidiary
earnings and profits (“E&amp;P”) as well as Global Intangible Low-Taxed Income (“GILTI”) and Base-Erosion
Anti-Abuse provisions. The Company had no adjustments related to these latter noted provisions at September 30, 2018.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt"><font style="font-size: 10pt">The components of
net deferred income tax assets as of September 30, 2019 and 2018 are as follows:</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt"><font style="font-size: 10pt"> </font></p>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.59in">
<tr style="vertical-align: bottom">
<td style="white-space: nowrap; border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 10pt">2019</font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 10pt">2018</font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 74%; text-align: left"><font style="font-size: 10pt">Net operating loss carryforwards</font></td><td style="width: 1%"><font style="font-size: 10pt"> </font></td>
<td style="width: 1%; text-align: left"><font style="font-size: 10pt">$</font></td><td style="width: 10%; text-align: right"><font style="font-size: 10pt">18,704,000</font></td><td style="width: 1%; text-align: left"><font style="font-size: 10pt"> </font></td><td style="width: 1%"><font style="font-size: 10pt"> </font></td>
<td style="width: 1%; text-align: left"><font style="font-size: 10pt">$</font></td><td style="width: 10%; text-align: right"><font style="font-size: 10pt">13,556,000</font></td><td style="width: 1%; text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left"><font style="font-size: 10pt">Research and development tax credit carryforwards</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">1,162,000</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">1,605,000</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left"><font style="font-size: 10pt">Stock-based compensation</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">6,570,000</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right">4<font style="font-size: 10pt">,677,000</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left"><font style="font-size: 10pt">Unpaid charges</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">69,000</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">91,000</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left"><font style="font-size: 10pt">Intangible asset costs</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">30,000</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">35,000</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left"><font style="font-size: 10pt">Foreign exchange and other</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">15,000</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">16,000</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; border-bottom: Black 1pt solid"><font style="font-size: 10pt">Valuation allowance deferred tax
    assets</font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 10pt">(26,551,000</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt">)</font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 10pt">(19,981,000</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; border-bottom: Black 1pt solid"><font style="font-size: 10pt">Net deferred tax assets</font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt">$</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 10pt">-</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt">$</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 10pt">-</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt"> </font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font-size: 10pt">Certain
deferred income tax assets in the table above as of September 30, 2018 have been adjusted to reflect state operating loss carryforwards
and tax rates with a corresponding offset in the valuation allowance of approximately $3.9 million.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<!-- Field: Page; Sequence: 58; Value: 1 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt">Anavex Life Sciences Corp.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt">Notes to the Consolidated Financial
Statements</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt">September 30, 2019 – Page
16</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.59in; text-align: left"><font style="font-size: 10pt">Note 6</font></td><td style="text-align: justify"><font style="font-size: 10pt"><u>Income
                                         Taxes</u> - Continued</font></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt"><font style="font-size: 10pt">A reconciliation
of income tax expense at the statutory federal income tax rate and income taxes as reflected in the financial statements for the
years ended September 30, 2019 and 2018 is as follows:</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt"><font style="font-size: 10pt"> </font></p>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.59in">
<tr style="vertical-align: bottom">
<td style="white-space: nowrap; border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 10pt">2019</font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 10pt">2018</font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 74%; text-align: left"><font style="font-size: 10pt">Income benefit at statutory federal rate</font></td><td style="width: 1%"><font style="font-size: 10pt"> </font></td>
<td style="width: 1%; text-align: left"><font style="font-size: 10pt">$</font></td><td style="width: 10%; text-align: right"><font style="font-size: 10pt">(5,505,000</font></td><td style="width: 1%; text-align: left"><font style="font-size: 10pt">)</font></td><td style="width: 1%"><font style="font-size: 10pt"> </font></td>
<td style="width: 1%; text-align: left"><font style="font-size: 10pt">$</font></td><td style="width: 10%; text-align: right"><font style="font-size: 10pt">(4,215,000</font></td><td style="width: 1%; text-align: left"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left"><font style="font-size: 10pt">Foreign income taxed at other rates</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">(825,000</font></td><td style="text-align: left"><font style="font-size: 10pt">)</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">(173,000</font></td><td style="text-align: left"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left"><font style="font-size: 10pt">Other permanent differences</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">140,000</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">131,000</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left"><font style="font-size: 10pt">Research and development credit benefit</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">914,000</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">(102,000</font></td><td style="text-align: left"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left"><font style="font-size: 10pt">Adjustment and true up to prior years' tax provision</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">194,000</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">(82,000</font></td><td style="text-align: left; vertical-align: middle"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left"><font style="font-size: 10pt">Effect of changes in tax rates</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">-</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">6,832,000</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left"><font style="font-size: 10pt">State minimum and excise taxes</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">82,181</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">72,746</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; border-bottom: Black 1pt solid"><font style="font-size: 10pt">Change in federal valuation
    allowance</font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 10pt">5,082,000</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 10pt">(2,391,000</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; border-bottom: Black 2.5pt double"><font style="font-size: 10pt">Income tax expense</font></td><td style="border-bottom: Black 2.5pt double"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 10pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 10pt">82,181</font></td><td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 2.5pt double"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 10pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 10pt">72,746</font></td><td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 10pt"> </font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt"></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">As of September 30, 2019, the Company
had U.S. federal net operating loss carryforwards of approximately $60.8 million (2018: $50.6 million) which will begin to expire
in 2027 and state net operating loss carryforwards of approximately $64.0 million which will begin to expire in 2036. In addition,
the Company had approximately $3.5 million (Approximately AUD$ 5.2 million) (2018: $1.0 million) net operating loss carryforwards
in Australia, which have an indefinite life and approximately $3.6 million (Approximately € 3.3 million) (2018: $0.6 million)
in Germany, available to offset future taxable income in those jurisdictions.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt"></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt">The
Company evaluates its valuation allowance requirements based on projected future operations. When circumstances change, and this
causes a change in management’s judgment about the recoverability of deferred tax assets, the impact of the change on the
valuation allowance is reflected in current income. Because management of the Company does not currently believe that it is more
likely than not that the Company will receive the benefit of these assets, a valuation allowance equal to the deferred tax asset
has been established at September 30, 2019 and 2018.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt">Uncertain
Tax Positions</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt">The
Company files income tax returns in the U.S. federal jurisdiction and various state and foreign jurisdictions. The Company’s
tax returns are subject to tax examinations by U.S. federal and state tax authorities, or examinations by foreign tax authorities
until the respective statutes of limitation expire. The Company is subject to tax examinations by tax authorities for all taxation
years commencing on or after 2012.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><font style="font-size: 10pt">Certain
of the Company’s net operating loss carryforwards in the United States may be subject to limitations by Section 382
of the Internal Revenue Code with respect to the amount utilizable each year. This limitation reduces the Company’s ability
to utilize net operating loss carryforwards, under certain circumstances. The Company completed a Section 382 analysis through
the fiscal year ended September 30, 2019 and currently does not believe Section 382 will apply to limit the utilization of these
tax losses. </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> <i> </i></font></p>
<!-- Field: Page; Sequence: 59; Value: 1 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"><b> </b></font></p>
<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt; font-style: normal"><a name="main_014"></a></section><section class="edgaug_item9" id="edgaug_item9_id">ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL MATTERS</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">Not Applicable</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt; font-style: normal"><a name="main_015"></a></section><section class="edgaug_item9a" id="edgaug_item9a_id">ITEM 9A. CONTROLS AND PROCEDURES</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b><i> </i></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b><i>Disclosure
Controls and Procedures</i></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b><i></i></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>
<p style="font: 10.5pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0">We
maintain disclosure controls and procedures that are designed to provide reasonable assurance that material information required
to be disclosed in our periodic reports filed under the Exchange Act is recorded, processed, summarized, and reported within the
time periods specified in the SEC’s rules and forms and to provide reasonable assurance that such information is accumulated
and communicated to our management, our chief executive officer and our principal financial officer, to allow timely decisions
regarding required disclosure. We carried out an evaluation, under the supervision and with the participation of our management,
including our principal executive and principal financial officer, of the effectiveness of the design and operation of our disclosure
controls and procedures, as defined in Rule 13(a)-15(e) under the Exchange Act. Based on this evaluation, our principal
executive officer and principal financial officer concluded that our disclosure controls and procedures were not effective, as
of September 30, 2019. This determination is based on the material weakness management identified in our internal control over
financial reporting for the Australian research and development incentive income, as described below. A material weakness is defined
as a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable
possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely
basis.</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0">During
the preparation of our financial statements for the year ended September 30, 2019, we identified an adjustment regarding our accounting
for research and development incentive income associated with the Australian research and development incentive program. Specifically,
previously the Company accounted for research and development incentive income when received in cash. During the preparation of
our financial statements for the year ended September 30, 2019, we determined, based on a continuing assessment of the Company’s
eligibility for the incentive programs under which it was receiving such income, that the income should have been accrued and
recorded earlier, specifically in the period in which the qualifying research and development expenditures were incurred. The
cumulative impact of adjusting the above noted historical amounts resulted in a decrease in our reported net loss for the year
ended September 30, 2018, as well as an increase in the reported assets as of September 30, 2018. As a result of the adjustment,
we identified a material weakness in internal control over financial reporting for the accounting of the Australian research and
development incentive program during the year ended September 30, 2019. </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b><i>Management’s
Annual Report on Internal Control over Financial Reporting </i></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b><i> </i></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">Our management
is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f)
and 15d-15(f) under the Exchange Act. Under the supervision and with the participation of our management, including our Principal
Executive Officer and Principal Financial Officer, we conducted an evaluation of the effectiveness of our internal control over
financial reporting based on criteria established in the framework in Internal Control — Integrated Framework (2013)
issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”).</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections
of any evaluation of effectiveness to future periods are subject to the risks that controls may become inadequate because of changes
in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify">We determined that our internal controls
over accounting for Australian research and development incentive income were not effective as of September 30, 2019, as a result
of adjustments required to prior period financial statements of that program.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify">BDO USA, LLP, an independent registered
public accounting firm, has provided an attestation report on the Company’s internal control over financial reporting as
of September 30, 2019, which is included herein.</p>
<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Remediation
of Material Weaknesses and Changes in Internal Control over Financial Reporting<br/>
</i></b></font> </p>
<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-size: 10pt">In response
to the above, related to accounting for the Australian research and development incentive program, with the oversight of the Audit
Committee of our Board of Directors, management has, and will continue to evaluate, our policies and procedures related to the
accounting for the Australian research and development incentive program to ensure that the accounting, estimates and disclosures
of this program are assessed and reconciled on a quarterly basis.</font></p>
<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt; font-style: normal"><a name="main_016"></a></section><section class="edgaug_item9b" id="edgaug_item9b_id">ITEM 9B OTHER INFORMATION</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">None.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<!-- Field: Page; Sequence: 60; Options: NewSection; Value: 35 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"><a name="main_017"></a>PART
III</font></p>
<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt; font-style: normal"> </font></p>
<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt; font-style: normal"><a name="main_018"></a></section><section class="edgaug_item10" id="edgaug_item10_id">ITEM 10 DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b><i> </i></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b><i>Directors
and Executive Officers</i></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">Our directors
are to be elected at our annual meeting and each director elected is to hold office until his or her successor is elected and
qualified. Our board of directors may remove our officers at any time.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">Our directors
and executive officers, their age, positions held, and duration of such, are as follows:</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="width: 26%; text-align: justify; white-space: nowrap"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></font></td>
<td style="width: 2%; white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="width: 40%; text-align: justify; white-space: nowrap"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position</b></font></td>
<td style="width: 2%; white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="width: 8%; text-align: justify; white-space: nowrap"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></font></td>
<td style="width: 2%; white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="width: 20%; text-align: justify; white-space: nowrap"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date
    first appointed</b></font></td></tr>
<tr style="vertical-align: top">
<td style="white-space: nowrap"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher Missling,
    PhD</font></td>
<td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="white-space: nowrap"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director, President,
    Chief Executive Officer, Secretary</font></td>
<td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: justify; white-space: nowrap"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</font></td>
<td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: justify; white-space: nowrap"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July
    5, 2013</font></td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; white-space: nowrap"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Athanasios
    Skarpelos</font></td>
<td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: justify; white-space: nowrap"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</font></td>
<td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: justify; white-space: nowrap"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</font></td>
<td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: justify; white-space: nowrap"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
    9, 2013</font></td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; white-space: nowrap"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Claus
    van der Velden, PhD</font></td>
<td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: justify; white-space: nowrap"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</font></td>
<td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: justify; white-space: nowrap"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</font></td>
<td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: justify; white-space: nowrap"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    2, 2018</font></td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; white-space: nowrap"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Elliot
    Favus, MD</font></td>
<td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: justify; white-space: nowrap"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</font></td>
<td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: justify; white-space: nowrap"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</font></td>
<td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: justify; white-space: nowrap"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    7, 2014</font></td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; white-space: nowrap"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steffen
    Thomas, PhD</font></td>
<td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: justify; white-space: nowrap"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</font></td>
<td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: justify; white-space: nowrap"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</font></td>
<td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: justify; white-space: nowrap"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    15, 2015</font></td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; white-space: nowrap"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Peter
    Donhauser, D.O.</font></td>
<td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: justify; white-space: nowrap"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</font></td>
<td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: justify; white-space: nowrap"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</font></td>
<td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: justify; white-space: nowrap"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    8, 2017</font></td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; white-space: nowrap"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sandra
    Boenisch, CPA, CGA</font></td>
<td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="white-space: nowrap"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Financial
    Officer, Treasurer</font></td>
<td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: justify; white-space: nowrap"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">38
    </font></td>
<td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: justify; white-space: nowrap"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
    1, 2015</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b><i> </i></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b><i>Business
Experience</i></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">The following
is a brief account of the education and business experience of directors and executive officers during at least the past five
years, indicating their principal occupation during the period, and the name and principal business of the organization by which
they were employed.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><u>Christopher
Missling, PhD</u>. Christopher Missling has over twenty years of healthcare industry experience in big pharmaceutical, biotech
industry and investment banking. Most recently, from March 2007 until his appointment by our Company, Dr. Missling served as the
head of healthcare investment banking at Brimberg &amp; Co. in New York, New York. Also, Dr. Missling served as the Chief Financial
Officer of Curis, Inc. (NASDAQ:CRIS) and ImmunoGen, Inc. (NASDAQ:IMGN). Dr. Missling earned his MS and PhD from the University
of Munich and an MBA from Northwestern University Kellogg School of Management and WHU Otto Beisheim School of Management.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><u>Athanasios
Skarpelos</u>. Athanasios (Tom) Skarpelos is a self-employed investor with 20 years of experience working with private and public
companies. For more than 12 years, he has been focused on biotechnology companies involved in drug discovery and drug development
projects. His experience has led to relationships with researchers at academic institutes in Europe and North America. Mr. Skarpelos
is a founder of Anavex.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><u>Claus
van der Velden, PhD</u>. Claus van der Velden, PhD, brings significant expertise in management, accounting, internal controls
and risk management. Since July of 2011, he has served as corporate head of Management Accounting, Internal Audit and Risk Management
at Stroeer SE &amp; Co KGaA, a publicly listed German digital media company. Previously, Dr. van der Velden served as the Director
of Corporate Business Controlling for the Nutrition &amp; Health business unit at Cognis, a worldwide supplier of global nutritional
ingredients and specialty chemicals. In this position, he was also a compliance representative and a member of the global leadership
team. After the acquisition of Cognis by BASF, he was responsible for the management accounting processes of the BASF Nutrition
&amp; Health division, developing and producing mostly natural-source ingredients for the food and healthcare industries. Dr.
van der Velden started his career as a strategy consultant at an international marketing and strategy consultancy firm. He studied
in Kiel and Stockholm and received a degree in economics from the University of Kiel and later obtained his doctorate in business
management from the WHU-Otto Beisheim School of Management where he also previously taught economics.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<!-- Field: Page; Sequence: 61; Value: 35 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><u>Elliot
Favus, MD.</u> Elliot Favus is Chief Executive Officer of Favus Institutional Research, a healthcare research firm serving institutional
investors. He has been a healthcare equity research analyst on Wall Street since 2006, starting at Lazard Capital Markets and
subsequently at Och-Ziff Capital Management Group. Prior to working on Wall Street, Dr. Favus was an Instructor in medicine at
Mount Sinai School of Medicine in New York. He attended the University of Michigan (BA, 1996), the University of Chicago Pritzker
School of Medicine (MD, 2001) and the NYU-Bellevue Hospital Internal Medicine Residency Program (2004). He is board-certified
in Internal Medicine (2004) and has 10 years of basic science laboratory experience working on human genetics projects at Harvard
Medical School, the University of Chicago and the University of Pittsburgh.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><u>Steffen
Thomas, PhD </u>Steffen Thomas, has over 15 years of experience as a European patent attorney and is currently practicing at Epping
Hermann Fischer, a major intellectual property law firm in Europe. Previously, he worked for Japan-based Takeda Pharmaceutical
Company, the largest pharmaceutical company in Asia and a top firm worldwide, as an in-house patent attorney. Prior to that, he
worked for Nycomed Pharma, acquired by Takeda in 2011 for approximately USD $10 billion. Dr. Thomas’ legal practice covers
drafting of patent applications, prosecuting patent applications before national and international patent offices, defending and
challenging patents in opposition, appeal, and nullity proceedings, enforcing patents before the infringement courts, and preparing
opinions on patentability and infringement in the technical field of chemistry. Dr. Thomas has particular expertise in small molecule
pharmaceuticals. He holds MS and PhD degrees in Chemistry from the University of Munich.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><u>Peter
Donhauser, D.O.</u> Peter Donhauser, had more than 20 years of expertise in clinical research prior to practicing osteopathic
medicine with an integrated medical approach in private practice beginning in 2000. He worked at the University Hospital of Munich
in the fields of geriatrics and neuromusculoskeletal diseases.  During this time, he was a clinical trial investigator in
multiple Phase 3 studies, including studies sponsored by Merck Sharp &amp; Dohme, Merck, Boehringer Mannheim, Roche, Servier and
Sanofi. He received his human medicine degree at the University of Munich and Doctor of Osteopathic Medicine (D.O.) from the German-American
Academy for Osteopathy, or DAAO, a member of the European Register for Osteopathic Physicians, or EROP, at the Philadelphia College
of Osteopathic Medicine.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><u>Sandra
Boenisch, CPA, CGA</u> Ms. Boenisch is a Chartered Professional Accountant (CPA, CGA) with over 15 years of accounting, audit,
and financial reporting experience in a variety of industries, both in the United States and Canada. Ms. Boenisch was an independent
consultant, providing financial reporting services to a range of public companies in the United States and Canada since January
2012. From 2008 until 2012, Ms. Boenisch was employed at BDO Canada LLP (Vancouver, BC) where she was hired as a Senior Accountant
and was later promoted to Manager, Audit Assurance. Ms. Boenisch specialized in managing assurance engagements for public companies
in the United States and Canada. Prior to that, Ms. Boenisch worked for another public accounting firm from 2001 to 2008. As an
independent consultant, Ms. Boenisch has acquired considerable experience in finance, governance, and regulatory compliance. She
holds a BComm from Laurentian University.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b><i>Family
Relationships</i></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">There are
no family relationships between any director or executive officer.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b><i>Involvement
in Certain Legal Proceedings</i></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">There are
no material proceedings to which any director or executive officer or any associate of any such director or officer is a party
adverse to our Company or has a material interest adverse to our Company.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<!-- Field: Page; Sequence: 62; Value: 35 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b><i>Compliance
with Section 16(a) of the Securities Exchange Act of 1934 </i></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">Section
16(a) of the Securities Exchange Act of 1934 requires our executive officers and directors and persons who own more than 10% of
our common stock to file with the Securities and Exchange Commission initial statements of beneficial ownership, reports of changes
in ownership and annual reports concerning their ownership of our common stock and other equity securities, on Forms 3, 4 and
5 respectively. Executive officers, directors and greater than 10% shareholders are required by the Securities and Exchange Commission
regulations to furnish us with copies of all Section 16(a) reports that they file.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><font style="font-size: 10pt">Based
solely on the copies of such reports and amendments thereto received by us, or written representations that no filings were required,
we believe that all Section 16(a) filing requirements applicable to our executive officers and directors and 10% stockholders
were met for the year ended September 30, 2019.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b><i>Code
of Ethics</i></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">We have
adopted a code of ethics that applies to our directors, principal executive officer, principal financial officer, principal accounting
officer or controller, or persons performing similar functions, and to all employees. We have posted our policy on our website
at <u>www.anavex.com</u>.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b><i>Audit
Committee and Audit Committee Financial Experts </i></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">The members
of the Audit Committee are Claus van der Velden (Chairman), Athanasios Skarpelos and Steffen Thomas. Our board of directors has
determined that Claus van der Velden is an “audit committee financial expert” as defined by applicable SEC and Nasdaq
rules.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">The Audit
Committee oversees and reports to our board of directors on various auditing and accounting-related matters, including, among
other things, the maintenance of the integrity of our financial statements, reporting process and internal controls; the selection,
evaluation, compensation and retention of our independent registered public accounting firm; legal and regulatory compliance,
including our disclosure controls and procedures; and oversight over our risk management policies and procedures.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">The Audit
Committee operates under a charter that was adopted by our board of directors. The Audit Committee met five times during fiscal
2019.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"><b><i> </i></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"><b><i>Nominating and Corporate
Governance Committee</i></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">The members
of our Nominating and Corporate Governance Committee are Claus van der Velden (Chairman), Steffen Thomas and Peter Donhauser.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">The Nominating
and Corporate Governance Committee is appointed by the Board to oversee and evaluate the Board's performance and the company's
compliance with corporate governance regulations, guidelines and principles, to identify individuals qualified to become Board
members, to recommend to the Board proposed nominees for Board membership, and to recommend to the Board directors to serve on
each standing committee. The Nominating and Corporate Governance Committee did not meet but did act by written consent during
fiscal 2019.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"><b><i> </i></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"><b><i>Compensation Committee</i></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">The members
of our Compensation Committee are Claus van der Velden (Chairman), Steffen Thomas and Peter Donhauser.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">The Compensation
Committee assists our board of directors in discharging its responsibilities relating to compensation of our directors and executive
officers. Its responsibilities include, among other things, reviewing, approving and recommending compensation programs and arrangements
applicable to our officers; determining the objectives of our executive officer compensation programs; overseeing the evaluation
of our senior executives; administering our incentive compensation plans and equity-based plans, including reviewing and granting
equity awards to our executive officers; and reviewing and approving director compensation and benefits. The Compensation Committee
can delegate to other members of our board of directors, or an officer or officers of the Company, the authority to review and
grant stock-based compensation for employees who are not executive officers.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<!-- Field: Page; Sequence: 63; Value: 35 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">The Compensation
Committee has the responsibilities and authority designated by Nasdaq rules. Specifically, the Compensation Committee has the
sole discretion to select and receive advice from a compensation consultant, legal counsel or other adviser and is directly responsible
for oversight of their work. The Compensation Committee must also determine reasonable compensation to be paid to such advisors
by us.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt">Prior to the formation of our
Compensation Committee, our board of directors performed the functions that would have been handled by the Compensation Committee.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">The Compensation
Committee operates under a charter that was adopted by our board of directors. The Compensation Committee met two times during
fiscal 2019.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt; font-style: normal"><a name="main_019"></a></section><section class="edgaug_item11" id="edgaug_item11_id">ITEM 11. EXECUTIVE COMPENSATION</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">The Company’s
compensation objectives are to offer our executive officers’ compensation and benefits that are competitive and meet our
goals of attracting, retaining and motivating highly skilled, talented management, which is necessary for the Company to achieve
its financial and strategic objectives and create long-term value for our stockholders.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">A significant
portion of the Company’s executive compensation opportunity is related to factors that directly and indirectly influence
shareholder value, including long-term stock performance and operational performance. We believe the levels of compensation we
provide should be competitive, reasonable and appropriate for our business needs and circumstances.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b><i> </i></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b><i>Our
Executive Compensation Program and Philosophy</i></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">The intent
of the Company’s compensation program is to attract and retain talent, to create incentives for and to reward excellent
performance. We seek to compensate our executives in a manner that is competitive, rewards performance that creates shareholder
value, recognizes individual contributions, and encourages long-term value creation.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">The Compensation
Committee meets at least twice per year to review and evaluate executive compensation and each executive officer’s performance.
The Compensation Committee utilizes quantitative and qualitative factors, including the accomplishment of initiatives, attitude,
and leadership and applies overall judgment to assess performance, taking into account the financial condition of the Company.
Ultimately, the Compensation Committee seeks to evaluate, based on the achievement of financial and nonfinancial objectives, the
variable compensation, including special awards, of executive officers of the Company and decide on the base salary and target
discretionary bonus for such persons taking into account relevant benchmark data.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">The Compensation
Committee believes that a significant portion of each executive’s compensation opportunity should be tied to variable compensation
and value creation for shareholders. The Compensation Committee believes this mix provides an appropriate balance between the
financial security required to attract and retain qualified individuals, and the Compensation Committee’s goal of ensuring
that executive compensation rewards performance that benefits shareholders over the long term.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b><i>Compensation
Consultants</i></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">The Compensation
Committee makes recommendations to the Board for all compensation for executives, including the structure and design of the compensation
programs. The Compensation Committee is responsible for retaining and terminating compensation consultants and determining the
terms and conditions of their engagement. During fiscal 2019, the Compensation Committee did not engage any compensation consultants.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<!-- Field: Page; Sequence: 64; Value: 35 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">  </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b><i>Annual
Discretionary Cash Bonuses</i></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">The Company
has an annual discretionary cash bonus program. The Compensation Committee, or board of directors works with the Chief Executive
Officer to evaluate the Company’s financial performance and overall financial condition to determine if discretionary bonuses
are to be paid.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b><i>Benefits</i></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">The Company’s
executives are entitled to participate in employee benefit plans, programs and arrangements implemented by the Company and generally
available to all salaried employees, such as medical, dental and insurance programs. Executives are also allowed to participate
in the Company’s tax-qualified 401(k) Plan offered to all similarly situated full-time employees.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b><i> </i></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b><i>Summary
Compensation </i></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">The particulars
of compensation paid to our named executive officers for the last two completed fiscal years:</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td style="white-space: nowrap; font-weight: bold"><font style="font-size: 10pt">Name and Principal <br/> Position</font></td><td style="font-weight: bold; white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 10pt">Year</font></td><td style="font-weight: bold; white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 10pt">Salary <br/>
    ($)</font></td><td style="font-weight: bold; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="font-weight: bold; white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 10pt">Bonus <br/>
    ($)</font></td><td style="font-weight: bold; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="font-weight: bold; white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 10pt">Stock <br/>
    Awards <br/> ($)</font></td><td style="font-weight: bold; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="font-weight: bold; white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 10pt">Option <br/>
    Awards <br/> ($)</font></td><td style="font-weight: bold; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="font-weight: bold; white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 10pt">Other  <br/>
    Compen- <br/> sation <br/> ($)</font></td><td style="font-weight: bold; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="font-weight: bold; white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 10pt">Total <br/>
    ($)</font></td><td style="font-weight: bold; white-space: nowrap"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 37%; text-align: left; white-space: nowrap"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher
    Missling, PhD<sup>(1)</sup></font></td><td style="width: 1%; white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="width: 8%; text-align: center; white-space: nowrap"><font style="font-size: 10pt">2019</font></td><td style="width: 1%; white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="width: 1%; text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="width: 6%; text-align: right; white-space: nowrap"><font style="font-size: 10pt">512,500</font></td><td style="width: 1%; text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="width: 1%; white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="width: 1%; text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="width: 6%; text-align: right; white-space: nowrap"><font style="font-size: 10pt">50,000</font></td><td style="width: 1%; text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="width: 1%; white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="width: 1%; text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="width: 6%; text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="width: 1%; text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="width: 1%; white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="width: 1%; text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="width: 6%; text-align: right; white-space: nowrap"><font style="font-size: 10pt">2,806,339</font></td><td style="width: 1%; text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="width: 1%; white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="width: 1%; text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="width: 6%; text-align: right; white-space: nowrap"><font style="font-size: 10pt">11,200</font></td><td style="width: 1%; text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="width: 1%; white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="width: 1%; text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="width: 6%; text-align: right; white-space: nowrap"><font style="font-size: 10pt">3,380,039</font></td><td style="width: 1%; text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt">President, Chief Executive Officer, and Director</font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: center; white-space: nowrap"><font style="font-size: 10pt">2018</font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">500,000</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">65,000</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">1,973,889</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">11,000</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">2,549,889</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: center; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="white-space: nowrap"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sandra Boenisch<sup>(2)</sup></font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: center; white-space: nowrap"><font style="font-size: 10pt">2019</font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">72,327</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">13,561</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">138,672</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">224,560</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt">Principal Financial Officer and Treasurer</font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: center; white-space: nowrap"><font style="font-size: 10pt">2018</font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">79,608</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">11,414</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">141,047</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">232,069</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td></tr>
</table>
<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-indent: -21.25pt"><font style="font-size: 10pt; font-style: normal"> </font></p>
<table cellpadding="0" cellspacing="0" style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 7.1pt"></td><td style="width: 21.25pt"><font style="font-size: 10pt; font-style: normal">(1)</font></td><td><font style="font-size: 10pt; font-style: normal">Christopher
                                         Missling was appointed as director, President, Chief Executive Officer, Chief Financial
                                         Officer, and Secretary on July 5, 2013.</font></td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 6.55pt"></td><td style="width: 21.8pt"><font style="font-size: 10pt">(2)</font></td><td><font style="font-size: 10pt">Compensation
                                         to Ms. Boenisch denominated in Canadian Dollars and has been translated to US dollars
                                         at an exchange rate of 0.7534 during the year ended September 30, 2019 (2018: 0.7805).</font></td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-indent: -21.8pt"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b><i>Employment
Agreements</i></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b><i> </i></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"><b>Christopher Missling</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">We and Dr.
Missling entered into an employment agreement dated July 5, 2013, as amended and extended (the “CEO Employment Agreement”),
whereby we currently pay to Dr. Missling an annual base salary of $550,000. In addition, Dr. Missling is eligible to earn an annual
cash bonus for each whole or partial calendar year of up to twenty percent of his base salary, and to participate in our employee
benefit plans. We have agreed to indemnify Dr. Missling in connection with his provision of services to us.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">During the
year ended September 30, 2019, in connection with the second amendment to the CEO Employment Agreement, Dr. Missling was granted
750,000 options for shares of the Company’s common stock, one third of which shall vest on each of July 5, 2020, July 5,
2021 and July 5, 2022.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>
<!-- Field: Page; Sequence: 65; Value: 35 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"><b>Sandra Boenisch</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"><b> </b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">We and Ms.
Boenisch entered into an employment agreement dated October 1, 2015, as amended and extended whereby we currently pay Ms. Boenisch
an annual base salary of $96,000 Canadian dollars. Ms. Boenisch is eligible for discretionary salary increases.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b><i>Outstanding
Equity Awards at Fiscal Year-End </i></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">The following
table sets forth for each named executive officer and director certain information concerning the outstanding equity awards as
of September 30, 2019.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td colspan="19" style="white-space: nowrap; text-align: center"><font style="font-size: 10pt">Option Awards</font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td colspan="14" style="white-space: nowrap; text-align: center"><font style="font-size: 10pt">Stock Awards</font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom">
<td style="white-space: nowrap; text-align: center"><font style="font-size: 10pt">Name</font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 10pt">Number of<br/> Securities<br/>
    Underlying<br/> Exercisable<br/> Options<br/> (#)</font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 10pt">Number of<br/> Securities<br/>
    Underlying<br/> Unexercisable<br/> Options<br/> (#)</font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 10pt">Equity<br/> Incentive<br/> Plan<br/>
    Awards:<br/> Number of<br/> Securities<br/> Underlying<br/> Unexercised<br/> Unearned<br/> Options<br/> (#)</font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 10pt">Option<br/> Exercise<br/> Price<br/>
    ($)</font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="white-space: nowrap; text-align: center"><font style="font-size: 10pt">Option<br/> Expiration<br/> Date</font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 10pt">Number<br/> of<br/> Shares of<br/>
    Units of<br/> Stock<br/> that<br/> have<br/> not<br/> Vested<br/> (#)</font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 10pt">Market<br/> Value of<br/> Shares<br/>
    or<br/> Units of<br/> Stock<br/> that<br/> have not<br/> Vested<br/> ($)</font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 10pt">Equity<br/> Incentive<br/> Plan<br/>
    Awards:<br/> Number<br/> of<br/> Unearned<br/> Shares,<br/> Units or<br/> Other<br/> Rights<br/> that have<br/> not<br/> Vested<br/>
    (#)</font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 10pt">Equity<br/> Incentive<br/> Plan<br/>
    Awards:<br/> Market or<br/> Payout<br/> Value of<br/> Unearned<br/> Shares,<br/> Units or<br/> Other<br/> Rights<br/> that<br/> have
    not<br/> Vested<br/> ($)</font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 10%; text-align: left; white-space: nowrap"><font style="font-size: 10pt">Christopher Missling</font></td><td style="width: 1%; white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="width: 1%; text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="width: 8%; text-align: right; white-space: nowrap"><font style="font-size: 10pt">500,000</font></td><td style="width: 1%; text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="width: 1%; white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="width: 1%; text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="width: 8%; text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="width: 1%; text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="width: 1%; white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="width: 1%; text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="width: 8%; text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="width: 1%; text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="width: 1%; white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="width: 1%; text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="width: 8%; text-align: right; white-space: nowrap"><font style="font-size: 10pt">1.60</font></td><td style="width: 1%; text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="width: 1%; white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="width: 10%; text-align: center; white-space: nowrap"><font style="font-size: 10pt">July 5, 2023</font></td><td style="width: 1%; white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="width: 1%; text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="width: 8%; text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="width: 1%; text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="width: 1%; white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="width: 1%; text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="width: 8%; text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="width: 1%; text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="width: 1%; white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="width: 1%; text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="width: 8%; text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="width: 1%; text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="width: 1%; white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="width: 1%; text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="width: 8%; text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="width: 1%; text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">125,000</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">1.32</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: center; white-space: nowrap"><font style="font-size: 10pt">May 8, 2024</font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">500,000</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">0.92</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: center; white-space: nowrap"><font style="font-size: 10pt">April 2, 2025</font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">187,500</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">5.04</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: center; white-space: nowrap"><font style="font-size: 10pt">Sept 18, 2025</font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">379,625</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">6.26</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: center; white-space: nowrap"><font style="font-size: 10pt">July 5, 2026</font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">861,429</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">7.06</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: center; white-space: nowrap"><font style="font-size: 10pt">July 18, 2026</font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">500,000</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">3.28</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: center; white-space: nowrap"><font style="font-size: 10pt">Sept 22, 2026</font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">375,000</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">75,000</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">5.92</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: center; white-space: nowrap"><font style="font-size: 10pt">May 12, 2027</font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">233,333</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">166,667</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">3.30</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: center; white-space: nowrap"><font style="font-size: 10pt">Dec 13, 2027</font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">450,000</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">2.30</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: center; white-space: nowrap"><font style="font-size: 10pt">May 15, 2028</font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">409,500</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">2.58</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: center; white-space: nowrap"><font style="font-size: 10pt">Oct. 1, 2028</font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">750,000</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">3.15</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: center; white-space: nowrap"><font style="font-size: 10pt">May 3, 2029</font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: center; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt">Sandra Boenisch</font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">25,000</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">5.68</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: center; white-space: nowrap"><font style="font-size: 10pt">Oct 2, 2025</font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">106,696</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">3.28</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: center; white-space: nowrap"><font style="font-size: 10pt">Sept 22, 2026</font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">29,168</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">5,832</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">5.92</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: center; white-space: nowrap"><font style="font-size: 10pt">May 12, 2027</font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">17,500</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">12,500</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">3.30</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: center; white-space: nowrap"><font style="font-size: 10pt">Dec 13, 2027</font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">30,000</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">2.30</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: center; white-space: nowrap"><font style="font-size: 10pt">May 15, 2028</font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">27,300</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">2.58</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: center; white-space: nowrap"><font style="font-size: 10pt">Oct. 1, 2028</font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">35,000</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">2.93</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: center; white-space: nowrap"><font style="font-size: 10pt">June 4, 2029</font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"><b><i> </i></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"><b><i>Stock Option Plans</i></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">For a description
of our Equity Compensation Plans, please see Item 5 to this annual report on Form 10-K.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b><i> </i></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>
<!-- Field: Page; Sequence: 66; Value: 35 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b><i>Compensation
of Directors </i></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">The table
below shows the compensation of our directors who were not our named executive officers for the fiscal year ended September 30,
2019:</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td style="white-space: nowrap; font-weight: bold"><font style="font-size: 10pt">Name</font></td><td style="font-weight: bold; white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 10pt">Fees Earned<br/>
    or Paid in<br/> Cash<br/> ($)</font></td><td style="font-weight: bold; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="font-weight: bold; white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 10pt">Stock<br/>
    Awards<br/> ($)</font></td><td style="font-weight: bold; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="font-weight: bold; white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option</b><br/>
<b>Awards</b><br/> <b>($) <sup>(1)</sup></b></font></td><td style="font-weight: bold; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="font-weight: bold; white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 10pt">Non-Equity<br/>
    Incentive<br/> Plan<br/> Compensation<br/> ($)</font></td><td style="font-weight: bold; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="font-weight: bold; white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 10pt">Nonqualified<br/>
    Deferred<br/> Compensation<br/> Earnings<br/> ($)</font></td><td style="font-weight: bold; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="font-weight: bold; white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 10pt">All Other<br/>
    Compensation<br/> ($)</font></td><td style="font-weight: bold; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="font-weight: bold; white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 10pt">Total<br/>
    ($)</font></td><td style="font-weight: bold; white-space: nowrap"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 30%; text-align: left; white-space: nowrap"><font style="font-size: 10pt">Athanasios Skarpelos</font></td><td style="width: 1%; white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="width: 1%; text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="width: 7%; text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="width: 1%; text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="width: 1%; white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="width: 1%; text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="width: 7%; text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="width: 1%; text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="width: 1%; white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="width: 1%; text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="width: 7%; text-align: right; white-space: nowrap"><font style="font-size: 10pt">93,871</font></td><td style="width: 1%; text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="width: 1%; white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="width: 1%; text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="width: 7%; text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="width: 1%; text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="width: 1%; white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="width: 1%; text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="width: 7%; text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="width: 1%; text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="width: 1%; white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="width: 1%; text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="width: 7%; text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="width: 1%; text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="width: 1%; white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="width: 1%; text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="width: 7%; text-align: right; white-space: nowrap"><font style="font-size: 10pt">93,871</font></td><td style="width: 1%; text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt">Claus van der Velden</font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">16,000</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">93,871</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">109,871</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt">Elliot Favus</font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">93,871</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">93,871</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt">Steffen Thomas</font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">93,871</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">93,871</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt">Peter Donhauser</font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">93,871</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">-</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">93,871</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">(1) At September
30, 2019, the aggregate number of outstanding vested and unvested stock option awards held by each director was: Mr. Skarpelos
options to purchase 195,500 shares, Mr. Van der Velden options to purchase 95,500 shares, Mr. Favus options to purchase 240,500
shares, Mr. Thomas options to purchase 195,500 shares and Mr. Donhauser options to purchase 95,500 shares.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">We currently
compensate Claus van der Velden $4,000 per quarter for performing the functions of Chairman of our Audit Committee, Compensation
Committee and Nominating and Corporate Governance Committee.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">In addition,
directors are entitled to reimbursement for reasonable travel and other out-of-pocket expenses incurred in connection with attendance
at meetings of our board of directors. Our board of directors may award further special remuneration to any director undertaking
any special services on our behalf other than services ordinarily required of a director.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b><i>Retirement
or Similar Benefit Plans</i></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">There are
no arrangements or plans in which we provide retirement or similar benefits for our directors or executive officers.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b><i>Resignation,
Retirement, Other Termination, or Change in Control Arrangements</i></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">Our Employment
Agreement with Dr. Missling contains provisions regarding our obligations upon his termination and upon a change of control. In
the event of a change of control, as such term is defined in the employment agreement, all previously granted but unvested stock
options held by Dr. Missling shall vest. Depending on the nature of the termination of Dr. Missling’s services, certain
of his salary, bonus and granted securities shall vest in the amounts at such time as set forth in the Employment Agreement. A
copy of Dr. Missling’s Second Amendment to Employment Agreement is set forth in its entirety as an exhibit to our Quarterly
Report on Form 10-Q filed with the SEC on May 9, 2019.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">Our employment
agreement with Sandra Boenisch contains provisions regarding our obligations to Ms. Boenisch upon a change of control. In the
event of a change of control, as such term is defined in the employment agreement, all of the remaining unvested option shares
granted to Ms. Boenisch will immediately vest with no restrictions on purchase or sales. A copy of Ms. Boenisch’s employment
agreement is set forth in its entirety as Exhibit 10.8 hereto.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<!-- Field: Page; Sequence: 67; Value: 35 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt; font-style: normal"><a name="main_020"></a></section><section class="edgaug_item12" id="edgaug_item12_id">ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND <font style="text-transform: uppercase">RELATED STOCKHOLDER
MATTERS.</font></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">The following
table sets forth, as of December 12, 2019, certain information with respect to the beneficial ownership of our common stock by
each stockholder known by us to be the beneficial owner of more than 5% of our common stock and by each of our current directors
and our named executive officers and by our current directors and executive officers as a group. We have determined the number
and percentage of shares beneficially owned by such person in accordance with Rule 13d-3 under the Securities Exchange Act of
1934. This information does not necessarily indicate beneficial ownership for any other purpose.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 10pt">Title of class</font></td><td style="font-weight: bold; white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 10pt">Name and address of<br/>
    beneficial owner</font></td><td style="font-weight: bold; white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 10pt">Amount and
    nature of<br/> beneficial ownership</font></td><td style="font-weight: bold; white-space: nowrap"><font style="font-size: 10pt"><sup> </sup></font></td><td style="font-weight: bold; white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Percent
    of</b><br/> <b>class <sup>(1)</sup></b></font></td><td style="font-weight: bold; white-space: nowrap"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom">
<td style="white-space: nowrap; text-align: center"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="white-space: nowrap; text-align: center"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"><sup> </sup></font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 18%; text-align: left; white-space: nowrap"><font style="font-size: 10pt">Common Stock</font></td><td style="width: 1%; white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="width: 43%; text-align: left; white-space: nowrap"><font style="font-size: 10pt">Christopher Missling (CEO/Director)</font></td><td style="width: 1%; white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="width: 1%; text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="width: 16%; text-align: right; white-space: nowrap"><font style="font-size: 10pt">5,163,430</font></td><td style="width: 1%; text-align: left; white-space: nowrap"><font style="font-size: 10pt"><sup>(2)</sup></font></td><td style="width: 1%; white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="width: 1%; text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="width: 16%; text-align: right; white-space: nowrap"><font style="font-size: 10pt">8.6</font></td><td style="width: 1%; text-align: left; white-space: nowrap"><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"><sup> </sup></font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt">Common Stock</font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt">Athanasios Skarpelos (Director)</font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">1,456,458</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"><sup>(3)</sup></font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">2.6</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"><sup> </sup></font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt">Common Stock</font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt">Claus van der Velden (Director)</font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">16,667</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"><sup>(4)</sup></font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"><sup> </sup></font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt">Common Stock</font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt">Elliot Favus (Director)</font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">195,000</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"><sup>(5)</sup></font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"><sup> </sup></font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt">Common Stock</font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt">Steffen Thomas (Director)</font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">150,000</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"><sup>(6)</sup></font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"><sup> </sup></font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt">Common Stock</font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt">Peter Donhauser (Director)</font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">50,000</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"><sup>(7)</sup></font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"><sup> </sup></font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt">Common Stock</font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt">Sandra Boenisch (Principal Financial Officer)</font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">236,743</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"><sup>(8)</sup></font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"><sup> </sup></font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt">Common Stock</font></td><td style="font-weight: bold; white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="font-weight: bold; text-align: left; white-space: nowrap"><font style="font-size: 10pt">Directors &amp; Executive
    Officers as a group (7 persons)</font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">7,268,298</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"><sup> </sup></font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">11.9</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"><sup> </sup></font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt">Common Stock</font></td><td style="font-weight: bold; white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="font-weight: normal; text-align: left; white-space: nowrap; font-style: normal"><font style="font-size: 10pt">Park
    West Asset Management LLC <br/></font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">3,495,615</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"><sup> </sup></font></td><td style="white-space: nowrap"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt"> </font></td><td style="text-align: right; white-space: nowrap"><font style="font-size: 10pt">6.2</font></td><td style="text-align: left; white-space: nowrap"><font style="font-size: 10pt">%</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0"><font style="font-size: 10pt">*Less
than 1%</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><font style="font-size: 10pt"> </font></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-size: 10pt">(1)</font></td><td style="text-align: justify"><font style="font-size: 10pt">Percentage
                                         of ownership is based on 56,123,076 of our common stock issued and outstanding as of
                                         December 12, 2019. Except as otherwise indicated, we believe that the beneficial owners
                                         of the common stock listed above, based on information furnished by such owners, have
                                         sole investment and voting power with respect to such shares, subject to community property
                                         laws where applicable. Beneficial ownership is determined in accordance with the rules
                                         of the Securities and Exchange Commission and generally includes voting or investment
                                         power with respect to securities. Shares of common stock subject to options or warrants
                                         currently exercisable or exercisable within 60 days, are deemed outstanding for purposes
                                         of computing the percentage ownership of the person holding such option or warrants but
                                         are not deemed outstanding for purposes of computing the percentage ownership of any
                                         other person.</font></td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><font style="font-size: 10pt"> </font></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-size: 10pt">(2)</font></td><td style="text-align: justify"><font style="font-size: 10pt">Includes
                                         options to purchase 500,000 shares of our common stock at $1.60 per share, options to
                                         purchase 125,000 shares of our common stock at $1.32 per share, options to purchase 500,000
                                         shares of our common stock at $0.92 per share, options to purchase 187,500 shares of
                                         our common stock at $5.04 per share, options to purchase 379,625 shares of our common
                                         stock at $6.26 per share, options to purchase 861,429 shares of our common stock at $7.06
                                         per share, options to purchase 500,000 shares of our common stock at $3.28 per share,
                                         and options to purchase 375,000 shares of our common stock at $5.92 per share, options
                                         to purchase 266,666 shares of our common stock at $3.30 per share, and options to purchase
                                         450,000 shares of our common stock at $2.30 per share that are vested or are vesting
                                         within 60 days. Excludes options to purchase 75,000 shares of our common stock at $5.92
                                         per share, options to purchase 133,334 shares of our common stock at $3.30 per share,
                                         options to purchase 409,500 shares of our common stock at $2.58 per share and options
                                         to purchase 750,000 shares of our common stock at $3.15 per share that do not vest within
                                         60 days.</font></td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><font style="font-size: 10pt"> </font></p>
<!-- Field: Page; Sequence: 68; Value: 35 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><font style="font-size: 10pt"> </font></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-size: 10pt">(3)</font></td><td style="text-align: justify"><font style="font-size: 10pt">Includes
                                         options to purchase 50,000 shares of our common stock at $0.92 per share and options
                                         to purchase 100,000 shares of our common stock at $3.28 per share that have vested or
                                         are vesting within 60 days. Excludes options to purchase 45,500 shares of our common
                                         stock at $2.30 per share that do not vest within 60 days.</font></td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><font style="font-size: 10pt"> </font></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-size: 10pt">(4)</font></td><td style="text-align: justify"><font style="font-size: 10pt">Includes
                                         options to purchase 16,667 shares of our common stock at $2.60 per share that have vested
                                         or are vesting within 60 days. Excludes options to purchase 33,333 shares of our
                                         common stock at $2.60 per share and options to purchase 45,500 shares of our common stock
                                         at $2.30 per share that are not vesting within 60 days.</font></td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><font style="font-size: 10pt"> </font></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-size: 10pt">(5)</font></td><td style="text-align: justify"><font style="font-size: 10pt">Includes options
                                         to purchase 37,500 shares of our common stock at $1.20 per share, options to purchase
                                         50,000 shares of our common stock at $0.92 per share, options to purchase 1,500 shares
                                         of our common stock at $5.64 per share, options to purchase 1,500 shares of our common
                                         stock at 5.57 per share, options to purchase 1,500 shares of our common stock at $4.90
                                         per share, options to purchase 1,500 shares of our common stock at $5.66 per share, options
                                         to purchase 1,500 shares of our common stock at $6.11 per share, and options to purchase
                                         100,000 shares of our common stock at $3.28 per share that have vested or are vesting
                                         within 60 days. Excludes options to purchase 45,500 shares of our common stock at $2.30
                                         per share that do not vest within 60 days.</font></td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><font style="font-size: 10pt"> </font></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-size: 10pt">(6)</font></td><td style="text-align: justify"><font style="font-size: 10pt">Includes
                                         options to purchase 50,000 shares of our common stock at $1.76 per share and options
                                         to purchase 100,000 shares of our common stock at $3.28 per share that have vested or
                                         are vesting within 60 days. Excludes options to purchase 45,500 shares of our common
                                         stock at $2.30 per share that do not vest within 60 days.</font></td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><font style="font-size: 10pt"> </font></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-size: 10pt">(7)</font></td><td style="text-align: justify"><font style="font-size: 10pt">Includes
                                         options to purchase 50,000 shares of our common stock at $5.39 per share that have vested
                                         or are vesting within 60 days. Excludes options to purchase 45,500 shares of our common
                                         stock at $2.30 per share that do not vest within 60 days.</font></td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><font style="font-size: 10pt"> </font></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-size: 10pt">(8)</font></td><td style="text-align: justify"><font style="font-size: 10pt">Includes
                                         options to purchase 25,000 shares of our common stock at $5.68 per share, options to
                                         purchase 106,696 shares of our common stock at $3.28 per share, options to purchase 32,084
                                         shares of our common stock at $5.92 per share, options to purchase 20,000 shares of our
                                         common stock at $3.30 per share, and options to purchase 30,000 shares of our common
                                         stock at $2.30 per share that have vested or are vesting within 60 days. Excludes options
                                         to purchase 2,916 shares of our common stock at $5.92 per share, options to purchase
                                         10,000 shares of common stock at $3.30 per share, options to purchase 27,300 shares of
                                         common stock at $2.58 per share and options to purchase 35,000 shares of common stock
                                         at $2.93 per share that do not vest within 60 days.</font></td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b><i>Change
in Control</i></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">We are unaware
of any contract or other arrangement the operation of which may at a subsequent date result in a change of control of our Company.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt; font-style: normal"><a name="main_021"></a></section><section class="edgaug_item13" id="edgaug_item13_id">ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b><i> </i></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b><i>Transactions
with related persons</i></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">There have
been no transactions, since October 1, 2017, or currently proposed transactions, in which we were or are to be a participant and
the amount involved exceeds $120,000, and in which any of the following persons had or will have a direct or indirect material
interest.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><font style="font-size: 10pt"> </font></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-size: 10pt">i.</font></td><td style="text-align: justify"><font style="font-size: 10pt">any
                                         director or executive officer of our Company;</font></td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-size: 10pt">ii.</font></td><td style="text-align: justify"><font style="font-size: 10pt">any
                                         beneficial owner of shares carrying more than 5% of the voting rights attached to our
                                         outstanding shares of common stock; and</font></td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-size: 10pt">iii.</font></td><td style="text-align: justify"><font style="font-size: 10pt">any
                                         member of the immediate family (including spouse, parents, children, siblings and in-laws)
                                         of any of the foregoing persons.</font></td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b><i>Compensation
of Named Executive Officers and Directors</i></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">For information
regarding compensation of named executive officers and directors, please see “Item 11. Executive Compensation.”</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<!-- Field: Page; Sequence: 69; Value: 35 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b><i>Director
Independence</i></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b><i> </i></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">Under the
NASDAQ Stock Market Rules, the Board has a responsibility to make an affirmative determination that those members of its Board
that serve as independent directors do not have any relationships with the Company and its businesses that would impair their
independence. The Board has determined that that Christopher Missling, PhD is not independent as that term is defined by NASDAQ
5605(a)(2) because Mr. Missling serves as our President, Chief Executive Officer, and Secretary.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">The Board
has determined that that Claus van der Velden, Elliot Favus, Athanasios Skarpelos, Steffen Thomas and Peter Donhauser are independent
as that term is defined by NASDAQ 5605(a)(2) and the applicable rules of the Securities and Exchange Commission.</font></p>
<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt; font-style: normal"> </font></p>
<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt; font-style: normal"><a name="main_022"></a></section><section class="edgaug_item14" id="edgaug_item14_id">ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b><i> </i></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b><i>Fees
Paid to Our Independent Registered Public Accounting Firm </i></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">The following
table sets forth the aggregate fees billed or expected to be billed to our Company for professional services rendered by our independent
registered public accounting firm, for the fiscal years ended September 30, 2019 and 2018:</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td style="white-space: nowrap; text-align: center"><font style="font-size: 10pt"> </font></td><td style="padding-bottom: 1pt"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"><font style="font-size: 10pt">2019</font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"><font style="font-size: 10pt">2018</font></td><td style="padding-bottom: 1pt"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 70%; text-align: center; padding-left: 5.4pt"><font style="font-size: 10pt">Audit Fees</font></td><td style="width: 1%"><font style="font-size: 10pt"> </font></td>
<td style="width: 1%; text-align: left"><font style="font-size: 10pt">$</font></td><td style="width: 12%; text-align: right"><font style="font-size: 10pt">229,763</font></td><td style="width: 1%; text-align: left"><font style="font-size: 10pt"> </font></td><td style="width: 1%"><font style="font-size: 10pt"> </font></td>
<td style="width: 1%; text-align: left"><font style="font-size: 10pt">$</font></td><td style="width: 12%; text-align: right"><font style="font-size: 10pt">224,181</font></td><td style="width: 1%; text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: center; padding-left: 5.4pt"><font style="font-size: 10pt">Audit Related Fees</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">-</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">-</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: center; padding-left: 5.4pt"><font style="font-size: 10pt">Tax Fees</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">-</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">-</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: center; padding-bottom: 1pt; padding-left: 5.4pt"><font style="font-size: 10pt">All Other Fees</font></td><td style="padding-bottom: 1pt"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 10pt">-</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 10pt">-</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: center; padding-left: 5.4pt"><font style="font-size: 10pt">Total Fees</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt">$</font></td><td style="text-align: right"><font style="font-size: 10pt">229,763</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt">$</font></td><td style="text-align: right"><font style="font-size: 10pt">224,181</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><u>Audit
Fees</u>. Consist of fees billed for professional services rendered for the audits of our financial statements, reviews of our
interim financial statements included in quarterly reports, services performed in connection with regular filings with the Securities
and Exchange Commission for the fiscal years ended September 30, 2019 and 2018 in connection with statutory and regulatory filings
or engagements.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b><i>Policy
on Pre-Approval by Audit Committee of Services Performed by Independent Registered Public Accounting Firm </i></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">Our Audit
Committee pre-approves all services provided by our independent registered public accounting firm. All of the above services and
fees were reviewed and approved by our Audit Committee before the respective services were rendered.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">Our Audit
Committee has considered the nature and amount of fees billed or expected to be billed by BDO USA, LLP and believes that the provision
of services for activities unrelated to the audit was compatible with maintaining BDO USA, LLP’s independence.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<!-- Field: Page; Sequence: 70; Value: 35 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"><a name="main_023"></a>PART
IV</font></p>
<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt; font-style: normal"> </font></p>
<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt; font-style: normal"><a name="main_024"></a></section><section class="edgaug_item15" id="edgaug_item15_id">ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt; text-transform: uppercase"><b> </b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="width: 12%; border: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    <br/>
    Number </b></font></td>
<td style="width: 88%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt; text-align: left; vertical-align: bottom"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></font></td></tr>
<tr style="vertical-align: top">
<td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(3)
    </b></font></td>
<td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Articles
    of Incorporation and Bylaws </b></font></td></tr>
<tr style="vertical-align: top">
<td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000113707005000007/ex31.htm" style="-sec-extract: exhibit"><font style="font-family: Times New Roman, Times, Serif">3.1
    </font></a></font></td>
<td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000113707005000007/ex31.htm" style="-sec-extract: exhibit"><font style="font-family: Times New Roman, Times, Serif">Articles
    of Incorporation (incorporated by reference to our Registration Statement on Form SB-2 filed on January 13, 2005)</font></a></font></td></tr>
<tr style="vertical-align: top">
<td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000108503707002199/exhibit3_1.htm" style="-sec-extract: exhibit"><font style="font-family: Times New Roman, Times, Serif">3.2
    </font></a></font></td>
<td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000108503707002199/exhibit3_1.htm" style="-sec-extract: exhibit"><font style="font-family: Times New Roman, Times, Serif">Bylaws
    (incorporated by reference to our Current Report on Form 8-K filed on September 28, 2007)</font></a></font></td></tr>
<tr style="vertical-align: top">
<td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000108503707000198/form8kexh99_1.htm" style="-sec-extract: exhibit"><font style="font-family: Times New Roman, Times, Serif">3.3
    </font></a></font></td>
<td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000108503707000198/form8kexh99_1.htm" style="-sec-extract: exhibit"><font style="font-family: Times New Roman, Times, Serif">Articles
    of Merger filed with the Secretary of State of Nevada on January 10, 2007 and which is effective January 25, 2007 (incorporated
    by reference to our Current Report on Form 8-K filed on January 25, 2007)</font></a></font></td></tr>
<tr style="vertical-align: top">
<td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(10)
    </b></font></td>
<td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Material
    Contracts</b></font></td></tr>
<tr style="vertical-align: top">
<td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000161577415003756/s102397_ex10-91.htm" style="-sec-extract: exhibit"><font style="font-family: Times New Roman, Times, Serif">10.1</font></a></font></td>
<td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000161577415003756/s102397_ex10-91.htm" style="-sec-extract: exhibit"><font style="font-family: Times New Roman, Times, Serif">2015
    Omnibus Incentive Plan (incorporated by reference to our Annual Report on Form 10-K filed on December 29, 2015)</font></a></font></td></tr>
<tr style="vertical-align: top">
<td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000161577419002242/s115994_def14a.htm" style="-sec-extract: exhibit"><font style="font-family: Times New Roman, Times, Serif">10.2</font></a></font></td>
<td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000161577419002242/s115994_def14a.htm" style="-sec-extract: exhibit"><font style="font-family: Times New Roman, Times, Serif">2019
    Omnibus Incentive Plan (incorporated by reference to our Proxy Statement, dated February 11, 2019, as filed on February 11,
    2019).</font></a></font></td></tr>
<tr style="vertical-align: top">
<td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000121390019010601/f8k060719ex10-1_anavexlife.htm" style="-sec-extract: exhibit"><font style="font-family: Times New Roman, Times, Serif">10.3</font></a></font></td>
<td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000121390019010601/f8k060719ex10-1_anavexlife.htm" style="-sec-extract: exhibit"><font style="font-family: Times New Roman, Times, Serif">Purchase
    Agreement, dated as of June 7, 2019, by and between the Company and Lincoln Park Capital Fund, LLC (incorporated by reference
    to our Current Report on Form 8-K filed on June 12, 2019)</font></a></font></td></tr>
<tr style="vertical-align: top">
<td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000121390019010601/f8k060719ex4-1_anavexlife.htm" style="-sec-extract: exhibit"><font style="font-family: Times New Roman, Times, Serif">10.4
    </font></a></font></td>
<td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000121390019010601/f8k060719ex4-1_anavexlife.htm" style="-sec-extract: exhibit"><font style="font-family: Times New Roman, Times, Serif">Registration
    Rights Agreement, dated as of June 7, 2019, by and between the Company and Lincoln Park Capital Fund, LLC (incorporated by
    reference to our Current Report on Form 8-K filed on June 12, 2019)</font></a></font></td></tr>
<tr style="vertical-align: top">
<td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000161577416006259/s103666_ex10-1.htm" style="-sec-extract: exhibit"><font style="font-family: Times New Roman, Times, Serif">10.5
    </font></a></font></td>
<td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000161577416006259/s103666_ex10-1.htm" style="-sec-extract: exhibit"><font style="font-family: Times New Roman, Times, Serif">First
    Amendment to Employment Agreement, dated as of July 5, 2016, by and between the Company and Christopher Missling, PhD (incorporated
    by reference to our Current Report on Form 8-K filed on July 7, 2016)</font></a></font></td></tr>
<tr style="vertical-align: top">
<td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000161577416006410/s103735_ex10-1.htm" style="-sec-extract: exhibit"><font style="font-family: Times New Roman, Times, Serif">10.6</font></a></font></td>
<td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000161577416006410/s103735_ex10-1.htm" style="-sec-extract: exhibit"><font style="font-family: Times New Roman, Times, Serif">Amended
    and Restated First Amendment to Employment Agreement, dated as of July 18, 2016, by and between the Company and Christopher
    Missling, PhD (incorporated by reference to our Current Report on Form 8-K filed on July 22, 2016)</font></a></font></td></tr>
<tr style="vertical-align: top">
<td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000161577419007324/s118023_ex10-1.htm" style="-sec-extract: exhibit"><font style="font-family: Times New Roman, Times, Serif">10.7</font></a></font></td>
<td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000161577419007324/s118023_ex10-1.htm" style="-sec-extract: exhibit"><font style="font-family: Times New Roman, Times, Serif">Second
    Amendment to Employment Agreement, dated as of May 3, 2019 by and between the Company and Christopher Missling, PhD (incorporated
    by reference to our Quarterly Report on Form 10-Q filed on May 9, 2019)</font></a></font></td></tr>
<tr style="vertical-align: top">
<td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000161577418006280/s111267_ex1-1.htm" style="-sec-extract: exhibit"><font style="font-family: Times New Roman, Times, Serif">10.8</font></a></font></td>
<td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000161577418006280/s111267_ex1-1.htm" style="-sec-extract: exhibit"><font style="font-family: Times New Roman, Times, Serif">Controlled
    Equity Offering<sup>SM</sup> Sales Agreement, dated July 6, 2018, by and between Anavex Life Sciences Corp. and Cantor Fitzgerald
    &amp; Co. (incorporated by reference to our Current Report on Form 8-K filed on July 6, 2018)</font></a></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>
<!-- Field: Page; Sequence: 71; Value: 35 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="width: 12%; border: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    <br/>
    Number </b></font></td>
<td style="width: 88%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt; text-align: left; vertical-align: bottom"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></font></td></tr>
<tr style="vertical-align: top">
<td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>14</b></font></td>
<td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Code
    of Ethics</b></font></td></tr>
<tr style="vertical-align: top">
<td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000161577416008914/s104917_ex14-1.htm" style="-sec-extract: exhibit"><font style="font-family: Times New Roman, Times, Serif">14.1</font></a></font></td>
<td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000161577416008914/s104917_ex14-1.htm" style="-sec-extract: exhibit"><font style="font-family: Times New Roman, Times, Serif">Code
    of Ethics Adopted on September 13, 2016 (incorporated by reference to our Annual Report on Form 10-K filed on December 14,
    2016)</font></a></font></td></tr>
<tr style="vertical-align: top">
<td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(21)</b></font></td>
<td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Subsidiaries</b></font></td></tr>
<tr style="vertical-align: top">
<td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><a href="e1624_ex21-1.htm"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1*</font></a></td>
<td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><a href="e1624_ex21-1.htm"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiaries
    of the Registrant</font></a></td></tr>
<tr style="vertical-align: top">
<td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(23)</b></font></td>
<td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consent</b></font></td></tr>
<tr style="vertical-align: top">
<td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><a href="e1624_ex23-1.htm"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1*</font></a></td>
<td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><a href="e1624_ex23-1.htm"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent
    of Independent Registered Public Accounting Firm</font></a></td></tr>
<tr style="vertical-align: top">
<td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(31)
    </b></font></td>
<td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section
    302 Certifications</b></font></td></tr>
<tr style="vertical-align: top">
<td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font-size: 10pt"><a href="e1624_ex31-1.htm" style="-sec-extract: exhibit"><font style="font-family: Times New Roman, Times, Serif">31.1*</font></a></font></td>
<td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font-size: 10pt"><a href="e1624_ex31-1.htm" style="-sec-extract: exhibit"><font style="font-family: Times New Roman, Times, Serif">Section
    302 Certification of Christopher Missling, PhD.</font></a></font></td></tr>
<tr style="vertical-align: top">
<td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font-size: 10pt"><a href="e1624_ex31-2.htm" style="-sec-extract: exhibit"><font style="font-family: Times New Roman, Times, Serif">31.2*</font></a></font></td>
<td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font-size: 10pt"><a href="e1624_ex31-2.htm" style="-sec-extract: exhibit"><font style="font-family: Times New Roman, Times, Serif">Section
    302 Certification of Sandra Boenisch</font></a></font></td></tr>
<tr style="vertical-align: top">
<td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(32)
    </b></font></td>
<td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section
    906 Certifications</b></font></td></tr>
<tr style="vertical-align: top">
<td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font-size: 10pt"><a href="e1624_ex32-1.htm" style="-sec-extract: exhibit"><font style="font-family: Times New Roman, Times, Serif">32.1*</font></a></font></td>
<td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font-size: 10pt"><a href="e1624_ex32-1.htm" style="-sec-extract: exhibit"><font style="font-family: Times New Roman, Times, Serif">Section
    906 Certification of Christopher Missling, PhD and Sandra Boenisch</font></a></font></td></tr>
<tr style="vertical-align: top">
<td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(99)</b></font></td>
<td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Additional
    Exhibits</b></font></td></tr>
<tr style="vertical-align: top">
<td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000161577417007272/s108360_ex99-1.htm" style="-sec-extract: exhibit"><font style="font-family: Times New Roman, Times, Serif">99.1</font></a></font></td>
<td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000161577417007272/s108360_ex99-1.htm" style="-sec-extract: exhibit"><font style="font-family: Times New Roman, Times, Serif">Insider
    Trading Policy Adopted August 9, 2017 (incorporated by reference to our Annual Report on Form 10-K filed on December 11, 2017)</font></a></font></td></tr>
<tr style="vertical-align: top">
<td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(101)</b></font></td>
<td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>XBRL</b></font></td></tr>
<tr style="vertical-align: top">
<td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS*</font></td>
<td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    INSTANCE DOCUMENT</font></td></tr>
<tr style="vertical-align: top">
<td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH*</font></td>
<td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    TAXONOMY EXTENSION SCHEMA</font></td></tr>
<tr style="vertical-align: top">
<td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL*</font></td>
<td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    TAXONOMY EXTENSION CALCULATION LINKBASE</font></td></tr>
<tr style="vertical-align: top">
<td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF*</font></td>
<td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    TAXONOMY EXTENSION DEFINITION LINKBASE</font></td></tr>
<tr style="vertical-align: top">
<td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB*</font></td>
<td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    TAXONOMY EXTENSION LABEL LINKBASE</font></td></tr>
<tr style="vertical-align: top">
<td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE*</font></td>
<td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    TAXONOMY EXTENSION PRESENTATION LINKBASE</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">* Filed
herewith.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt; font-style: normal"><a name="main_025"></a>ITEM 16. FORM 10-K SUMMARY</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt">Not Applicable.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<!-- Field: Page; Sequence: 72; Value: 35 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-size: 10pt"><b>SIGNATURES</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><font style="font-size: 10pt">Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report
to be signed on its behalf by the undersigned thereunto duly authorized.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><font style="font-size: 10pt"> </font></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="background-color: white">
<td style="vertical-align: top"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date: December
    16, 2019</b></font></td>
<td style="vertical-align: bottom"><font style="font-size: 10pt"> </font></td>
<td colspan="3" style="vertical-align: top"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ANAVEX
    LIFE SCIENCES CORP.</b></font></td></tr>
<tr style="background-color: white">
<td><font style="font-size: 10pt"> </font></td>
<td colspan="2"><font style="font-size: 10pt"> </font></td>
<td colspan="2"><font style="font-size: 10pt"> </font></td></tr>
<tr style="background-color: white">
<td style="vertical-align: top; width: 45%"><font style="font-size: 10pt"> </font></td>
<td style="vertical-align: bottom; width: 5%"><font style="font-size: 10pt"> </font></td>
<td style="vertical-align: top; width: 5%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</font></td>
<td style="vertical-align: bottom; width: 1%"><font style="font-size: 10pt"> </font></td>
<td style="vertical-align: top; width: 45%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 0.75pt solid"><font style="font-size: 10pt"><i>/s/
                                         Christopher Missling, PhD</i></font></p></td></tr>
<tr style="background-color: white">
<td style="vertical-align: top"><font style="font-size: 10pt"> </font></td>
<td style="vertical-align: bottom"><font style="font-size: 10pt"> </font></td>
<td style="vertical-align: top"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</font></td>
<td style="vertical-align: bottom"><font style="font-size: 10pt"> </font></td>
<td style="vertical-align: top"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher Missling,
    PhD</font></td></tr>
<tr style="background-color: white">
<td style="vertical-align: top"><font style="font-size: 10pt"> </font></td>
<td style="vertical-align: bottom"><font style="font-size: 10pt"> </font></td>
<td style="vertical-align: top"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</font></td>
<td style="vertical-align: bottom"><font style="font-size: 10pt"> </font></td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt">Chief
                                       Executive Officer (Principal Executive Officer)</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><font style="font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf
of the registrant and in the capacities and on the dates indicated.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><font style="font-size: 10pt"> </font></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal">
<tr style="vertical-align: top">
<td style="width: 30%; border-bottom: Black 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Signatures</b></font></td>
<td style="width: 1%; text-align: center"><font style="font-size: 10pt"> </font></td>
<td style="width: 50%; border-bottom: Black 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title(s)</b></font></td>
<td style="width: 1%; text-align: center"><font style="font-size: 10pt"> </font></td>
<td style="width: 18%; border-bottom: Black 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></font></td></tr>
<tr style="vertical-align: top">
<td><font style="font-size: 10pt"> </font></td>
<td><font style="font-size: 10pt"> </font></td>
<td><font style="font-size: 10pt"> </font></td>
<td><font style="font-size: 10pt"> </font></td>
<td><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: top">
<td style="border-bottom: Black 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Christopher Missling, PhD</i></font></td>
<td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td><font style="font-size: 10pt"> </font></td>
<td><font style="font-size: 10pt"> </font></td>
<td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 16, 2019</font></td></tr>
<tr style="vertical-align: top">
<td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher Missling, PhD</font></td>
<td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer (Principal Executive
    Officer)</font></td>
<td><font style="font-size: 10pt"> </font></td>
<td><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: top">
<td><font style="font-size: 10pt"> </font></td>
<td><font style="font-size: 10pt"> </font></td>
<td><font style="font-size: 10pt"> </font></td>
<td><font style="font-size: 10pt"> </font></td>
<td><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: top">
<td style="border-bottom: Black 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Sandra Boenisch</i></font></td>
<td><font style="font-size: 10pt"> </font></td>
<td><font style="font-size: 10pt"> </font></td>
<td><font style="font-size: 10pt"> </font></td>
<td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 16, 2019</font></td></tr>
<tr style="vertical-align: top">
<td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sandra Boenisch, CPA, CGA</font></td>
<td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Financial Officer and Treasurer (Principal
    Accounting Officer)</font></td>
<td><font style="font-size: 10pt"> </font></td>
<td><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: top">
<td><font style="font-size: 10pt"> </font></td>
<td><font style="font-size: 10pt"> </font></td>
<td><font style="font-size: 10pt"> </font></td>
<td><font style="font-size: 10pt"> </font></td>
<td><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: top">
<td style="border-bottom: Black 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Athanasios Skarpelos</i></font></td>
<td><font style="font-size: 10pt"> </font></td>
<td><font style="font-size: 10pt"> </font></td>
<td><font style="font-size: 10pt"> </font></td>
<td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 16, 2019</font></td></tr>
<tr style="vertical-align: top">
<td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Athanasios Skarpelos</font></td>
<td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</font></td>
<td><font style="font-size: 10pt"> </font></td>
<td><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: top">
<td><font style="font-size: 10pt"> </font></td>
<td><font style="font-size: 10pt"> </font></td>
<td><font style="font-size: 10pt"> </font></td>
<td><font style="font-size: 10pt"> </font></td>
<td><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: top">
<td style="border-bottom: Black 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Claus van der Velden, PhD</i></font></td>
<td><font style="font-size: 10pt"> </font></td>
<td><font style="font-size: 10pt"> </font></td>
<td><font style="font-size: 10pt"> </font></td>
<td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 16, 2019</font></td></tr>
<tr style="vertical-align: top">
<td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Claus van der Velden, PhD</font></td>
<td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</font></td>
<td><font style="font-size: 10pt"> </font></td>
<td><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: top">
<td><font style="font-size: 10pt"> </font></td>
<td><font style="font-size: 10pt"> </font></td>
<td><font style="font-size: 10pt"> </font></td>
<td><font style="font-size: 10pt"> </font></td>
<td><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: top">
<td style="border-bottom: Black 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Elliot Favus, MD</i></font></td>
<td><font style="font-size: 10pt"> </font></td>
<td><font style="font-size: 10pt"> </font></td>
<td><font style="font-size: 10pt"> </font></td>
<td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 16, 2019</font></td></tr>
<tr style="vertical-align: top">
<td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Elliot Favus, MD</font></td>
<td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</font></td>
<td><font style="font-size: 10pt"> </font></td>
<td><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: top">
<td><font style="font-size: 10pt"> </font></td>
<td><font style="font-size: 10pt"> </font></td>
<td><font style="font-size: 10pt"> </font></td>
<td><font style="font-size: 10pt"> </font></td>
<td><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: top">
<td style="border-bottom: Black 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Steffen Thomas, PhD</i></font></td>
<td><font style="font-size: 10pt"> </font></td>
<td><font style="font-size: 10pt"> </font></td>
<td><font style="font-size: 10pt"> </font></td>
<td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 16, 2019</font></td></tr>
<tr style="vertical-align: top">
<td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steffen Thomas, PhD</font></td>
<td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</font></td>
<td><font style="font-size: 10pt"> </font></td>
<td><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: top">
<td><font style="font-size: 10pt"> </font></td>
<td><font style="font-size: 10pt"> </font></td>
<td><font style="font-size: 10pt"> </font></td>
<td><font style="font-size: 10pt"> </font></td>
<td><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: top">
<td style="border-bottom: Black 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Peter Donhauser, D.O.</i></font></td>
<td><font style="font-size: 10pt"> </font></td>
<td><font style="font-size: 10pt"> </font></td>
<td><font style="font-size: 10pt"> </font></td>
<td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 16, 2019</font></td></tr>
<tr style="vertical-align: top">
<td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Peter Donhauser, D.O.</font></td>
<td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</font></td>
<td><font style="font-size: 10pt"> </font></td>
<td><font style="font-size: 10pt"> </font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<!-- Field: Page; Sequence: 73; Options: Last -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"><b> </b></font></p>
<p style="margin: 0"></p>
</text>
</body></html>